Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

(Mark One)

 

[x] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (D) OF THE SECURITIES AND EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 20162017

 

or

 

[_]  ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (D) OF THE SECURITIES AND EXCHANGE ACT OF 1934

 

For the transition period from to _______to______

 

MARATHON PATENT GROUP, INC.

(Exact Name of Registrant as Specified in Charter)

 

Nevada

001-36555

01-0949984

(State or other jurisdiction
of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

 

11100 Santa Monica Blvd., Ste. 380
Los Angeles, CA

90025

(Address of principal executive offices)

(Zip Code)

 

Registrant’s telephone number, including area code: 703-232-1701

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [x] No [_][  ]

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [x] No [_][  ]

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”filer,” “smaller reporting company” and “smaller reporting“emerging growth company” in Rule 12b-2 of the Exchange Act. [X]

 

Large accelerated filer

[_]

  ]

Accelerated filer

[_]

  ]

Non-accelerated filer

(Do not check if smaller reporting company)

[_]

  ]

Smaller reporting company

Emerging growth company

[x]X]

[  ]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [  ]

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) Yes [_][  ] No [x]

 

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date. 15,070,4758,747,931 shares of common stock are issued and outstanding as of November 9, 2016.



Table of Contents14, 2017.

 

Table of Contents

TABLE OF CONTENTS

 

Page No.

PART I. - FINANCIAL INFORMATION

Item 1.

Financial Statements

3

Consolidated Condensed Balance Sheets as of September 30, 2017 (unaudited) and December 31, 2016

3

Consolidated Condensed Statements of Operations and Comprehensive IncomeLoss for the Three and Nine Months Ended September 30, 2017 and 2016 (unaudited)

4

Consolidated Condensed Statements of Cash Flows for the Nine Months Ended September 30, 2017 and 2016 (unaudited)

5

Notes to Unaudited Consolidated Condensed Financial Statements

6

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

33

29

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

43

39

Item 4.

Controls and Procedures

43

39

PART II – OTHER INFORMATION

Item 1.

Legal Proceedings

44

40

Item 1A

Risk Factors

44

40

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

44

41

Item 3.

Defaults upon Senior Securities

44

41

Item 4.

Mine Safety Disclosures

44

41

Item 5.

Other Information

44

41

Item 6.

Exhibits

44

41

 

OTHER PERTINENT INFORMATION

 

Unless specifically set forth to the contrary, “Marathon Patent Group, Inc.,” “we,” “us,” “our” and similar terms refer to Marathon Patent Group, Inc., a Nevada corporation, and its subsidiaries. Unless otherwise indicated, the per share information has been adjusted to reflect the four for one reverse stock split that went into effect on October 30, 2017 (the “Reverse Split”).

2
Table of Contents

Item 1. Financial Statements

 

MARATHON PATENT GROUP, INC. AND SUBSIDIARIES

CONSOLIDATED CONDENSED BALANCE SHEETS

(Unaudited)

 

 

 

September 30, 2016

 

December 31, 2015

 

 

(Unaudited)

 

(Audited)

ASSETS

 

 

 

 

Current Assets

 

 

 

 

Cash

 

$

1,294,950

 

$

2,555,151

Accounts receivable - net of allowance for bad debt of $387,976 and $375,750 for September 30, 2016 and December 31, 2015

 

81,865

 

136,842

Bonds posted with courts

 

980,919

 

1,748,311

Prepaid expenses and other current assets, net of discounts of $2,483 for September 30, 2016 and $3,414 for December 31, 2015

 

153,388

 

338,598

Total current assets

 

$

2,511,122

 

$

4,778,902

 

 

 

 

 

Other assets:

 

 

 

 

Property and equipment, net of accumulated depreciation of $98,347 and $67,052 for September 30, 2016 and December 31, 2015

 

$

38,389

 

$

61,297

Intangible assets, net of accumulated amortization of $16,438,643 and $15,557,353 for September 30, 2016 and December 31, 2015

 

19,551,678

 

25,457,639

Deferred tax assets

 

11,918,920

 

12,437,741

Other non current assets, net of discounts of $2,969 and $4,831 for September 30, 2016 and December 31, 2015

 

201,031

 

9,169

Goodwill

 

4,483,129

 

4,482,845

Total other assets

 

$

36,193,147

 

$

42,448,691

 

 

 

 

 

Total Assets

 

$

38,704,269

 

$

47,227,593

 

 

 

 

 

 

 

 

 

 

 

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

 

Current liabilities:

 

 

 

 

Accounts payable and accrued expenses

 

$

6,054,015

 

$

6,534,825

Clouding IP earn out - current portion

 

110,100

 

33,646

Notes payable, net of discounts of $818,919 and $730,945 for September 30, 2016 and December 31, 2015

 

11,139,623

 

10,383,177

Total current liabilities

 

$

17,303,738

 

$

16,951,648

 

 

 

 

 

Long-term liabilities

 

 

 

 

Notes payable, net of discount of $798,966 and $1,425,167 for September 30 , 2016 and December 31, 2015

 

$

6,456,740

 

$

12,223,884

Clouding IP earn out

 

1,082,586

 

3,281,238

Deferred tax liability

 

438,709

 

1,044,997

Revenue share liability

 

1,000,000

 

1,000,000

Other long term liability

 

45,763

 

50,084

Total long-term liabilities

 

$

9,023,798

 

$

17,600,203

 

 

 

 

 

Total Liabilities

 

$

26,327,536

 

$

34,551,851

 

 

 

 

 

Stockholders’ Equity:

 

 

 

 

Preferred stock Series B, $.0001 par value, 50,000,000 shares  authorized: 782,004 issued and outstanding at September 30, 2016 and December 31, 2015

 

$

78

 

$

78

Common stock, $.0001 par value; 200,000,000 shares authorized;  15,047,141 and 14,867,141 at September 30, 2016 and December 31, 2015

 

1,505

 

1,487

Additional paid-in capital

 

44,901,535

 

43,217,513

Accumulated other comprehensive income (loss)

 

(959,401)

 

(1,265,812)

Accumulated deficit

 

(31,539,066)

 

(29,277,524)

 

 

 

 

 

Total Marathon Patent Group stockholders’ equity

 

$

12,404,651

 

$

12,675,742

 

 

 

 

 

Noncontrolling interests

 

(27,918)

 

-

 

 

 

 

 

Total Stockholders’ Equity

 

$

12,376,733

 

$

12,675,742

 

 

 

 

 

Total liabilities and stockholders’ equity

 

$

38,704,269

 

$

47,227,593

  September 30, 2017  December 31, 2016 
         
ASSETS        
Current assets:        
Cash $122,172  $4,998,314 
Restricted Cash  3,919,718   - 
Total cash  4,041,890   4,998,314 
Accounts receivable - net of allowance for bad debt of $387,976 and $387,976 for September 30, 2017 and December 31, 2016  123,630   95,069 
Note receivable  588,864   225,982 
Prepaid expenses and other current assets, net of discounts of $2,659 for September 30, 2017 and $3,724 for December 31, 2016  108,878   202,067 
Total current assets  4,863,262   5,521,432 
         
Other assets:        
Property and equipment, net of accumulated depreciation of $133,224 and $108,407 for September 30, 2017 and December 31, 2016  9,803   28,329 
Intangible assets, net of accumulated amortization of $12,813,915 and $11,323,185 for September 30, 2017 and December 31, 2016  7,590,213   12,314,628 
Other non current assets, net of discounts of $797 for December 31, 2016  -   201,203 
Goodwill  228,401   222,843 
Total other assets  7,828,417   12,767,003 
         
Total Assets $12,691,679  $18,288,435 
         
LIABILITIES AND STOCKHOLDERS' EQUITY        
Current liabilities:        
Accounts payable and accrued expenses $1,954,836  $7,217,078 
Clouding IP earn out - current portion  32,637   81,930 
Revenue share liability  1,225,000   - 
Warrant liability  2,411,750   - 
Notes payable, net of discounts of $5,837,363 and $852,404 for September 30, 2017 and December 31, 2016  15,582,156   13,162,007 
   21,206,379   20,461,015 
         
Long-term liabilities        
Notes Payable, net of discount of $57,763 for December 31, 2016  -   4,670,502 
Clouding IP earn out  681,175   1,400,082 
Revenue share liability  -   1,000,000 
Other long term liability  37,236   43,978 
Total long-term liabilities  718,411   7,114,562 
         
Total liabilities  21,924,790   27,575,577 
         
Stockholders' Deficit:        
Preferred stock Series B, $.0001 par value, 50,000,000 shares  authorized: 195,501 issued and outstanding at September 30, 2017 and December 31, 2016  78   78 
Common stock, $.0001 par value; 200,000,000 shares authorized; 7,776,016 and 4,638,118 at September 30, 2017 and December 31, 2016  3,111   1,856 
Additional paid-in capital  61,833,077   49,877,710 
Accumulated other comprehensive income (loss)  (450,623)  (1,060,390)
Accumulated deficit  (70,427,472)  (57,942,548)
         
Total Marathon Patent Group stockholders' equity  (9,041,829)  (9,123,294)
         
Noncontrolling interests  (191,282)  (163,848)
         
Total deficit  (9,233,111)  (9,287,142)
         
Total liabilities and stockholders' deficit $12,691,679  $18,288,435 

 

The accompanying notes are an integral part to these unaudited consolidated condensed financial statements.

3
Table of Contents

MARATHON PATENT GROUP, INC. AND SUBSIDIARIES

CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME

(Unaudited)

 

 

 

For The Three

 

For The Three

 

For The Nine

 

For The Nine

 

 

 

Months Ended

 

Months Ended

 

Months Ended

 

Months Ended

 

 

 

September 30, 2016

 

September 30, 2015

 

September 30, 2016

 

September 30, 2015

 

 

 

(Unaudited)

 

(Unaudited)

 

(Unaudited)

 

(Unaudited)

 

Revenues

 

$

43,113

 

$

6,407,997

 

$

36,452,551

 

$

11,870,851

 

 

 

 

 

 

 

 

 

 

 

Expenses

 

 

 

 

 

 

 

 

 

Cost of revenues

 

1,094,378

 

4,002,040

 

19,202,118

 

12,190,415

 

Amortization of patents and website

 

2,030,886

 

2,884,269

 

6,018,196

 

8,511,730

 

Compensation and related taxes

 

1,252,571

 

903,685

 

3,406,841

 

3,571,817

 

Consulting fees

 

257,420

 

643,702

 

903,032

 

1,869,326

 

Professional fees

 

432,496

 

882,213

 

1,336,201

 

2,230,748

 

General and administrative

 

183,771

 

177,494

 

612,284

 

681,951

 

Goodwill impairment

 

-

 

-

 

83,000

 

-

 

Patent impairment

 

5,531,383

 

-

 

6,525,273

 

766,498

 

Total Operating Expenses

 

10,782,905

 

9,493,403

 

38,086,945

 

29,822,485

 

 

 

 

 

 

 

 

 

 

 

Operating loss

 

(10,739,792)

 

(3,085,406)

 

(1,634,394)

 

(17,951,634)

 

 

 

 

 

 

 

 

 

 

 

Other income (expenses)

 

 

 

 

 

 

 

 

 

Other expense

 

(37,116)

 

6,646

 

(68,647)

 

14,085

 

Foreign exchange gain (loss)

 

(175,850)

 

(20,090)

 

(238,073)

 

(57,593)

 

Change in fair value adjustments of Clouding IP earn out

 

1,954,378

 

597,047

 

2,122,208

 

2,901,348

 

Interest Income

 

931

 

135

 

2,793

 

137

 

Interest expense.

 

(649,065)

 

(1,078,615)

 

(2,500,321)

 

(3,587,238)

 

Loss on debt extinguishment

 

-

 

(654,000)

 

-

 

(654,000)

 

Total Other income (expenses)

 

1,093,278

 

(1,148,877)

 

(682,040)

 

(1,383,261)

 

 

 

 

 

 

 

 

 

 

 

Loss before (provision for) benefit from income taxes

 

(9,646,514)

 

(4,234,283)

 

(2,316,434)

 

(19,334,895)

 

 

 

 

 

 

 

 

 

 

 

(Provision for) benefit from income taxes

 

3,347,909

 

483,815

 

26,974

 

6,300,159

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

(6,298,605)

 

(3,750,468)

 

(2,289,460)

 

(13,034,736)

 

 

 

 

 

 

 

 

 

 

 

Net loss attributible to noncontrolling interests

 

24,195

 

-   

 

27,918

 

-

 

 

 

 

 

 

 

 

 

 

 

Net loss attributable to Marathon Patent Group, Inc. common shareholders

 

$

(6,274,410)

 

$

(3,750,468)

 

$

(2,261,542)

 

$

(13,034,736)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss per common share:

 

 

 

 

 

 

 

 

 

Basic and fully diluted

 

$

(0.42)

 

$

(0.26)

 

$

(0.15)

 

$

(0.92)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:

 

 

 

 

 

 

 

 

 

Basic and fully diluted

 

15,047,141

 

14,376,118

 

14,944,852

 

14,094,891

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other comprehensive income (loss)

 

 

 

 

 

 

 

 

 

Foreign currency translation adjustments

 

209,159

 

45,628

 

306,411

 

$

(584,706)

 

  For the Three
Months Ended
30-Sep-17
  For the Three
Months Ended
30-Sep-16
  For the Nine
Months Ended
30-Sep-17
  For the Nine
Months Ended
30-Sep-16
 
             
Revenues $162,713  $43,113  $609,650  $36,452,551 
                 
Expenses                
Cost of revenues  64,836   1,094,378   1,544,322   19,202,118 
Amortization of patents and website  457,419   2,030,886   1,803,264   6,018,196 
Compensation and related taxes  1,871,946   1,252,571   3,718,034   3,406,841 
Consulting fees  133,018   257,420   189,819   903,032 
Professional fees  616,125   432,496   1,686,955   1,336,201 
General and administrative  213,130   183,771   599,416   612,284 
Goodwill impairment  -   -   -   83,000 
Patent impairment  723,218   5,531,383   723,218   6,525,273 
Total operating expenses  4,079,692   10,782,905   10,265,028   38,086,945 
                 
Operating loss from continuing operations  (3,916,979)  (10,739,792)  (9,655,378)  (1,634,394)
                 
Other income (expenses)                
Other income (expense)  2,252,886   (37,116)  3,151,418   (68,647)
Foreign exchange (loss)  (480,240)  (175,850)  (463,191)  (238,073)
Loss on debt extinguishment  (283,237)  -   (283,237)  - 
Loss on sale of company  (1,519,875)  -   (1,519,875)  - 
Change in fair value adjustment of Clouding IP earn out  754,321   1,954,378   768,200   2,122,208 
Warrant income (expense)  (1,909,879)  -   (1,914,786)  - 
Interest income  931   931   2,793   2,793 
Interest expense  (1,283,223)  (649,065)  (2,416,722)  (2,500,321)
Total other income (expenses)  (2,468,316)  1,093,278   (2,675,400)  (682,040)
                 
Loss from continuing operations before benefit for income taxes  (6,385,295)  (9,646,514)  (12,330,778)  (2,316,434)
                 
Income tax benefit (expense)  (12,191)  3,347,909   (29,433)  26,974 
                 
Net Income (loss)  (6,397,486)  (6,298,605)  (12,360,211)  (2,289,460)
                 
Net income (loss) attributable to Noncontrolling interests  (280,000)  24,195   (124,714)  27,918 
                 
Net (loss) attributable to common shareholders $(6,677,486) $(6,274,410) $(12,484,925) $(2,261,542)
                 
Income (loss) per common share:                
Basic $(1.06) $(1.67) $(2.24) $(0.61)
Diluted                
                 
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:                
Basic  6,270,299   3,761,786   5,564,465   3,736,213 
                 
Net loss $(6,677,486) $(6,274,410) $(12,484,925) $(2,261,542)
Other comprehensive loss:                
Unrealized gain on foreign currency translation  482,622   209,159   609,768   306,411 
Comprehensive loss  (6,194,864)  (6,065,251)  (11,875,157)  (1,955,131)
Less: comprehensive income (loss) related to non-controlling interest  (280,000)  24,195   (124,714)  27,918 
Comprehensive loss attributable to Marathon Patent Group, Inc. $(6,474,864) $(6,041,056) $(11,999,871) $(1,927,213)

 

The accompanying notes are an integral part to these unaudited consolidated condensed financial statements.

4
Table of Contents

MARATHON PATENT GROUP, INC. AND SUBSIDIARIES

CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS

(Unaudited)

 

 

For The Nine

 

For The Nine

 

Months Ended

 

Months Ended

 

September 30, 2016

 

September 30, 2015

 

(Unaudited)

 

(Unaudited)

 For The
Nine Months Ended
September 30, 2017
 For The
Nine Months Ended
September 30, 2016
 

Cash flows from operating activities:

 

 

 

 

        

Net loss attributable to Marathon Patent Group, Inc common shareholders

 

$

(2,261,542)

 

$

(13,034,736)

Net loss $(12,484,924) $(2,261,542)

Adjustments to reconcile net loss to net cash provided by (used in) operating activities:

 

 

 

 

        

Depreciation

 

3,780

 

5,668

  1,248   3,780 

Amortization of patents and website

 

6,018,196

 

8,511,730

  1,803,264   6,018,196 

Allowance for doubtful accounts

 

12,226

 

-

Deferred tax asset

 

531,757

 

(5,579,418)

  -   531,757 

Deferred tax liability

 

(638,268)

 

(709,280)

  -   (638,268)
Loss on sale of companies  -   - 
Warrant liability  -   - 

Impairment of intangible assets

 

6,525,273

 

766,498

  704,678   6,525,273 

Impairment of goodwill

 

83,000

 

-

  -   83,000 

Stock based compensation

 

1,541,615

 

1,961,505

  1,523,187   1,541,615 

Stock issued for services

 

136,000

 

1,084,834

  -   136,000 

Loss on debt exstinguishment

 

-

 

654,000

Non-cash interest, discount, and financing costs

 

952,231

 

1,926,865

  (4,397,381)  952,231 

Change in fair value of Clouding earnout

 

(2,122,198)

 

(2,901,348)

  (768,200)  (2,122,198)

Non-controlling interest

 

(27,918)

 

-

Allowance for doubtful accounts  -   12,226 
Beneficial conversion feature  4,017,729   - 
Noncontrolling interest  (27,435)  (27,918)

Other non-cash adjustments

 

96,996

 

(13,244)

  182,024   96,996 

Changes in operating assets and liabilities

 

 

 

 

        

Accounts receivable

 

43,763

 

(2,109,984)

  (28,561)  43,763 
Bonds posted with courts  -   883,695 

Prepaid expenses and other assets

 

(6,652)

 

60,938

  (269,693)  (6,652)

Bonds posted with courts

 

883,695

 

-

Other non current assets  201,203   - 

Accounts payable and accrued expenses

 

(557,832)

 

6,454,467

  (5,262,242)  (557,832)

 

 

 

 

        

Net cash provided by (used in) operating activities

 

11,214,122

 

(2,921,505)

Net cash and restricted cash provided by (used in) operating activities  (14,805,103)  11,214,122 

 

 

 

 

        

Cash flows from investing activities:

 

 

 

 

        

Acquisition of patents

 

(3,552,656)

 

-

  -   (3,552,656)
Disposal of patents  2,771,757   - 

Purchase of property, equipment, and other intangible assets

 

(8,387)

 

(22,520)

  (6,291)  (8,387)

Net cash provided by (used in) investing activities

 

(3,561,043)

 

(22,520)

  2,765,466   (3,561,043)

 

 

 

 

        

Cash flows from financing activities:

 

 

 

 

        

Payment on note payable in connection with the acquisition of Medtech and Orthophoenix

 

(2,953,779)

 

(4,200,000)

  -   (2,953,779)

Payment on note payable in connection with the acquisition of Orthophoenix

 

-

 

(5,000,000)

Payment on note payable in connection with the acquisition of Sarif

 

-

 

(276,250)

Payment on note payable in connection with the acquisition of IP Liquidity

 

-

 

(1,109,375)

Payment on note payable in connection with the acquisition of Dynamic Advances

 

-

 

(2,624,375)

Payment on MdR Escrow TLI

 

-

 

(50,000)

Cash received upon issuance of notes payable (net of issuance costs)

 

-

 

19,600,000

Repayment of notes payable

 

(5,379,105)

 

-

Cash received upon exercise of warrants

 

-

 

18,751

Repayment of convertible notes payable

 

-

 

(5,050,000)

Payment on note payable

 

(578,804)

 

(42,500)

Payment on Fortress note payable  (63,286)  (5,379,105)
Payment on 3D Nano license note payable  (100,000)  - 
Cash received upon issuance of equity (net of issuance costs)  5,158,906   - 
Issuance of warrants  2,549,084   - 
Issuance of convertible notes payable  5,500,000     
Medtronic note payable  600,000   - 
Payment of Medtronic note payable  (600,000)    
Payments on Seimens notes payable  (1,750,000)  - 
Payments on notes payable to vendors  (125,000)  - 
Payments on notes payable, net  (103,000)  (578,804)

Net cash provided (used in) by financing activities

 

(8,911,688)

 

1,266,251

  11,066,704   (8,911,688)

 

 

 

 

        

Effect of exchange rate changes on cash

 

(1,592)

 

4,044

  16,509   (1,592)

 

 

 

 

        

Net decrease in cash

 

(1,260,201)

 

(1,673,730)

  (956,424)  (1,260,201)

 

 

 

 

        

Cash at beginning of period

 

2,555,151

 

5,082,569

  4,998,314   2,555,151 

 

 

 

 

        

Cash at end of period

 

$

1,294,950

 

$

3,408,839

 

 

 

 

 

 

Cash and restricted cash at end of period $4,041,890  $1,294,950 

 

 

 

 

        

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:

 

 

 

 

        

Cash paid for:

 

 

 

 

        

Interest expense

 

$

1,391,567

 

$

1,660,372

 $368,923  $1,187,074 

 

 

 

 

 

 

Taxes paid

 

$

36,218

 

$

54,437

 $29,433  $27,682 

 

 

 

 

 

 

Loan fees

 

$

-

 

$

400,000

 

 

 

 

 

 

Cash invested in 3D Nano $-  $115,000 

 

 

 

 

        

SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:

 

 

 

 

        

Common stock issued in conjunction with note payable

 

$

-

 

$

1,000,000

 

 

 

 

 

 

Warrant issued in conjunction with note payable

 

$

-

 

$

318,679

 

 

 

 

 

 

Revenue share liability incurred in conjunction with note payable

 

$

-

 

$

1,000,000

 $225,000  $- 

 

 

 

 

 

 

Note payable issuance in conjunction with the acquisition of GE patent

 

$

1,000,000

 

$

-

 

 

 

 

 

 

Non-cash interest increase in debt assumed in the Orthophoenix acquisition

 

$

-

 

$

750,000

 

 

 

 

 

 

Common stock issued in conjunction with debt extinguishment

 

$

-

 

$

654,000

 

 

 

 

 

 

Note payable issuance in conjunction with the acquisition of BATO patent

 

$

-

 

$

10,000,000

 

 

 

 

 

 

Note payable issuance in conjunction with the acquisition of Siemens patent

 

$

1,755,635

 

$

-

 

 

 

 

 

 

Note payable issuance in conjunction with the acquisition of 3DNano License

 

$

200,000

 

$

-

 

 

 

 

 

 

Conversion from AP to NP

 

$

-

 

$

705,093

 

 

 

 

 

 

Warrant issued in conjunction with common stock issuance $257,957  $- 
Note payable issued in conjunction with the acquisition of Munitech patents $-  $1,755,635 
Note payable issued in conjunction with the acquisition of GE patent  -   1,000,000 
Note payable issued in conjunction with the acquisition of3D Nano license  -   200,000 

 

The accompanying notes are an integral part to these unaudited consolidated condensed financial statementsstatements.

5
Table of Contents

Notes to Unaudited Consolidated Condensed Financial Statements

NOTE 1 - ORGANIZATION AND DESCRIPTION OF BUSINESS

 

Organization

Marathon is an IP licensing and commercialization company. The Company acquires and manages IP rights from a variety of sources, including large and small corporations, universities and other IP owners. Marathon has a global focus on IP acquisition and management. The Company’s commercialization division is focused on the full commercialization lifecycle which includes discovering opportunities, performing due diligence, providing capital, managing development, protecting and developing IP, assisting in execution of the business plan, and realizing shareholder value.

 

Marathon Patent Group, Inc.’s (the “Company”) business is to acquire patents and patent rights and to monetize the value of those assets to generate revenue and profit for the Company. We acquire patents and patent rights from their owners, who range from individual inventors to Fortune 500 companies. Part of our acquisition strategy is to acquire or invest in patents and patent rights that cover a wide-range of subject matter, which allows us to achieve the benefits of a growing diversified portfolio of assets. Generally, the patents and patent rights that we acquire are characterized by having large identifiable companies who are or have been using technology that infringes our patents and patent rights. We generally monetize our portfolio of patents and patent rights by entering into license discussions, and if that is unsuccessful, initiating enforcement activities against any infringing parties with the objective of entering into a standard form of comprehensive settlement and license agreement that may include the granting of non-exclusive retroactive and future rights to use the patented technology, a covenant not to sue, a release of the party from certain claims, the dismissal of any pending litigation and other terms that are appropriate in the circumstances. Our strategy has been developed with the expectation that it will result in a long-term, diversified revenue stream for the Company.

The Company was incorporated in the State of Nevada on February 23, 2010 under the name Verve Ventures, Inc. On December 7, 2011, we changed our name to American Strategic Minerals Corporation and were engaged in the business of exploration and potential development of uranium and vanadium minerals business. In June 2012, we discontinued our minerals business and began to invest in real estate properties in Southern California. In October 2012, we discontinued our real estate business when our CEO joined the firm and we commenced our current business, at which time the Company’s name was changed to Marathon Patent Group, Inc.

 

On December 7, 2011, the Company filed a Certificate of Amendment to its Articles of Incorporation with the Secretary of State of the State of Nevada in order to change its name to “American Strategic Minerals Corporation” from “Verve Ventures, Inc.”, and increase the Company’s authorized capital to 200,000,000 shares of common stock, par value $0.0001 per share, and 100,000,000 shares of preferred stock, par value $0.0001 per share. During June 2012, the Company decided to discontinue its exploration and potential development of uranium and vanadium minerals business.

On August 1, 2012, the shareholders holding a majority of the Company’s voting capital voted in favor of (i) changing the name of the Company to “Fidelity Property Group, Inc.” and (ii) the adoption the 2012 Equity Incentive Plan and reserving 10,000,000 shares of common stock for issuance thereunder (the “2012 Plan”).  The board of directors of the Company (the “Board of Directors”) approved the name change and the adoption of the 2012 Plan on August 1, 2012. The Company did not file an amendment to its Articles of Incorporation with the Secretary of State of Nevada and subsequently abandoned the decision to adopt the “Fidelity Property Group, Inc.” name and discontinued its real estate business.

On October 1, 2012, the shareholders holding a majority of the Company’s voting capital had voted and authorized the Company to (i) change the name of the Company to Marathon Patent Group, Inc. (the “Name Change”) and (ii) effectuate a reverse stock split of the Company’s common stock by a ratio of 3-for-2 (the “Reverse Split”) within one year from the date of approval of the stockholders of the Company.. The Board of Directors approved the Name Change and the Reverse Split on October 1, 2012. The Board of Directors determined the name “Marathon Patent Group, Inc.” better reflected the long-term strategy in exploring other opportunities and the identity of the Company going forward. On February 15, 2013, the Company filed the Certificate of Amendment with the Secretary of State of the State of Nevada in order to effectuate the Name Change.

On May 31, 2013,July 18, 2017, shareholders of record holding a majority of the outstanding voting capital of the Company approved a reverse stock split of the Company’s issued and outstanding common stock by a ratio of not less than one-for-fiveone-for-four and not more than one-for-fifteen at any time prior to April 30, 2014,one-for-twenty-five, with such ratio to be determined by the Board of Directors, in its sole discretion. On June 24, 2013,October 25, 2017, the reverse stock split ratio of one (1) for thirteen (13)four (4) basis was approved by the Board of Directors. On July 18, 2013,October 30, 2017, the Company filed a certificate of amendment to its Amended and Restated Articles of Incorporation with the Secretary of State of the State of Nevada in order to effectuate a reverse stock split of the Company’s issued and outstanding common stock, par value $0.0001 per share on a one (1) for thirteen (13)four (4) basis.

On September 6, 2017, the Board of Directors approved and adopted, subject to shareholder approval on or prior to September 6, 2018, the Company’s 2017 Equity Incentive Plan. The Company’s 2017 Equity Incentive Plan was approved by the shareholders of the Company at a special meeting held on September 29, 2017.

All share and per share values for all periods presented in the accompanying consolidated financial statements arehave been retroactively restated foradjusted to reflect the effect of the reverse stock split.Reverse Split.

On September 16, 2014, the Board of Directors approved and adopted, subject to shareholder approval on or prior to September 16, 2015, the Company’s 2014 Equity Incentive Plan. The Company’s 2014 Equity Incentive Plan was approved by the shareholders of the Company at the annual meeting held on July 31, 2015.

On November 19, 2014, the Board of Directors of the Company declared a stock dividend pursuant to which holders of the Company’s Common Stock as of the close of business of the record date of December 15, 2014 received one additional share of Common Stock at the close of business on December 22, 2014 for each share of Common Stock held by such holders. Throughout this report, all share and per share values for all periods presented in the accompanying consolidated financial statements are retroactively restated for the effect of the stock dividend.

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation and Principles of Consolidation

 

The unauditedaccompanying consolidated condensed financial statements arehave been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). Certain information and disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted accounting principles in the United States of America (“US GAAP”)(U.S. GAAP) have been condensed or omitted pursuant to such rules and present theregulations. These consolidated condensed financial statements of the Company and its wholly-owned subsidiaries. In the preparation of consolidated financial statements of the Company,reflect all intercompany transactions and balances were eliminated. All adjustments (consisting only of normal recurring items)adjustments) which, in the opinion of management, are necessary to present fairly the Company’s consolidated financial position, as of September 30, 2016, the results of operations for the three and nine months ended September 30, 2016 and the cash flows for the nine months ended September 30, 2016 have been included. The results of operations and cash flows of the Company for the nine months ended September 30, 2016periods presented. It is suggested that these consolidated condensed financial statements be read in conjunction with the consolidated financial statements and the notes thereto included in the Company’s most recent Annual Report on Form 10-K. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the full year. Other than where noted, the accounting policies and procedures employed in the preparation of these consolidated financial statements have been derived from the audited consolidated financial statements of the Company for the year ended December 31, 2015, which are contained in Form 10-K as filed with the Securities and Exchange Commission (“SEC”) on March 30, 2016. The consolidated balance sheet as of December 31, 2015 was derived from those financial statements.

 

Cash

6
Table of Contents

 

The Company considers all highly liquid debt instruments and other short-term investments with maturity of three months or less, when purchased, to be cash equivalents.  The Company maintains cash and cash equivalent balances at one financial institution that is insured by the Federal Deposit Insurance Corporation. The Company’s accounts held at this institution, up to a limit of $250,000, are insured by the Federal Deposit Insurance Corporation (“FDIC”). As of September 30, 2016, the Company had bank balances exceeding the FDIC insurance limit. To reduce its risk associated with the failure of such financial institution, the Company evaluates at least annually the rating of the financial institution in which it holds deposits.

Variable Interest Entities

Financial Accounting Standards Board, or FASB, accounting guidance concerning variable interest entities, or VIE, addresses the consolidation of a business enterprise to which the usual condition of consolidation (ownership of a majority voting interest) does not apply. This guidance focuses on controlling financial interests that may be achieved through arrangements that do not involve voting interests. The guidance requires an assessment of who the primary beneficiary is and whether the primary beneficiary should consolidate the VIE. The primary beneficiary is identified as the variable interest holder that has both the power to direct the activities of the variable interest entity that most significantly impacts the entity’s economic performance and the obligation to absorb losses or the right to receive benefits from the entity that could potentially be significant to the variable interest entity. Application of the VIE consolidation requirements may require the exercise of significant judgment by management.

On August 11, 2016, PG Technologies S.a.r.l. (“PG Tech”), a Luxembourg limited liability company jointly owned with a large litgation financing fund, entered into a Patent Funding and Exclusive License Agreement (the “ELA”) to manage the monetization of greater than 10,000 patents in a single industry vertical with a Fortune 50 company. The patents cover all the major global economies including China, France, Germany, the United Kingdom and the United States. The Company determined that the the Company’s ownership interest constitutes a VIE and that the Company is the primary beneficiary because the Company satisfies both the power and benefits criterion pursuant to ASC 810. As a result, the Company will consolidate the VIE within its financial statements.

Use of Estimates and Assumptions

 

The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates made by management include, but are not limited to, estimating the useful lives of patent assets, the assumptions used to calculate fair value of warrants and options granted, goodwill impairment, intangible asset impairment, realization of long-lived assets, deferred income taxes, unrealized tax positions and business combination accounting.

Accounts ReceivableCash

The Company considers all highly liquid debt instruments and other short-term investments with maturity of three months or less, when purchased, to be cash equivalents. The Company maintains cash and cash equivalent balances at one financial institution that is insured by the Federal Deposit Insurance Corporation and restricted cash, held in escrow pursuant to the terms of the Unit Purchase Agreement entered into on August 14, 2017, with another financial institution that is also insured by the Federal Deposit Insurance Corporation. The Company’s accounts held at this institution, up to a limit of $250,000, are insured by the Federal Deposit Insurance Corporation (“FDIC”). As of September 30, 2017, the Company had bank balances exceeding the FDIC insurance limit. To reduce its risk associated with the failure of such financial institution, the Company evaluates at least annually the rating of the financial institution in which it holds deposits.

 

Accounts Receivable

The Company has a policy of reserving for questionable accounts based on its best estimate of the amount of probable credit losses in its existing accounts receivable. The Company periodically reviews its accounts receivable to determine whether an allowance is necessary based on an analysis of past due accounts and other factors that may indicate that the realization of an account may be in doubt. Account balances deemed to be uncollectible are charged to the bad debt expense after all means of collection have been exhausted and the potential for recovery is considered remote. At each of September 30, 20162017 and December 31, 2015,2016, the Company had recorded an allowance for bad debts in the amountsamount of $387,976 and $375,750,$387,976, respectively. Accounts receivable-netreceivable, net at September 30, 20162017 and December 31, 2015,2016, amounted to $81,865$123,630 and $136,842,$95,069, respectively. As of September 30, 2016, there were no accounts receivable related to the issuance of one-time licenses, accounts receivable related to recurring royalties represented approximately 100% of total accounts receivable. As of December 31, 2015, accounts receivable related to one license accounted for approximately 54% of the Company’s total accounts receivable and accounts receivable related to recurring royalties represented 46% of total accounts receivable.

 

Concentration of Revenue and Geographic Area

 

Patent license revenueRevenue from the Company’s patent enforcement activities originates in either theis considered United States or Germany. Revenue attributable to therevenue as any payments for licenses included in that revenue are for United States involves US patents, revenue attributable to Germany is based onoperations irrespective of the enforcementlocation of German patents and in the event that the Company enters into a worldwide license, the revenue is allocated between the two. The Company commenced enforcement actions in France in 2015, but has not yet had any revenue attributable to this country; the Company has not initiated enforcement actions in any other countries, but is evaluating a number of countries for future action.licensee’s or licensee’s parent home domicile.

 

The Company entered into no newhad $0 in revenues from newly issued patent licenses for both the three months ended September 30, 2017 and the three months ended September 30, 2016. The revenue for the three months ended September 30, 2017 is attributable to a non-enforcement technology access license for one of the Company’s subsidiaries and running royalties from the Company’s Medtech portfolio and for the three months ended September 30, 2016, and revenue from the five largest licenses accounting for 87% of the revenue for the three months ended September 30, 2015 as set forth below:

For the Three Months Ended September 30, 2016

 

 

For the Three Months Ended September 30, 2015

 

Licensor

 

License Amount

 

% of Revenue

 

Licensor

 

License Amount

 

% of Revenue

 

 

 

 

 

 

 

Orthophoenix LLC

 

$

2,050,000

 

32%

 

 

 

 

 

 

 

IP Liquidity Ventures, LLC

 

$

1,800,000

 

28%

 

 

 

 

 

 

 

TLI Communications LLC / TLI Cummications GmbH

 

$

800,000

 

13%

 

 

 

 

 

 

 

Clouding Corp.

 

$

500,000

 

8%

 

 

 

 

 

 

 

Signal IP, Inc.

 

$

400,000

 

6%

 

 

Total

 

0%

 

 

 

Total

 

87%

The remainder of the revenue is attributable to smaller licenses and running royalties infrom the Company’s Medtech portfolio.

 

WhileAt the current time, we define customers as firms that obtain licenses to the Company’s patents, either prior to or during enforcement litigation. These firms generally enter into non-recurring, non-exclusive, non-assignable license agreements with the Company, has a growing portfolio of patents,and these customers do not generally engage in ongoing, recurring business activity with the Company. The Company has historically receivedhad a significant portion of its revenue and expects that a significant portion of its future revenues were and will be based on one-time grants of similar non-recurring, non-exclusive, non-assignable licenses to a relatively small number of entities and their affiliates. Further, with the expected small numbercustomers enter into such agreements, resulting in higher levels of firms with which the Company enters into license agreements, and the amount and timing of such license agreements, the Company also expects that its revenues may be highly variable from one period to the next.

In connection with our enforcement activities, we are currently involved in multiple patent infringement cases. As of September 30, 2016, the Company is involved in a total of 21 lawsuits against defendants in the following jurisdictions:revenue concentration.

 

United States

Number of  
Cases

District of Delaware

5

Eastern District of Michigan

1

Central District of California

1

7

Foreign

Table of Contents

Number of 
Cases

Germany

9

France

3

Italy

3

 

Revenue Recognition

 

The Company recognizes revenue in accordance with ASCAccounting Standards Codification (“ASC”) Topic 605, “Revenue Recognition”. Revenue is recognized when (i) persuasive evidence of an arrangement exists, (ii) all obligations have been substantially performed, (iii) amounts are fixed or determinable and (iv) collectability of amounts is reasonably assured. In general, revenue arrangements provide for the payment of contractually determined fees in consideration for the grant of certain intellectual property rights for patented technologies owned or controlled by the Company.

These rights typically include some combination of the following: (i) the grant of a non-exclusive, perpetual license to use patented technologies owned or controlled by the Company, (ii) a covenant-not-to-sue, (iii) the dismissal of any pending litigation.

The intellectual property rights granted typically are perpetual in nature. Pursuant to the terms of these agreements, the Company has no further obligation with respect to the grant of the non-exclusive licenses, covenants-not-to-sue, releases, and other deliverables, including no express or implied obligation on the Company’s part to maintain or upgrade the technology, or provide future support or services. Generally, the agreements provide for the grant of the licenses, covenants-not-to-sue, releases, and other significant deliverables upon execution of the agreement. As such, the earnings process is complete and revenue is recognized upon the execution of the agreement, when collectability is reasonably assured, and when all other revenue recognition criteria have been met.

 

The Company also considers the revenue generated from its settlement and licensing and enforcement activitiesagreements as one unit of accounting under ASC 605-25, “Multiple-Element Arrangements” as the delivered items do not have value to customers on a standalone basis, there are no undelivered elements and there is no general right of return relative to the license. Under ASC 605-25, the appropriate recognition of revenue is determined for the combined deliverables as a single unit of accounting and revenue is recognized upon delivery of the final elements, including the license for past and future use and the release.

 

Also, due to the fact thatsince the settlement element and license element for past and future use are the Company’s major central business, the Company does not presentpresents these two elements as differentone revenue streamscategory in its statement of operations. The Company does not expect to provide licenses that do not provide some form of settlement or release. The Company derived approximately 0% and 99% of its revenuesThere was no revenue from newly issued patent licenses for the three and nine months ended September 30, 2016, respectively, from the one-time issuance of non-recurring, non-exclusive, non-assignable licenses for certain of the Company’s patents, with the balance comprised of recurring royalties2017 and approximately 97% and 94% of its revenues for the three and nine months ended September 30, 2015, respectively, from the one-time issuance of non-recurring, non-exclusive, non-assignable licenses for certain of the Company’s patents, with the balance comprised of recurring royalties.

The Company’s subsidiaries entered into 0 and 11 new license agreements that generated revenue during the three and nine months ended September 30, 2016, respectively.

 

Cost of Revenues

Cost of revenues mainly includes expenses incurred in connection with the Company’s patent enforcement activities, such as legal fees, consulting costs, patent maintenance, royalty fees for acquired patents and other related expenses. Cost of revenues does not include patent amortization expenses, which are included as a separate line item in operating expenses and cost of revenues also does not include expenses related to product development, integration or support, as these are included in general and administrative expenses.

Prepaid Expenses Bonds Posted and Other Current Assets

 

Prepaid expenses and other current assets of $153,388$108,878 and $338,598$202,067 at September 30, 20162017 and December 31, 2015,2016, respectively, consist primarily of costs paid for future services, which will occur within a year. Prepaid expenses include prepayments in cash and equity instruments for public relation services, business advisory, consulting, and prepaid insurance, which are being amortized over the terms of their respective agreements.

 

Bonds Posted with Courts

Under certain circumstances related to litigations in Germany, the Company is either required to or may decide to enter a bond with the courts. As of September 30, 2017 and December 31, 2016, the Company had no outstanding bonds posted with the German courts.

Related Party Transactions

Parties are considered related to the Company if the parties, directly or indirectly, through one or more intermediaries, control, are controlled by, or are under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management and other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. The Company discloses all related party transactions.

On May 13, 2013, we entered into a nine-year advisory services agreement (the “Advisory Services Agreement”) with IP Navigation Group, LLC (“IP Nav”), of which Erich Spangenberg is founder and former Chief Executive Officer. Mr. Spangenberg is an affiliate of the Company. The terms of the Advisory Services Agreement provide that, in consideration for its services as intellectual property licensing agent, the Company will pay to IP Navigation Group, LLC between 10% and 20% of the gross proceeds of certain licensing campaigns in which IP Navigation Group, LLC acts as intellectual property licensing agent.

8
Table of Contents

On November 18, 2013, we entered into a consulting agreement with Jeff Feinberg (“Feinberg Agreement”), pursuant to which we agreed to grant Mr. Feinberg 25,000 shares of our restricted Common Stock, 50% of which shall vest on the one-year anniversary of the Feinberg Agreement and the remaining 50% of which shall vest on the second-year anniversary of the Feinberg Agreement. Mr. Feinberg is the trustee of The Feinberg Family Trust and holds voting and dispositive power over shares held by The Feinberg Family Trust, which is a 10% beneficial owner of our Common Stock.

On May 2, 2014, the Company completed the acquisition of certain ownership rights (the “Acquired Intellectual Property”) from TechDev, Granicus and SFF pursuant to the terms of three purchase agreements between: (i) the Company, TechDev, SFF and DA Acquisition LLC, a newly formed Texas limited liability company and wholly-owned subsidiary of the Company; (ii) the Company, Granicus, SFF and IP Liquidity Ventures Acquisition LLC, a newly formed Delaware limited liability company and wholly-owned subsidiary of the Company; and (iii) the Company, TechDev, SFF and Sarif Biomedical Acquisition LLC, a newly formed Delaware limited liability company and wholly-owned subsidiary of the Company. TechDev, SFF and Granicus are owned or controlled by Erich Spangenberg or family members or associates.

Pursuant to the DA Agreement, the Company acquired 100% of the limited liability company membership interests of Dynamic Advances, LLC, a Texas limited liability company, in consideration for: (i) two cash payments of $2,375,000, one payment due at closing and the other payment was due on or before June 30, 2014, with such second payment being subject to increase to $2,850,000 if not made on or before June 30, 2014; and (ii) 97,750 shares of the Company’s Series B Convertible Preferred Stock. The remaining cash payment was made on April 1, 2015 and is fully paid. Under the terms of the DA Agreement, TechDev and SFF are entitled to possible future payments for a maximum consideration of $250,000,000 pursuant to the Pay Proceeds Agreement described below.
Pursuant to the IP Liquidity Agreement, the Company acquired 100% of the limited liability company membership interests of IP Liquidity Ventures, LLC, a Delaware limited liability company, in consideration for: (i) two cash payments of $2,375,000, one payment due at closing and the other payment was due on or before June 30, 2014, with such second payment being subject to increase to $2,850,000 if not made on or before June 30, 2014; and (ii) 97,750 shares of the Company’s Series B Convertible Preferred Stock. The remaining cash payment was made on April 1, 2015 and is fully paid. Under the terms of the IP Liquidity Agreement, Granicus and SFF are entitled to possible future payments for a maximum consideration of $250,000,000 pursuant to the Pay Proceeds Agreement described below.
Pursuant to the Sarif Agreement, the Company acquired 100% of the limited liability company membership interests of Sarif Biomedical, LLC, a Delaware limited liability company, in consideration for two cash payments of $250,000, one payment due at closing and the other payment was due on or before June 30, 2014, with such second payment being subject to increase to $300,000 if not made on or before June 30, 2014. The remaining cash payment was made on February 24, 2015 and is fully paid. Under the terms of the Sarif Agreement, TechDev and SFF are entitled to possible future payments for a maximum consideration of $250,000,000 pursuant to the Pay Proceeds Agreement described below.
Pursuant to the Pay Proceeds Agreement, the Company may pay the sellers a percentage of the net recoveries (gross revenues minus certain defined expenses) that the Company makes with respect to the assets held by the entities that the Company acquired pursuant to the DA Agreement, the IP Liquidity Agreement and the Sarif Agreement. Under the terms of the Pay Proceeds Agreement, as amended in 2016, if the Company recovers $10,000,000 or less with regard to the IP Assets, then nothing is due to the sellers; if the Company recovers between $13,000,000 and $40,000,000 with regard to the IP Assets, then the Company shall pay 40% of the cumulative gross proceeds of such recoveries to the sellers; and if the Company recovers over $40,000,000 with regard to the IP Assets, the Company shall pay 50% of the cumulative gross proceeds of such recoveries to the sellers. Pursuant to the amendment to the Pay Proceeds Agreement, the Company paid TechDev, Granicus and SFF $2.4 million. In no event will the total payments made by the Company under the Pay Proceeds Agreement exceed $250,000,000.

9
Table of Contents

On May 2, 2014, we entered into an opportunity agreement (the “Marathon Opportunity Agreement”) with Erich Spangenberg, who is an affiliate of the Company. The terms of the Marathon Opportunity Agreement provide that we have ten business days after receiving notice from Mr. Spangenberg to provide up to 50% of the funding for certain opportunities relating to the licensing, intellectual property acquisitions and/or intellectual property enforcement actions in which Mr. Spangenberg, IP Nav or any entity controlled by Mr. Spangenberg, other than: (i) IP Nav or any of its affiliates, and (ii) Medtech Development, LLC or any of its affiliates.

On June 17, 2014, Selene Communication Technologies Acquisition LLC (“Acquisition LLC”), a Delaware limited liability company and newly formed wholly-owned subsidiary of the Company, entered into a merger agreement with Selene Communication Technologies, LLC (“Selene”). Selene owned a patent portfolio consisting of three United States patents in the field of search and network intrusion that relate to tools for intelligent searches applied to data management systems as well as global information networks such as the internet. IP Nav provided patent monetization and support services under an existing agreement with Selene prior to the return of the patents to Stanford Research Institute (“SRI”), the original owners of the patents.

On August 29, 2014, the Company entered into a patent purchase agreement to acquire a portfolio of patents from Clouding IP, LLC for an aggregate purchase price of $2.4 million, of which $1.4 million was paid in cash and $1.0 million was paid in the form of a promissory note issued by the Company that matured on October 31, 2014 and was fully paid prior to the maturation date. The Company also issued 6,250 shares of its restricted common stock in connection with the acquisition. Clouding IP, LLC is also entitled to certain possible future cash payments. Clouding IP LLC is owned or controlled by Erich Spangenberg or family members or associates.

On October 10, 2014, the Company entered into an interest sale agreement with MedTech Development, LLC (“MedTech”) to acquire from MedTech 100% of the limited liability membership interests of OrthoPhoenix and TLIF as well as 100% of the shares of MedTech GmbH. In connection with the transaction, the Company is obligated to pay to MedTech $1 million at closing and $1 million on each of the following nine (9) month anniversary dates of the closing. On July 16, 2015, the Company entered into a forbearance agreement (the “Agreement”) with MedTech Development, the holder of a Promissory Note issued by the Company, dated October 10, 2014. Pursuant to the Agreement, the term of the Note was extended to October 1, 2015 and the Note began accruing interest starting from May 13, 2015. In addition, the Company had outstanding litigation bondsagreed to make certain mandatory prepayments under certain circumstances and issue to MedTech Development 500,000 shares of restricted common stock of the Company. In accordance with ASC 470-50, the Company recorded this agreement as debt extinguishment and $654,000 was recorded as loss on debt extinguishment during the year ended September 30, 2015. On October 23, 2015, the Company entered into Amendment No. 1 to the Forbearance Agreement (the “Amendment”) entered into with MedTech Development on July 16, 2015. Pursuant to the Amendment, the due date of the Promissory Note was extended to October 23, 2016 in return for which the Company made a payment of $100,000 on October 23, 2015 and modified the terms under which the Company agreed to make mandatory prepayments under certain circumstances. The acquired subsidiaries are also obligated to make certain additional payments to MedTech from recoveries following the receipt by the acquired subsidiaries of 200% of the purchase payments, plus recovery of out of pocket expenses in connection with patent claims. The participation payments may be paid, at the election of the Company, in common stock of Marathon at the market price on the date of issuance. In connection with the transaction, the Company entered into a promissory note, common interest agreement and in the amountevent of $980,919issuance of common stock to MedTech, will enter into a lockup and $1,748,311 at September 30,registration rights agreement. Approximately forty-five percent (45%) of MedTech is owned or controlled by Erich Spangenberg or family members or associates.

On October 1, 2016, and December 31, 2015, respectively. These bonds were entered into in Germany after the successful ruling by the court in first instance trials related to someone of the Company’s patents in German courts. The differencesubsidiaries, PG Technologies S.a.r.l. entered into an advisory services agreement with Granicus IP, LLC, an entity owned or controlled by one of the Company’s employees, whereby Granicus receives a percentage of pre-tax return from PG Technologies after certain revenue thresholds have been met.

During 2016, certain officers and directors of the Company received restricted common stock in the balanceCompany’s 3D Nanocolor Corp. (“3D Nano”) subsidiary.

At December 31, 2016, ‘‘Other noncurrent assets’’ in the Balance Sheets consists of a note receivable from an entity controlled by one of the litigation bonds at September 30, 2016 compared to December 31, 2015Company’s employees that is attributable to $175,883 in currency translation impact, the return of $1,944,085 in bonds relateduncollateralized. The note receivable does not carry interest and is repayable to the IP Liquidity and Medtech litigations andCompany at the placingearlier of bonds in Germany related toMarch 31, 2022 or based on certain milestones. The note receivable balance has been classified as current assets because the TLI litigationsCompany believes that it will be collected within one year from the Balance Sheet dates.

10
Table of Contents

On September 29, 2017, the Company entered into an Irrevocable Stock Power whereby the Company sold the shares it owns in the amountCompany’s subsidiary, 3D Nano to Doug Croxall, the Company’s Chief Executive Officer with such assignment including the assumption of $1,000,810.all of 3D Nano’s liabilities. The Company engaged a third party to value the assignment, the results of which were that the valuation and assignment were deemed to be at fair value.

Fair Value of Financial Instruments

 

The Company adopted FASB ASC 820, “Fair Value Measurementsmeasures at fair value certain of its financial and Disclosures” (“ASC 820”), fornon-financial assets and liabilities measured atby using a fair value on a recurring basis. ASC 820 establishes a common definition forhierarchy that prioritizes the inputs to valuation techniques used to measure fair value. Fair value to be applied to existing US GAAP that require the use of fair value measurements, establishes a framework for measuring fair value and expands disclosure about such fair value measurements. The adoption of ASC 820 did not have an impact on the Company’s financial position or operating results, but did expand certain disclosures. ASC 820 defines fair value asis the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Additionally, ASC 820 requiresdate, essentially an exit price, based on the highest and best use of valuation techniques that maximize the useasset or liability. The levels of observable inputs and minimize the use of unobservable inputs. These inputs are prioritized below:fair value hierarchy are:

 

Level 1:

Observable inputs such as quoted market prices in active markets for identical assets or liabilities

Level 2:

Observable market-based inputs or unobservable inputs that are corroborated by market data

Level 3:

Unobservable inputs for which there is little or no market data, which require the use of the reporting entity’s own assumptions.

 

The carrying amounts reported in the consolidated condensed balance sheet for cash, accounts receivable, bonds posted with courts, accounts payable, and accrued expenses, approximate their estimated fair market value based on the short-term maturity of these instruments. The carrying value of notes payable and other long-term liabilities approximates fair value as the related interest rates approximate rates currently available to the Company.

 

As of December 31, 2015, the Company had $4,482,845 in Level 3 goodwill. During the nine months ended September 30, 2016, the Company added $0 in goodwill associated with acquisitions and the Company impaired the goodwill associated with one of its portfolios in the amount of $83,000. In addition, the Company experienced a gain in the value of the goodwill held by foreign subsidiaries to to foreign exchange adjustments in the amount of $83,284.  This resulted in a fair value of the Company’s Level 3 goodwill as of September 30, 2016 of $4,483,129.

Clouding IP earn out liability was determined to beas a Level 3 liability, which requires the remeasurementan assessment of fair value at each period end by using discounted cash flow analysisas a valuation technique using unobservable inputs, such as revenue and expenses forecasts, timing of proceeds, and a discount rate. Based on the remeasurementreassessment of fair value as of September 30, 2016,2017, the Company determined that there was a reduction in the Clouding IP earn out liability was $110,100 for current portion and $1,082,586 for the long-term portion, which resulted in gain from change in fair value of $1,954,368 and $2,122,208 for three and nine months ended September 30, 2016, respectively and a gain from change in fair value adjustment of $597,047 and $2,901,348 forduring the three and nine months ended September 30, 2015,2017 in the amounts of $754,321and $754,321, respectively and a reduction in the carrying value of the Clouding IP intangible assets during the three and nine months ended September 30, 2017 in the amounts of $723,218 and $723,218, respectively.

 

Under certain circumstances relatedThe Company determined that the Warrants issued pursuant to litigationsthe Unit Purchase Agreement should be treated as a Level 2 liability, which determine the value based on observable market-based inputs. in Germany,this instance, the Company is either required to or may decide to enter intoWarrants were valued using a bond with the courts. AsMonte-Carlo simulation utilizing market-based inputs for volatility and risk-free rate of September 30, 2016 and December 31, 2015, the Company had outstanding bondsinterest, which resulted in the amount of $980,919 and $1,748,311, respectively. The Company adjusted the value as of September 30, 2016 of the bonds to reflect changesWarrants issued pursuant to the exchange rate between the EuroAugust 31, 2017 close being fair valued at $0.0364 per share and the US Dollar.Warrants issued pursuant to the September 29, 2017 close being fair valued at $0.0877 per share.

 

Accounting for Acquisitions

 

In the normal course of its business, the Company makes acquisitions of patent assets and may also make acquisitions of businesses. With respect to each such transaction, the Company evaluates facts of the transaction and follows the guidelines prescribed in accordance with ASC 805 — Business Combinations to determine the proper accounting treatment for each such transaction and then records the transaction in accordance with the conclusions reached in such analysis.  Theanalysis.The Company performs such analysis with respect to each material acquisition within the consolidated group of entities.

 

Income Taxes

 

The Company accounts for income taxes pursuant to the provision of ASC 740-10, “Accounting for Income Taxes” which requires, among other things, an asset and liability approach to calculating deferred income taxes. The asset and liability approach requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. A valuation allowance is provided to offset any net deferred tax assets for which management believes it is more likely than not that the net deferred asset will not be realized.

The Company follows the provision of the ASC 740-10 related to Accounting for Uncertain Income Tax Position. When tax returns are filed, it is highly certainmore likely than not that some positions taken would be situatedsustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. In accordance with the guidance of ASC 740-10, the benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is moremost likely that not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions.

 

11
Table of Contents

Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent50% likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above should be reflected as a liability for uncertain tax benefits in the accompanying balance sheet along with any associated interest and penalties that would be payable to the taxing authorities upon examination. The Company believes its tax positions are all highly certain of beingwill more likely than not be upheld upon examination. As such, the Company has not recorded a liability for uncertain tax benefits.

 

The Company has adopted ASC 740-10-25 Definition of Settlement, which provides guidance on how an entity should determine whether a tax position is effectively settled for the purpose of recognizing previously unrecognized tax benefits and provides that a tax position can be effectively settled upon the completion and examination by a taxing authority without being legally extinguished. For a tax position considered effectively settled, an entity would recognize the full amount of tax benefit, even if the tax position is not considered more likely than not to be sustained based solely on the basis of its technical merits and the statute of limitations remains open. The federal and state income tax returns of the Company are subject to examination by the Internal Revenue Service and state taxing authorities, generally for three years after they were filed. The Company is in the process of filing the 20152016 tax returns. After review of the 2015prior year financial statements and the results of operations through September 30,December 31, 2016, the Company has recorded a full valuation allowance on its deferred tax asset in the amount of $11,918,920, from which the Company expects to realize benefits in the future, and a deferred tax liability of $438,709.asset.

 

The Company files U.S. and state income tax returns with varying statutes of limitations. The 2011 through 2015 tax years generally remain subject to examination by federal and state tax authorities.

Basic and Diluted Net Earnings (Loss)Loss per Share

 

Net earnings (loss)loss per common share is calculated in accordance with ASC Topic 260: Earnings Per Share (“ASC 260”). Basic earnings (loss)loss per share is computed by dividing net earnings (loss)loss by the weighted average number of shares of common stock outstanding during the period. The computation of diluted net loss per share does not include dilutive common stock equivalents in the weighted average shares outstanding, as they would be anti-dilutive. The Company has options to purchase 3,665,314613,195 shares of common stock andCommon Stock, warrants to purchase 556,6727,487,894 shares of common stockCommon Stock, Convertible Notes convertible into up to 13,750,000 shares of Common Stock and shares of Series B Convertible Preferred Stock convertible into 195,501 shares of Common Stock outstanding at September 30, 2016, but since2017, which were excluded from the Company is in a loss position, there is no calculationcomputation of diluted earnings (loss) per share.shares outstanding, as they would have had an anti-dilutive impact on the Company’s net loss.

The following table sets forth the computation of basic and diluted earnings (loss)loss per share:

 

 

 

For the Three
Months Ended
September 30,2016

 

For the Three
Months Ended
September 30, 2015

 

For the Nine Months
Ended September 30,
2016

 

For the Nine Months
Ended September 30,
2015

Net income (loss) attributable to Marathon Patent Group, Inc. common shareholders

 

(6,274,410)

 

(3,750,468)

 

(2,261,542)

 

(13,034,736)

 

 

 

 

 

 

 

 

 

Denominator

 

 

 

 

 

 

 

 

Weighted Average Common Shares - Basic and Diluted

 

15,047,141

 

14,376,118

 

14,944,852

 

14,094,891

 

 

 

 

 

 

 

 

 

Earnings (Loss) per common share:

 

 

 

 

 

 

 

 

Income (Loss) - Basic and Diluted

 

$

(0.42)

 

$

(0.26)

 

$

(0.15)

 

$

(0.92)

  

For the Three Months Ended

September 30, 2017

  

For the Three Months Ended

September 30, 2016

  

For the Nine Months
Ended

September 30, 2017

  

For the Nine Months
Ended

September 30, 2016

 
Net income (loss) attributable to Common shareholders $(6,677,485) $(6,274,410) $(12,484,924) $(2,261,542)
                 
Denominator                
Weighted average common shares – Basic and Diluted  6,270,299   3,761,786   5,564,465   3,736,213 
                 
Earnings (loss) per common share:                
Earnings (loss) – Basic and Diluted $(1.06) $(1.67) $(2.24) $(0.60)

 

Intangible Assets - Patents

 

Intangible assets include patents purchased and patents acquired in lieu of cash in licensing transactions. The patents purchased are recorded based on the cost to acquire them and patents acquired in lieu of cash are recorded at their fair market value. The costs of these assets are amortized over their remaining useful lives. Useful lives of intangible assets are periodically evaluated for reasonableness and the assets are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may no longer be recoverable. The Company recorded impairment charges to its intangible assets during the three and nine months ended September 30, 20162017 in the amountsamount of $5,531,383$723,218 and 6,525,273$723,218, respectively, compared to impairment charges associated with the end of life of a number of the Company’s portfolios compared to an impairment charge in the amount of $0 and $766,498, respectively, during the three and nine months ended September 30, 2015 associated with the reduction2016 in the carrying valueamounts of one the Company’s portfolios.$5,531,383 and $6,525,273, respectively.

 

12
Table of Contents

Goodwill

 

Goodwill is tested for impairment at the reporting unit level at least annually in accordance with ASC 350, and between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying value. In accordance with ASC 350-30-65, “Intangibles - Goodwill and Others”, the Company assesses the impairment of identifiable intangibles whenever events or changes in circumstances indicate that the carrying value may not be recoverable. Factors the Company considers to be important which could trigger an impairment review include the following:

 

1.                   Significant underperformance relative to expected historical or projected future operating results;

2.                   Significant changes in the manner of use of the acquired assets or the strategy for the overall business;

3.                   Significant negative industry or economic trends; and

4.                   Significant reduction or exhaustion of the potential licenses of the patents which gave rise to the goodwill.

When the Company determines that the carrying value of intangibles may not be recoverable based upon the existence of one or more of the above indicators of impairment and the carrying value of the asset cannot be recovered from projected undiscounted cash flows, the Company records an impairment charge. The Company measures any impairment based on a projected discounted cash flow method using a discount rate determined by management to be commensurate with the risk inherent in the current business model. When conducting its annual goodwill impairment assessment, the Company initially performs a qualitative evaluation of whether it is more likely than not that goodwill is impaired. If it is determined by a qualitative evaluation that it is more likely than not that goodwill is impaired, the Company then applies a two-step impairment test. The two-step impairment test first compares the fair value of the Company’s reporting unit to its carrying or book value. If the fair value of the reporting unit exceeds its carrying value, goodwill is not impaired and the Company is not required to perform further testing.impaired. If the carrying value of the reporting unit exceeds its fair value, the Company determines the implied fair value of the reporting unit’s goodwill and if the carrying value of the reporting unit’s goodwill exceeds its implied fair value, then an impairment loss equal to the difference is recorded in the consolidated condensed statement of operations. The Company performedperforms the annual testing for impairment of goodwill at the reporting unit level during the quarter ended September 30, 2016.30.

 

For the three and nine months ended September 30, 2017 the Company recorded no impairment charge to its goodwill and for the three and nine months ended September 30, 2016, the Company recorded an impairment charge to its goodwill in the amount of $0 and $83,000, respectively.

Other Intangible Assets

In accordance with ASC 350-30, “Intangibles - Goodwill and Others”, the Company assesses the impairment of identifiable intangibles whenever events or changes in circumstances indicate that the carrying value may not be recoverable. Factors the Company considers to be important which could trigger an impairment review include the following: (1) significant underperformance relative to expected historical or projected future operating results; (2) significant changes in the manner of use of the acquired assets or the strategy for the overall business; and (3) significant negative industry or economic trends.

When the Company determines that the carrying value of intangibles may not be recoverable based upon the existence of one or more of the above indicators of impairment and the carrying value of the asset cannot be recovered from projected undiscounted cash flows, the Company records an impairment charge. The Company measures any impairment based on a projected discounted cash flow method using a discount rate determined by management to be commensurate with the risk inherent in the current business model.

For the three and nine months ended September 30, 20152017 and September 30, 2016, the Company recorded anno impairment charge to its goodwill in the amount of $0 and $0, respectively. The impairment charge to goodwill for the three and nine months ended September 30, 2016 resulted from the determination that one or the Company’s portfolios had reached the end of its useful life.other intangible assets.

Impairment of Long-lived Assets

 

The Company accounts for the impairment or disposal of long-lived assets according to the ASC 360 “Property, Plant and Equipment”. The Company continually monitors events and changes in circumstances that could indicate that the carrying amounts of long-lived assets may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated future net undiscounted cash flows expected to be generated by the asset. When necessary, impaired assets are written down to estimated fair value based on the best information available. Estimated fair value is generally based on either appraised value or measured by discounting estimated future cash flows. Considerable management judgment is necessary to estimate discounted future cash flows. Accordingly, actual results could vary significantly from such estimates. The Company recognizes an impairment loss when the sum of expected undiscounted future cash flows is less than the carrying amount of the asset.

 

The Company did not record any impairment charges on its long-lived assets during the three and nine months ended September 30, 2017 and September 30, 2016.

Stock-based Compensation

 

Stock-based compensation is accounted for based on the requirements of the Share-Based Payment Topic of ASC 718 which requires recognition in the consolidated financial statements of the cost of employee and director services received in exchange for an award of equity instruments over the period the employee or director is required to perform the services in exchange for the award (presumptively, the vesting period). The ASC also requires measurement of the cost of employee and director services received in exchange for an award based on the grant-date fair value of the award. As stock-based compensation expense is recognized based on awards expected to vest, forfeitures are also estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.

13
Table of Contents

For the three and nine months ended September 30, 2017, the expected forfeiture rate was 12.75%, which resulted in an expense of $60,115 and $108,748, for the three and nine months ended September 30, 2017, respectively, recognized in the Company’s compensation expenses. For the three and nine months ended September 30, 2016, the expected forfeiture rate was 11.03%, which resulted in an expense of $9,570 and $36,832 for the three and nine months ended September 30, 2016, respectively, recognized in the Company’s compensation expenses. The Company will continue to re-assess the impact of forfeitures if actual forfeitures increase in future quarters.

 

Pursuant to ASC Topic 505-50, for share-based payments to consultants and other third-parties,third parties, compensation expense is determined at the “measurement date.” The expense is recognized over the vesting period of the award. Until the measurement date is reached, the total amount of compensation expense remains uncertain. The Company initially records compensation expense based on the fair value of the award at the reporting date. As stock-based compensation expense is recognized based on awards expected to vest, forfeitures are also estimated at the time of grant

Liquidity and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. For both the three and nine months endedCapital Resources

At September 30, 2016, the expected forfeiture rate was 11.03%, which resulted2017, we had approximately $0.1 million in unrestricted cash and cash equivalents, $3.9 million in restricted cash and an expenseunrestricted working capital deficit of $9,570 and $36,832 for the three and nine months ended September 30, 2016, respectively, recognized inapproximately $20.3 million.

Based on the Company’s compensation expenses. For both the threecurrent revenue and nine months ended September 30, 2015, the expected forfeiture rate was 11.66%, which resulted in an expense of $8,423 and $16,004 for the three and nine months ended September 30, 2015, respectively, recognized inprofit projections, management is uncertain that the Company’s compensation expenses.existing cash and accounts receivables will be sufficient to fund its operations through at least the next twelve months from the issuance date of the financial statements, raising substantial doubt regarding the Company’s ability to continue operating as a going concern. If we do not meet our revenue and profit projections or the business climate turns negative, then we will need to:

raise additional funds to support the Company’s operations; provided, however, there is no assurance that the Company will be able to raise such additional funds on acceptable terms, if at all. If the Company raises additional funds by issuing securities, existing stockholders may be diluted; and
 review strategic alternatives.

If adequate funds are not available, we may be required to curtail our operations or other business activities or obtain funds through arrangements with strategic partners or others that may require us to relinquish rights to certain technologies or potential markets. The accompanying consolidated condensed financial statements have been prepared assuming the Company will continue to re-assessoperate as a going concern, which contemplates the impactrealization of forfeitures if actual forfeitures changeassets and settlements of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future quarters.effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from uncertainty related to the Company’s ability to continue as a going concern

 

Reclassification

Certain amounts in the financial statements of prior year have been reclassified to conform to the fiscal 2016 presentation, with no effect on net earnings.

Recent Accounting Pronouncements

In July 2017, the FASB issued ASU 2017-11, “Earnings Per Share (Topic 260) Distinguishing Liabilities from Equity (Topic 480) Derivatives and Hedging (Topic 815),” which addresses the complexity of accounting for certain financial instruments with down round features. Down round features are features of certain equity-linked instruments (or embedded features) that result in the strike price being reduced on the basis of the pricing of future equity offerings. Current accounting guidance creates cost and complexity for entities that issue financial instruments (such as warrants and convertible instruments) with down round features that require fair value measurement of the entire instrument or conversion option. For public business entities, the amendments in Part I of this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018 with early adoption permitted.

 

In August 2016,May 2017, the FASB issued ASU No. 2017-09,Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting. This ASU provides clarity about which changes to the terms or conditions of a share-based payment award require the application of modification accounting. Specifically, ASU 2017-09 clarifies that changes to the terms or conditions of an award should be accounted for as a modification unless all of the following are met: 1) the fair value of the modified award is the same as the fair value of the original award immediately before the original award is modified, 2) the vesting conditions of the modified award are the same as the vesting conditions of the original award immediately before the original award is modified and 3) the classification of the modified award as an equity instrument or a liability instrument is the same as the classification of the original award immediately before the original award is modified. ASU 2017-09 is effective for annual reporting periods beginning after December 15, 2017 and early adoption is permitted. The Company does not expect the adoption of ASU 2017-09 to significantly impact its accounting for share-based payment awards, as changes to awards’ terms and conditions subsequent to the grant date are unusual and infrequent in nature.

14
Table of Contents

In January 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-152017-04Intangibles—Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment (“ASU 2017-04”). This guidance removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation. Under the amended guidance, a goodwill impairment charge will now be recognized for the amount by which the carrying value of a reporting unit exceeds its fair value, not to exceed the carrying amount of goodwill. This guidance is effective for interim and annual period beginning after December 15, 2019, with early adoption permitted for any impairment tests performed after January 1, 2017.

In January 2017, the FASB issued ASU 2017-01Business Combinations (Topic 805): Clarifying the Definition of a Business (“ASU 2017-01”), which clarifies the definition of a business and assists entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. Under this guidance, when substantially all of the fair value of gross assets acquired is concentrated in a single asset (or group of similar assets), the assets acquired would not represent a business. In addition, in order to be considered a business, an acquisition would have to include at a minimum an input and a substantive process that together significantly contribute to the ability to create an output. The amended guidance also narrows the definition of outputs by more closely aligning it with how outputs are described in FASB guidance for revenue recognition. This guidance is effective for interim and annual periods beginning after December 15, 2017, with early adoption permitted.

In November 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) No.2016-18, Statement of Cash Flows (Topic 230): Restricted Cash (a consensus of the FASB Emerging Issues Task Force), which addresses classification and presentation of changes in restricted cash on the statement of cash flows. The standard requires an entity’s reconciliation of the beginning-of-period and end-of-period total amounts shown on the statement of cash flows to include in cash and cash equivalents amounts generally described as restricted cash and restricted cash equivalents. The ASU does not define restricted cash or restricted cash equivalents, but an entity will need to disclose the nature of the restrictions. The ASU is effective for public business entities for annual and interim periods in fiscal years beginning after December 15, 2017. Early adoption is permitted, including adoption in an interim period.

In October 2016, the FASB issued ASU 2016-16Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory (“ASU 2016-16”), which eliminates the exception in existing guidance which defers the recognition of the tax effects of intra-entity asset transfers other than inventory until the transferred asset is sold to a third party. Rather, the amended guidance requires an entity to recognize the income tax consequences of an intra-entity transfer of an asset other than inventory when the transfer occurs. This guidance is effective for interim and annual periods beginning after December 15, 2017, with early adoption permitted as of the beginning of an annual reporting period. The Company is currently assessing the impact of this guidance on its consolidated condensed financial statements.

In August 2016, the FASB issued ASU 2016-15Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments(“ASU 2016-15”). The standard is intended to eliminate diversity in practice in how certain cash receipts and cash payments are presented and classified in the statement of cash flows. ASU 2016-15 will be effective for fiscal years beginning after December 15, 2017. Early adoption is permitted for all entities. The Company is currently evaluating the impact of this guidance on its consolidated condensed financial statements.

 

In March 2016,May 2014, the FASB Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers, as a new Topic, (ASC) Topic 606. The new revenue recognition standard provides a five-step analysis of transactions to determine when and how revenue is recognized. The core principle is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In August 2015, the FASB issued ASU No. 2016-09, “Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting” (“ASU 2016-09”). The standard is intended to simplify several areas of accounting for share-based compensation arrangements, including the income tax impact, classification on the statement of cash flows and forfeitures. ASU 2016-09 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2016, and early adoption is permitted. Accordingly, the standard is effective for us on September 1, 2017 and we are currently evaluating the impact that the standard will have on our consolidated financial statements.

In March 2016, the FASB issued ASU 2016-07, “Simplifying the Transition to the Equity Method of Accounting.” The amendments inthe ASU eliminate the requirement that when an investment qualifies for use2015-14, Revenue from Contracts with Customers: Deferral of the equity method as a result of an increase inEffective Date, which deferred the level of ownership interest or degree of influence, an investor must adjust the investment, results of operations, and retained earnings retroactively on a step-by-step basis as if the equity method had been in effect during all previous periods that the investment had been held. The amendments require that the equity method investor add the cost of acquiring the additional interest in the investee to the current basiseffective date of the investor’s previously held interest and adopt the equity method of accounting as of the date the investment becomes qualifiednew revenue standard for equity method accounting. Therefore, upon qualifying for the equity method of accounting, no retroactive adjustment of the investment is required. This ASU is effective for annual reporting periods beginning after December 15, 2016 and interim periods within those years and shouldto December 15, 2017, with early adoption permitted but not earlier than the original effective date. This ASU must be applied prospectively uponretrospectively to each period presented or as a cumulative-effect adjustment as of the effective date. Earlydate of adoption. We are considering the alternatives of adoption is permitted. The Company is currently evaluating the provisions of this guidance.ASU and we are conducting our review of the likely impact to the existing portfolio of customer contracts entered into prior to adoption. After completing our review, we will continue to evaluate the effect of adopting this guidance upon our results of operations, cash flows and financial position.

15
Table of Contents

 

In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842)” (“ASU 2016-02”). The standard requires a lessee to recognize assets and liabilities on the balance sheet for leases with lease terms greater than 12 months. ASU 2016-02 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018, and early adoption is permitted. Accordingly, the standard is effective for us on September 1, 2019 using a modified retrospective approach. We are currently evaluating the impact that the standard will have on our consolidated condensed financial statements.

In November 2015, the FASB issued ASU 2015-17, Balance Sheet Classification of Deferred Taxes.  This update requires an entity to classify deferred tax liabilities and assets as noncurrent within a classified statement of financial position.  ASU 2015-17 is effective for annual and interim reporting periods beginning after December 15, 2016.  This update may be applied either prospectively to all deferred tax liabilities and assets or retrospectively to all periods presented.  Early application is permitted as of the beginning of the interim or annual reporting period.  The Company adopted this standard for the annual period ending December 31, 2015.  The effect of adopting the new guidance on the balance sheet was not significant.

In September 2015, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update No. 2015-16, Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments, or ASU 2015-16. This amendment requires the acquirer in a business combination to recognize in the reporting period in which adjustment amounts are determined, any adjustments to provisional amounts that are identified during the measurement period, calculated as if the accounting had been completed at the acquisition date. Prior to the issuance of ASU 2015-16, an acquirer was required to restate prior period financial statements as of the acquisition date for adjustments to provisional amounts.  The new standard for an annual reporting period beginning after December 15, 2017 with an earlier effective application is permitted only as of annual reporting periods beginning after December 15, 2016.  The new guidance is not expected to have significant impact on the Company’s consolidated financial statements.

In April 2015, the FASB issued ASU 2015-05, Intangibles-Goodwill and Other — Internal-Use Software; Customer’s Accounting for Fees Paid in a Cloud Computing Arrangement. Prior to this ASU, U.S. GAAP did not include explicit guidance about a customer’s accounting for fees paid in a cloud computing arrangement. Examples of cloud computing arrangements include software as a service, platform as a service, infrastructure as a service, and other similar hosting arrangements. This ASU provides guidance to customers about whether a cloud computing arrangement includes a software license, in which case the customer should account for such license consistent with the acquisitions of other software licenses. If the cloud computing arrangement does not include a software license, the customer should account for the arrangement as a service contract. The ASU does not change the accounting for service contracts. The new standard is effective for us on January 1, 2016 with early adoption permitted. We do not expect the adoption of ASU 2015-05 to have a significant impact on our consolidated financial statements.

In April 2015, the FASB issued new guidance on the presentation of debt issuance costs (ASU 2015-03, Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs), effective for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years and should be applied retrospectively to all periods presented. Early adoption of the new guidance is permitted for financial statements that have not been previously issued. The new guidance will require that debt issuance costs be presented in the balance sheet as a direct deduction from the related debt liability rather than as an asset, consistent with debt discounts.  The Company adopted ASU 2015-03 and as such, the debt issuance costs for Fortress note was presented in the balance sheet as direct deduction from the related debt liability.

In August 2014, the FASB issued Accounting Standards Update No. 2014-15, Disclosure of Uncertainties About an Entity’s Ability to Continue as a Going Concern. This standard update provides guidance around management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote disclosures. The new guidance is effective for all annual and interim periods ending after December 15, 2016. The new guidance is not expected to have a significant impact on the Company’s consolidated financial statements.

In May 2014, the Financial Accountings Standards Board (“FASB”) issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers, or ASU 2014-09, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The standard will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective and shall take effective on January 1, 2017. The standard permits the use of either the retrospective or cumulative effect transition method and the early application of the standard is not permitted. The Company is presently evaluating the effect that ASU 2014-09 will have on its consolidated financial statements and related disclosures and has not yet selected a transition method.

 

There were other updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to have a material impact on the Company’s financial position, results of operations or cash flows.

NOTE 3 — ACQUISITIONS

 

HISTORICAL ACQUSITIONS

Dynamic Advances, IP Liquidity and Sarif Biomedical

On May 2, 2014, the Company completed the acquisition of certain ownership rights (the “Acquired Intellectual Property”) from TechDev, Granicus IP, LLC (“Granicus”) and the Spangenberg Family Foundation (“SFF”) pursuant to the terms of three purchase agreements between: (i) the Company, TechDev, SFF and DA Acquisition LLC, a newly formed Texas limited liability company and wholly-owned subsidiary of the Company; (ii) the Company, Granicus, SFF and IP Liquidity Ventures Acquisition LLC, a newly formed Delaware limited liability company and wholly-owned subsidiary of the Company; and (iii) the Company, TechDev, SFF and Sarif Biomedical Acquisition LLC “(Sarif”), a newly formed Delaware limited liability company and wholly-owned subsidiary of the Company (the “DA Agreement,” the “IP Liquidity Agreement” and the “Sarif Agreement,” respectively and the collective transactions, the “Acquisitions”).

Dynamic Advances

Pursuant to the DA Agreement, the Company acquired 100% of the limited liability company membership interests of Dynamic Advances, LLC, a Texas limited liability company, in consideration for: (i) two cash payments of $2,375,000, one payment due at closing and the other payment due on or before September 30, 2014, with such second payment being subject to increase to $2,850,000 if not made on or before June 30, 2014; and (ii) 195,500 shares of the Company’s Series B Convertible Preferred Stock. Under the terms of the DA Agreement, TechDev and SFF are entitled to possible future payments for a maximum consideration of $250,000,000 pursuant to the Pay Proceeds Agreement described below. Dynamic Advances holds exclusive license to monetize certain patents owned by a third party.

On May 2, 2014, the Company issued TechDev and SFF a promissory note in order to evidence the second cash payment due under the terms of the DA Agreement in the amount of $2,375,000 due on or before September 30, 2014, with such amount due under the terms of the promissory note being subject to increase to $2,850,000 if the Company’s payment pursuant to the terms of the DA Agreement were not made on or before June 30, 2014. The promissory note matured on September 30, 2014; effective September 30, 2014, TechDev and SFF extended the maturity to March 31, 2015 in return for a payment of $249,375, payable within thirty days. The payment for this extension of the maturity date was made on October 10, 2014 and the promissory note was repaid on April 1, 2015. The promissory note did not otherwise include any interest payable by the Company. Since the Company did not make the payment on the promissory note prior to June 30, 2014, the Company included in the consideration paid for Dynamic Advances the promissory note balance of $2,850,000.  Further, the Company had the Series B Convertible Preferred Stock valued by a third party firm that determined, based on the rights and privileges of the Series B Convertible Preferred Stock, that it was on par with the value of the Company’s Common Stock. The total amount of consideration paid by the Company for Dynamic Advances, including capitalized costs associated with the purchase, was $6,653,078.

After evaluating the facts and circumstances of the purchase, the Company determined that this was an asset purchase. In coming to its conclusion, the Company reviewed the status of the assets, the historical activity and the absence of any employees, licenses, revenues, and any other assets other than the IP Assets.  Further, as there were no assumed licensees or historical revenues, the Company was not certain that it would be able to obtain access to customers pursuant to AC 805-10-55-7.

IP Liquidity

Pursuant to the IP Liquidity Agreement, the Company acquired 100% of the limited liability company membership interests of IP Liquidity Ventures, LLC, a Delaware limited liability company, in consideration for: (i) two cash payments of $2,375,000, one payment due at closing and the other payment due on or before September 30, 2014, with such second payment being subject to increase to $2,850,000 if not made on or before June 30, 2014; and (ii) 195,500 shares of the Company’s Series B Convertible Preferred Stock.  Under the terms of the IP Liquidity Agreement, Granicus and SFF are entitled to possible future payments for a maximum consideration of $250,000,000 pursuant to the Pay Proceeds Agreement described below.  IP Liquidity Ventures, LLC holds contract rights to the proceeds from the monetization of certain patents owned by a number of third parties.

On May 2, 2014, the Company issued Granicus and SFF a promissory note in order to evidence the second cash payment due under the terms of the IP Liquidity Agreement in the amount of $2,375,000 due on or before September 30, 2014, with such amount due under the terms of the promissory note being subject to increase to $2,850,000 if the Company’s payment pursuant to the terms of the IP Liquidity Agreement were not made on or before June 30, 2014. The promissory note matured on September 30, 2014; effective September 30, 2014, Granicus and SFF extended the maturity to March 31, 2015 in return for a payment of $249,375, payable within thirty days. The payment for this extension of the maturity date was made on October 10, 2014 and the promissory note was repaid on April 1, 2015. The promissory note did not otherwise include any interest payable by the Company. Since the Company did not make the payment on the promissory note prior to June 30, 2014, the Company included in the consideration paid for IP Liquidity the promissory note balance of $2,850,000.  Further, the Company had the Series B Convertible Preferred Stock valued by a third party firm that determined, based on the rights and privileges of the Series B Convertible Preferred Stock that it was on par with the value of the Company’s Common Stock. The total amount of consideration paid by the Company for IP Liquidity, including capitalized costs associated with the purchase, was $6,653,078.

After evaluating the facts and circumstances of the purchase, the Company determined that this was an asset purchase. In coming to its conclusion, the Company reviewed the status of the assets, the historical activity and the absence of any employees, licenses, revenues, and any other assets other than the IP Assets.  Further, as there were no assumed licensees or historical revenues, the Company was not certain that it would be able to obtain access to customers pursuant to AC 805-10-55-7.

Sarif Biomedical

Pursuant to the Sarif Agreement, the Company acquired 100% of the limited liability company membership interests of Sarif, a Delaware limited liability company, in consideration for two cash payments of $250,000, one payment due at closing and the other payment due on or before September 30, 2014, with such second payment being subject to increase to $300,000 if not made on or before June 30, 2014.  Under the terms of the Sarif Agreement, TechDev is entitled to possible future payments for a maximum consideration of $250,000,000 pursuant to the Pay Proceeds Agreement described below. Sarif holds ownership rights to certain patents.

On May 2, 2014, the Company issued TechDev a promissory note in order to evidence the second cash payment due under the terms of the Sarif Agreement in the amount of $250,000 due on or before September 30, 2014, with such amount due under the terms of the promissory note being subject to increase to $300,000 if the Company’s payment pursuant to the terms of the Sarif Agreement were not made on or before September 30, 2014. The promissory note matured on September 30, 2014. Effective September 30, 2014, TechDev extended the maturity to March 31, 2015 in return for a payment of $26,250, payable within thirty days. The payment for this extension of the maturity date was made on October 10, 2014 and the promissory note was repaid on February 24, 2015. The promissory note did not otherwise include any interest payable by the Company. Since the Company did not make the payment on the promissory note prior to June 30, 2014, the Company included in the consideration paid for Dynamic Advances the higher principal amount of the promissory note. The total amount of consideration paid by the Company for Sarif, including capitalized costs associated with the purchase, was $552,024.

After evaluating the facts and circumstances of the purchase, the Company determined that this was an asset purchase. In coming to its conclusion, the Company reviewed the status of the assets, the historical activity and the absence of any employees, licenses, revenues, and any other assets other than the IP Assets. Further, as there were no assumed licensees or historical revenues, the Company was not certain that it would be able to obtain access to customers pursuant to AC 805-10-55-7.

Dynamic Advances, IP Liquidity and Sarif Biomedical

Pursuant to the Pay Proceeds Agreement, the Company may pay the sellers a percentage of the net recoveries (gross revenues minus certain defined expenses) that the Company makes with respect to the assets held by the entities that the Company acquired pursuant to the DA Agreement, the IP Liquidity Agreement and the Sarif Agreement (the “IP Assets”).  Under the terms of the Pay Proceeds Agreement, if the Company recovers $10,000,000 or less with regard to the IP Assets, then nothing is due to the sellers; if the Company recovers between $10,000,000 and $40,000,000 with regard to the IP Assets, then the Company shall pay 40% of the net proceeds of such recoveries to the sellers; and if the Company recovers over $40,000,000 with regard to the IP Assets, the Company shall pay 50% of the net proceeds of such recoveries to the sellers.  In no event will the total payments made by the Company under the Pay Proceeds Agreement exceed $250,000,000.

Pursuant to a Registration Rights Agreement with the sellers (the “Acquisition Registration Rights Agreement”), the Company agreed to file a “resale” registration statement with the SEC covering at least 10% of the registrable shares of the Company’s Series B Convertible Preferred Stock issued to the sellers under the terms of the DA Agreement and the IP Liquidity Agreement, at any time on or after November 2, 2014 upon receipt of a written demand from the sellers which describes the amount and type of securities to be included in the registration and the intended method of distribution thereof.  The Company shall not be required to file more than three such registration statements not more than 60 days after the receipt of each such written demand from the sellers.

TechDev and Mr. Erich Spangenberg (the founder of IP Nav) and his spouse Audrey Spangenberg have jointly filed a Schedule 13G and are deemed to be affiliates of the Company.

Selene Communication Technologies

On June 17, 2014, Selene Communication Technologies Acquisition LLC (“Acquisition LLC”), a Delaware limited liability company and newly formed wholly owned subsidiary of the Company, entered into a merger agreement (the “Selene Interests Sale Agreement”) with Selene Communication Technologies, LLC (“Selene”).

Selene owns a patent portfolio consisting of three United States patents in the field of search and network intrusion that relate to tools for intelligent searches applied to data management systems as well as global information networks such as the internet. IP Nav will continue to support and manage the portfolio of patents and retain a contingent participation interest in all recoveries.  IP Nav provides patent monetization and support services under an existing agreement with Selene.

Pursuant to the terms of the Selene Interests Sale Agreement, Selene merged with and into Acquisition LLC with Selene surviving the merger as the wholly owned subsidiary of the Company.  The Company (i) issued 100,000 shares of common stock to the sellers of Selene (“Selene Sellers”) and (ii) paid the Selene Sellers $50,000 cash.  The Company valued these common shares at the fair market value on the date of grant at $9.80 per share or $980,000. The transaction resulted in a business combination and caused Selene to become a wholly-owned subsidiary of the Company.

The Company accounted for the acquisition as a business combination in accordance with ASC 805 “Business Combinations” in which the Company is the acquirer for accounting purposes and Selene is the acquired company.  The Company engaged a third party valuation firm to determine the fair value of the assets purchases, and the net purchase price paid by the Company was subsequently allocated to assets acquired and liabilities assumed on the records of the Company as follows:

Intangible assets

 

$

990,000

 

Net working capital

 

37,000

 

Goodwill

 

3,000

 

Net purchase price

 

$

1,030,000

 

Clouding Corp.

 

On August 29, 2014, the Company entered into a patent purchase agreement (the “Clouding Agreement”) between Clouding Corp., a Delaware corporation and a wholly-owned subsidiary of the Company (“Clouding”) and Clouding IP, LLC, a Delaware limited liability company (“Clouding IP”), pursuant to which Clouding acquired a portfolio of patents from Clouding IP. The Clouding owns patents relatedAgreement included an earn out payable to network and data management technology.

The Company paid Clouding IP, (i) $1.4 million in cash, (ii) $1.0 million in the form of a promissory note issued by the Company that would have matured on October 31, 2014, (iii) 25,000 shares of its restricted common stock valued at $281,000 and (iv) fifty percent (50%) of the net recoveries (gross revenues minus certain defined expenses) in excess of $4.0 million in net revenues that the Company makes with respect to the patents purchased from Clouding IP. The Company valued the Common Stock at the fair market value on the date of the Clouding Agreement at $11.24 per share or $281,000 and the promissory note was paid in full prior to October 31, 2014. The revenue share under item (iv) abovewhich was booked as an earn out liability on the balance sheet in accordance with the appraisal of the consideration and intangible value.

The Company booked a payable to the sellers pursuant to theClouding IP earn out liability inwas determined to be a Level 3 liability, which requires assessment of fair value at each period end by using a discounted cash flow model as the amountvaluation methodology, using unobservable inputs, such as revenue and expenses forecasts, timing of $2,148,000 atproceeds, and discount rates. Based on the reassessment of fair value as of September 30, 2014, based on license agreements entered into during the quarter. No further amount is owed until2017, the Company generates additional revenue, if any, fromdetermined the Clouding patents.IP earn out liability to be $32,637 (current portion) and $681,175 (long-term portion) and as of December 31, 2016, the Company determined the Clouding IP earn out liability to be $81,930 (current portion) and $1,400,082 (long-term portion).

 

The Company accounted for the acquisition as a business combination in accordance with ASC 805 “Business Combinations”. The Company engaged a third party valuation firm to determine the fair value of the assets purchases, and the net purchase price paid by the Company was subsequently allocated to assets acquired and liabilities assumed on the records of the Company as follows:

Intangible assets

 

$

14,500,000

 

Goodwill

 

1,296,000

 

Net purchase price

 

$

15,796,000

 

Total consideration paid of the following:

Cash

 

$

1,400,000

 

Promissory Note

 

1,000,000

 

Common Stock

 

281,000

 

Earn Out Liability

 

13,115,000

 

Net purchase price

 

$

15,796,000

 

Historical financial statements of CloudingMunitech IP and the pro forma condensed combined consolidated financial statements (both carve-out of certain operations of Clouding IP) can be found on the Form 8-K/A filed with the SEC on November 12, 2014.  The unaudited pro forma condensed combined consolidated financial statements are not necessarily indicative of the results that actually would have been attained if the merger had been in effect on the dates indicated or which may be attained in the future. Such statements should be read in conjunction with the historical financial statements of the Company.

TLI Communications LLCS.a.r.l. (“Munitech”)

On September 19, 2014, TLI Acquisition Corp (“TLIA”), a Virginia corporation and newly formed wholly-owned subsidiary of the Company, entered into an interest sale agreement to purchase 100% of the membership interests of TLI Communications LLC (“TLIC”), a Delaware limited liability company (the “TLIC Interests Sale Agreement”). TLIC owns a patent in the telecommunications field.

Pursuant to the terms of the TLIC Interests Sale Agreement, TLIC merged with and into TLIA with TLIC surviving the merger as the wholly-owned subsidiary of the Company.  The Company (i) agreed to issue 60,000 shares of Common Stock to the sellers of TLIC (“TLIC Sellers”), (ii) paid the TLIC Sellers $350,000 cash and (iii) agreed to pay the TLIC Sellers a fifty percent (50%) of the net recoveries (gross revenues minus certain defined expenses and the cash portion of the acquisition consideration) that the Company makes with respect to the patent purchased pursuant to the acquisition of TLIC.  The Company valued the Common Stock at the fair market value on the date of the TLIC Interests Sale Agreement at $13.63 per share or $818,000. The cash portion of the consideration was outstanding at September 30, 2014 and was subsequently paid in October 2014. The transaction resulted in a business combination and caused TIC to become a wholly-owned subsidiary of the Company.

The Company accounted for the acquisition as a business combination in accordance with ASC 805 “Business Combinations”. The Company is the acquirer for accounting purposes and TLIC is the acquired company.  The Company engaged a third party valuation firm to determine the fair value of the assets purchases, and the net purchase price paid by the Company was subsequently allocated to assets acquired and liabilities assumed on the records of the Company as follows:

Intangible assets

 

$

940,000

 

Goodwill

 

228,000

 

Net purchase price

 

$

1,168,000

 

Medtech Entities

On October 13, 2014, Medtech Group Acquisition Corp (“Medtech Corp.”), a Texas corporation and newly formed wholly-owned subsidiary of the Company, entered into an interest sale agreement (the “Interest Sale Agreement”) to purchase 100% of the equity or membership interests of OrthoPhoenix, LLC (“OrthoPhoenix”), a Delaware limited liability company, TLIF, LLC (“TLIF”) and MedTech Development Deutschland GmbH (“MedTech GmbH” and along with OrthoPhoenix and TLIF, the “Medtech Entities”) from MedTech Development, LLC (“MedTech Development”). The Medtech Entities own patents in the medical technology field.

Pursuant to the terms of the Interest Sale Agreement between MedTech Development, Medtech Corp. and the Medtech Entities, the Company (i) paid MedTech Development $1,000,000 cash and (ii) issued a Promissory Note to MedTech Development in the amount of $9,000,000 and (iii) assumed existing debt payable to Medtronics, Inc.  The assumed debt payable to Medtronics was renegotiated, as a result of which, the outstanding amount was $6.25 million prior to any repayment by the Company. The debt was due in installments through July 20, 2015; in the event that the Company paid the total amount due by June 30, 2015, the Company would receive a reduction in the remaining principal owed by the Company in the amount of $750,000. The transaction resulted in a business combination and caused the Medtech Entities to become wholly-owned subsidiaries of the Company.

The Company accounted for the acquisition as a business combination in accordance with ASC 805 “Business Combinations”. The Company is the acquirer for accounting purposes and TLIC is the acquired company.  The Company engaged a third party valuation firm to determine the fair value of the assets purchases, and the net purchase price paid by the Company was subsequently allocated to assets acquired and liabilities assumed on the records of the Company as follows:

Intangible assets

 

$

12,800,000

 

Goodwill

 

2,700,000

 

Net purchase price

 

$

15,500,000

 

Historical financial statements of the Medtech Entities and the pro forma condensed combined consolidated financial statements can be found on the Form 8-K/A filed with the SEC on December 24, 2014. The unaudited pro forma condensed combined consolidated financial statements are not necessarily indicative of the results that actually would have been attained if the merger had been in effect on the dates indicated or which may be attained in the future. Such statements should be read in conjunction with the historical financial statements of the Company.

Munitech S.a.r.l.

 

On June 27, 2016, Munitech S.a.r.l. (“Munitech”), a Luxembourg limited liability company and newly formed wholly-owned subsidiary of the Company, entered into two Patent Purchase Agreements (the “PPA” or together, the “PPAs”) to purchase 221 patents from Siemens Aktiengesellschaft (“Siemens”).Aktiengesellschaft. The patents purchased by Munitech relate to W-CDMA and GSM cellular technology and cover all the major global economies including China, France, Germany, the United Kingdom and the United States. Significantly, many of the patent families have been declared to be Standard Essential Patents (“SEPs”) with the European Telecommunications Standard Institute (“ETSI”) and/or the Association of Radio Industries and Businesses (“ARIB”) related to Long Term Evolution (“LTE”), Universal Mobile Telecommunications System (“UMTS”), and/or General Packet Radio Service (“GPRS”).

 

Pursuant to the terms of the PPAs, Munitech (i) paid Siemens Aktiengesellschaft $1,150,000 in cash upon closing and (ii) agreed to two future payments, one in the amount of $1,000,000 payable on December 31, 2016 and the second in the amount of $750,000 payable on September 30, 2017.

 

After evaluating the facts and circumstances of the purchase, the Company determined that this was an asset purchase. In coming to its conclusion, the Company reviewed the status of the assets, the historical activity and the absence of any employees, licensing activity, vendors associated with the patents, any royalties, and any other assets other than the patents.

 

ACQUISITIONS DURING THE THREE MONTHS ENDED SEPTEMBER 30, 2016On September 1, 2017, the Company entered into a Share Purchase Agreement with GPat Technologies, LLC (“GPat”) whereby the Company sold its 100% interest in Munitech to GPat.

 

16

MarathonMagnus IP GmbH (“Magnus”)

 

On July 5, 2016, Marathon IP GmbH (“Marathon IP”), a German corporationcorporate entity and newly formed wholly-owned subsidiary of Marathon Group SA (“Marathon SA”), a wholly-owned subsidiary of the Company, entered into thea Patent Purchase Agreements (the “PPA”) to purchase 6286 patents from Siemens Switzerland Ltd.Ltd and Siemens Industry Inc., (together, “Siemens”). On September 15, 2016, the patents were assigned by Marathon IP to Magnus, both of which are wholly-owned subsidiaries of the Company. The patents purchased by Marathon IP relate to Internet-of-Things (IOT) technology. Generally, the internet-of-thingsportfolio’s subject matter is directed toward self-healing control networks for automation systems. The patents are relevant to wireless mesh or home area networks for use in IOT, or connected home devices and cover allenable simple commissioning, application level security, simplified bridging, and end-to-end IP security. The technology can support a wide variety of IOT enabled devices including lighting, sensors, appliances, security, and more. Pursuant to the major global economies including China, France, Germany,terms of the United Kingdom and the United States.PPA, Marathon IP paid Siemens $250,000 in cash upon closing.

 

Pursuant to the terms of the PPAs, Munitech (i) paid Siemens $250,000 in cash upon closing and (ii) will pay a percentage of gross proceeds in excess of a reserve threshold on behalf of Marathon IP.

 

After evaluating the facts and circumstances of the purchase, the Company determined that this was an asset purchase. In coming to its conclusion, the Company reviewed the status of the assets, the historical activity and the absence of any employees, licensing activity, vendors associated with the patents, any royalties, and any other assets other than the patents.

 

On October 20, 2017, the Company assigned the patents held by Magnus to DBD, pursuant to the First Amendment to Amended and Restated Revenue Sharing and Securities Purchase Agreement and Restructuring Agreement (the “First Amendment and Restructuring Agreement”) entered into with DBD. In exchange for the assignment of three of the Company’s portfolios, of which Magnus was one, DBD cancelled all indebtedness owed by the Company to DBD.

Traverse Technologies Corp. (“Traverse”)

 

On August 3, 2016, Traverse Technologies Corp. (“Traverse”), a United States corporation and newly formed wholly-owned subsidiary of the Company, entered into a Patent Purchase Agreement (the “PPA”) to purchase 12 patents from CPT IP Holdings (“CPT”). The patents purchased by Traverse relate to batteries and principally cover various Asian and the United States markets.

 

Pursuant to the terms of the PPAs, Traverse (i) paid CPT $1,300,000 in cash upon closing and (ii) will pay a percentage of net recoveries in excess of a reserve threshold on behalf of Traverse.

 

After evaluating the facts and circumstances of the purchase, the Company determined that this was an asset purchase. In coming to its conclusion, the Company reviewed the status of the assets, the historical activity and the absence of any employees, licensing activity, vendors associated with the patents, any royalties, and any other assets other than the patents.

On October 20, 2017, the Company assigned the patents held by Traverse to DBD, pursuant to the First Amendment and Restructuring Agreement entered into with DBD. In exchange for the assignment of three of the Company’s portfolios, of which Traverse was one, DBD cancelled all indebtedness owed by the Company to DBD.

PG Technologies S.a.r.l. (“PG Tech”)

 

On August 11, 2016, PG Technologies S.a.r.l. (“PG Tech”), a Luxembourg limited liability company jointly owned with a large litigation financing fund, entered into a Patent Funding and Exclusive License Agreement (the “ELA”) to manage the monetization of greater than 10,000 patents in a single industry vertical with a Fortune 50 company. The patents cover all the major global economies including China, France, Germany, the United Kingdom and the United States. The Company determined that its ownership in PG Tech constitutes a VIE and that the Company is the primary beneficiary, as a result of which, the Company consolidated PG Tech in its financial statements. See Note 2 for additional details.

 

Pursuant to the terms of the ELA, PG Tech agreed with the Fortune 50 company to pay (i) $1,000,000 in cash upon closing, (ii) a future payment in the amount of $1,000,000 payable on or before December 31, 2016, (iii) minimum quarterly payments of $250,000 starting on April 1, 2017 and (iv) split 50% of the net licensing revenues.

 

17

After evaluating the facts and circumstances of the purchase, the Company determined that this was an asset purchase. In coming to its conclusion, the Company reviewed the status of the assets, the historical activity and the absence of any employees, licensing activity, vendors associated with the patents, any royalties, and any other assets other than the patents.

 

Motheye Technologies, LLC

On September 13, 2016, Motheye Technologies, LLC (“Motheye”), a United States corporation and newly formed wholly-owned subsidiary ofOctober 27, 2017, the Company entered into a Patent Purchase Agreementsan Assignment and Confirmation Agreement (the “PPA”“Assignment”) with Luxone Ventures S.a.r.l. (“Luxone”) whereby the Company assigned all of its ownership interest in PG Technologies, S.a.r.l. (“PG Tech”) to purchase 1 patent from Cirrex Systems, LLC (“Cirrex”). The patent purchased by Motheye relates to LED lighting and is issued in the United States.

Luxone. Pursuant to the terms ofAssignment, Luxone assumed the PPA, Motheye pays no determined cash consideration, but is required to pay a percentage of net recoveriesCompany’s ownership interest in excess of a reserve threshold on behalf of Motheye.

After evaluating the factsPG Tech and circumstances of the purchase, the Company determined that this was an asset purchase. In coming toremoved from its conclusion,balance sheet all the Company reviewed the status of the assets, the historical activityliabilities and the absence of any employees, licensing activity, vendorsdebt associated with PG Tech and received in return a revenue share associated with future earnings from the patents, any royalties, and any other assets other than the patents.PG Tech portfolio.

 

NOTE 4 – INTANGIBLE ASSETS

 

Intangible assets include patents purchased and patents acquired in lieu of the Company, including adjustments for currency translation adjustments,cash in licensing transactions. Patents purchased are recorded based at their acquisition cost and patents acquired in lieu of cash are recorded at their fair market value. Intangible assets consisted of the following:

 

 

September 30, 2016

 

December 31, 2015

 

 September 30, 2017 December 31, 2016 

 

 

 

 

 

     

Intangible Assets

 

  $

35,990,321

 

  $

41,014,992

 

 $20,403,408  $23,637,813 

Accumulated Amortization & Impairment

 

(16,438,643)

 

(15,557,353)

 

  (12,813,195)  (11,323,185)
        

Intangible assets, net

 

  $

19,551,678

 

  $

25,457,639

 

 $7,590,213  $12,314,628 

 

Other than the Company’s website as set forth in the table above, intangibleIntangible assets are comprised of patents with estimated useful lives between approximately 1 to 15 years. The website was determined to have an estimated useful life of 316 years. Once placed in service, the Company will amortize the costs of intangible assets over their estimated useful lives on a straight-line basis. During the three and nine months ended September 30, 2017, respectively, the Company capitalized a total of $0 and $0 in patent acquisition costs and during the three and nine months ended September 30, 2016, respectively, the Company capitalized a total of $3,550,000 and $6,450,000 in patent acquisition costs. Costs incurred to acquire patents, including legal costs, are also capitalized as long-lived assets and amortized on a straight-line basis with the associated patent. Amortization of patents is included inas an operating expensesexpense as reflected in the accompanying consolidated condensed statements of operations. The Company assesses fair market value for any impairment to the carrying values. The Company recorded impairment charges to its intangible assets during the three and nine months ended September 30, 20162017 in the amountsamount of $5,531,383$723,218 and 6,525,273,$723,218, respectively, compared to impairment charges associated with the end of life of a number of the Company’s portfolios compared to an impairment charge in the amount of $0 and $766,498, respectively, during the three and nine months ended September 30, 2015 associated with the reduction2016 in the carrying valueamounts of one the Company’s portfolios.$5,531,383 and $6,525,273, respectively.

Patent and website amortization expense for the three and nine months ended September 30, 20162017 was $2,030,886$457,419 and $6,018,196,$1,803,264, respectively, and patent and website amortization expense for the three and nine months ended September 30, 20152016, patent amortization expense was $2,884,269$2,030,886 and $8,511,730, respectively,$6,018,196, respectively. All patent amortization expense figures are net of foreign currency translation adjustments. Future amortization of intangible assets, net of foreign currency translation adjustments is as follows:

 

2016

 

  $

1,466,249

 

2017

 

4,614,613

 

 $401,804 

2018

 

3,251,099

 

  1,517,219 

2019

 

2,551,034

 

  1,447,660 

2020

 

1,902,950

 

  1,154,767 

2021 and thereafter

 

5,765,733

 

2021  1,004,600 
2022 and thereafter  2,064,163 

Total

 

  $

19,551,678

 

 $7,590,213 

 

 

 

 

 

The Company made the following patent purchases:

-      In April 2013, the Company through its subsidiary, Relay IP, Inc. acquired a US patent for $350,000;

-      In April 2013, the Company acquired 10 US patents, 27 foreign patents and 1 patent pending from CyberFone Systems valued at $1,135,512;

-      In June 2013, in connection with the closing of a licensing agreement with Siemens Technology, we acquired a patent portfolio from that company valued at $1,000,000;

-      In September 2013, the Company acquired 14 US patents for a total purchase price of $1,100,000;

-      In November 2013, the Company acquired four patents for 150,000 shares of the Company’s Common Stock, which the Company valued at $718,500 based on the fair market value of the stock issued;

-      In December 2013, the Company acquired certain patents from Delphi Technologies, Inc. for $1,700,000 pursuant to a Patent Purchase Agreement entered into on October 31, 2013 and Amended on December 16, 2013;

-      In December 2013, in connection with a licensing agreement with Zhone, the Company acquired a portfolio of patents from Zhone;

-      In December 2013, in connection with a settlement and license agreement, we agreed to settle and release another defendant for past and future use of our patents, whereby the defendant agreed to assign and transfer 2 U.S. patents and rights to the Company;

-      In May 2014, we acquired ownership rights of Dynamic Advances, LLC, a Texas limited liability company, IP Liquidity Ventures, LLC, a Delaware limited liability company, and Sarif Biomedical, LLC, a Delaware limited liability company, all of which hold patent portfolios or contract rights to the revenue generated from the patent portfolios;

-      In June 2014, we acquired Selene Communication Technologies, LLC, which holds multiple patents in the search and network intrusion field;

-      In August 2014, we acquired patents from Clouding IP LLC, with such patents related to network and data management technology;

-      In September 2014, we acquired TLI Communications, which owns a single patent in the telecommunication field;

-      In October 2014, we acquired three patent portfolios from MedTech Development, LLC, which owns medical technology patents;

-      In June 2016, we acquired two patent portfolios from Siemens covering W-CDMA and GSM cellular technology;

-      In July 2016, we acquired a patent portfolio from Siemens covering internet-of-things technology;

-      In August 2016, we acquired a patent portfolio from CPT IP Holdings, LLC covering battery technology;

-      In August 2016, we entered into a Patent Funding and Exclusive License Agreement with a Fortune 50 company to monetize more than 10,000 patents in a single industry vertical;

-      In September 2016, we acquired a patent from Cirrex Systems, LLC covering LED technology.

As of September 30, 2016, the Company’s patent portfolios consist2017, our operating subsidiaries owned 170 patents, as set forth below, and had economic rights to over 10,000 additional patents, both of 519which include U.S. and foreign patents and patent rights.certain foreign counterparts. In the aggregate, the earliest date for expiration of a patent in the Company’s patent portfolio has passed (the patent is expired, but patent rules allow for six-yearnine-year look-back for royalties), the median expiration date for patents in the Company’s portfolio is August 15, 2018,September 13, 2021, and the latest expiration date for a patent in any of the Company’s patent portfolios is July 29,February 27, 2033. A summary of the Company’s patent portfolios is as follows:

 

Subsidiary

18

 

Subsidiary

Number
of
Patents

Earliest
Expiration
Date

Median
Expiration
Date

Latest
Expiration
Date

Subject Matter

Bismarck IP Inc.

17

09/15/16

08/02/16

01/22/18

Communication and PBX equipment

Clouding Corp.

59

25

Expired

08/06/21

2/3/18

03/

9/10/215/29/29

Network and data management

CRFD Research, Inc.

5

5

05/

5/25/21

09/

9/17/21

08/

8/19/23

Web page content translator and device-to-device transfer system

Cyberfone Systems, LLC

30

Expired

09/15/15

06/07/20

Telephony and data transactions

Dynamic Advances, LLC

4

2

Expired

10/02/17

11/6/21

03/06/23

9/7/237/9/25Natural language interface

E2E Processing, Inc.

4

04/27/20

11/17/23

07/18/24

Manufacturing schedules using adaptive learning

Hybrid Sequence IP, Inc.

2

Expired

09/09/16

07/17/17

Asynchronous communications

IP Liquidity Ventures, LLC

3

Expired

06/06/15

06/06/15

Pharmaceuticals / tire pressure systems

Loopback Technologies, Inc.

9

Expired

08/05/16

08/27/22

Automotive

Magnus IP

62

55

10/28/29

09/29/24

1/28/22

10/15/30

9/27/2512/9/31Network Management/Connected Home Devices

Medtech Group Acquisition Corp.

86

45

Expired

06/28/19

Expired

08/09/29

12/8/188/9/29Medical technology

Motheye Technologies

1

06/07/21

06/07/21

06/07/21

Optical Networking

Munitch IP

173

9/16/18

6/21/26

5/29/32

W-CDMA and GSM cellular technology

Relay IP, Inc.

1

Expired

Expired

Expired

Multicasting

Sampo IP, LLC

3

03/13/18

12/01/19

11/16/23

Centrifugal communications

Sarif Biomedical LLC

4

Expired

Expired

Expired

Microsurgery equipment

Signal IP, Inc.

7

2

Expired

12/01/15

8/28/20

08/06/22

8/17/218/6/22Automotive

TLI Communications, LLC

6

06/17/17

06/17/17

06/17/17

Telecommunications

Traverse Technologies

12

20

02/

2/27/222/25/29

06/05/29

07/29/2/27/33

Li-Ion Battery/High Capacity Electrodes

Vantage Point Technology, Inc.

Soems Acquisition

31

16

Expired

05/31/16

11/11/17

03/09/18

Computer networking and operations

4/6/197/18/24N/A

Median

08/15/18

09/13/21

On October 20, 2017, the Company assigned the patent held by Dynamic Advances LLC, Magnus IP GmbH and Traverse Technologies Corp. (all wholly-owned subsidiaries of the Company) to DBD.

On October 27, 2017, the Company assigned the economic rights to its more than 10,000 patents to Luxone.

 

NOTE 5 - STOCKHOLDERS’ EQUITY

 

On December 7, 2011, theThe Company increased itshas authorized capital to 200,000,000 shares of Common Stock from 75,000,000 shares, changed thewith par value to $0.0001 per share, from $.001 per share, and has authorized 100,000,000capital of 50,000,000 shares of preferred stock, par value $0.0001 per share.

 

On June 24, 2013,July 18, 2017, shareholders of record holding a majority of the outstanding voting capital of the Company approved a reverse stock split of the Company’s issued and outstanding common stock by a ratio of not less than one-for-four and not more than one-for-twenty-five, with such ratio to be determined by the Board of Directors, in its sole discretion. On October 25, 2017, the reverse stock split ratio of one (1) for thirteen (13)four (4) basis was approved by the Board of Directors. On July 18, 2013,October 30, 2017, the Company filed a certificate of amendment to its Amended and Restated Articles of Incorporation with the Secretary of State of the State of Nevada in order to effectuate a reverse stock split of the Company’s issued and outstanding Common Stock,common stock, par value $0.0001 per share on a one (1) for thirteen (13)four (4) basis.

 

On November 19, 2014, the Board of Directors of the Company declared a stock dividend pursuant to which holders of the Company’s Common Stock as of the close of business of the record date of December 15, 2014 shall receive one additional share of Common Stock at the close of business on December 22, 2014 for each share of Common Stock held by such holders.  All share and per share values for all periods presented in the accompanying consolidated financial statements are retroactively restated for the effect of the reverse stock split and stock dividend.

Series B Convertible Preferred Stock

 

On May 1, 2014,The terms of the Company filed with the Secretary of State of Nevada a Certificate of DesignationsSeries B Convertible Preferred Stock are summarized below:

Dividend. The holders of Series B Convertible Preferred Stock (the “Serieswill be entitled to receive such dividends paid and distributions made to the holders of Common Stock, pro rata to the same extent as if such holders had converted the Series B Convertible Preferred Stock into Common Stock (without regard to any limitations on conversion herein or elsewhere) and had held such shares of Common Stock on the record date for such dividends and distributions.

Liquidation Preference. In the event of a liquidation, dissolution or winding up of the Company, after provision for payment of all debts and liabilities of the Company, any remaining assets of the Company shall be distributed pro rata to the holders of Common Stock and the holders of Series B Convertible Preferred Stock as if the Series B Convertible Preferred Stock had been converted into shares of Common Stock on the date of such liquidation, dissolution or winding up of the Company.

Voting Rights. The Series B Convertible Preferred Stock have no voting rights except with regard to certain customary protective provisions set forth in the Series B Convertible Preferred Stock Certificate of Designations”) authorizing 500,000Designations and as otherwise provided by applicable law.

Conversion. Each share of Series B Convertible Preferred Stock may be converted at the holder’s option at any time after issuance into one share of Common Stock, provided that the number of shares of Common Stock to be issued pursuant to such conversion does not exceed, when aggregated with all other shares of Common Stock owned by such holder at such time, result in such holder beneficially owning (as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended, and the rules thereunder) in excess of 9.99% of all of the Common Stock outstanding at such time, unless otherwise waived in writing by the Company with ninety-one (61) days’ notice.

19

Series D Convertible Preferred Stock

The Company issued Series D Convertible Preferred Stock in exchange for the outstanding convertible note issued in October 2014 and prior to September 30, 2017, all of the Series D Convertible Preferred Stock was converted to the Company’s Common Stock and no shares of the Series D Convertible Preferred Stock remain outstanding. The terms of the Series D Convertible Preferred Stock are summarized below:

Dividend. The holders of Series D Convertible Preferred Stock will be entitled to receive such dividends paid and distributions made to the holders of Common Stock, pro rata to the same extent as if such holders had converted the Series D Convertible Preferred Stock into Common Stock (without regard to any limitations on conversion herein or elsewhere) and had held such shares of Common Stock on the record date for such dividends and distributions.

Liquidation Preference. In the event of a liquidation, dissolution or winding up of the Company, after provision for payment of all debts and liabilities of the Company, any remaining assets of the Company shall be distributed pro rata to the holders of Series B Convertible Preferred Stock and establishing the designations, preferences, and other rights of the Series B Convertible Preferred Stock. The Series B Certificate of Designations became effective upon filing.

On May 2, 2014, the Company issued an aggregate of 782,000 shares of Series BD Convertible Preferred Stock valued at $2,807,380 to acquire IP Liquidity Ventures, LLC, Dynamic Advances, LLC and Sarif Biomedical, LLC. The transaction did not involve any underwriters, underwriting discounts or commissions, or any public offering. The issuance of these securities was deemed to be exempt from the registration requirements of the Securities Act of 1933, as amended, by virtue of Section 4(a)(2) thereof, as a transaction by an issuer not involving a public offering.

On September 17, 2014, the Company entered into a consulting agreement (the “GRQ Consulting Agreement”) with GRQ Consultants, Inc. (“GRQ”), pursuant to which GRQ shall provide certain consulting services including, but not limited to, advertising, marketing, business development, strategic and business planning, channel partner development and other functions intended to advance the business of the Company.  As consideration, GRQ was entitled to 200,000 shares of the Company’s Series B Convertible Preferred Stock, 50% of which vested upon execution of the GRQ Consulting Agreement, and 50% of which shall vest in six (6) equal monthly installments of commencing on October 17, 2014.  The first tranche of 100,000 shares of Series B Convertible Preferred Stock was issued to GRQ on October 6, 2014. In addition, the GRQ Consulting Agreement allows for GRQ to receive additional shares of Series B Convertible Preferred Stock upon the achievement of certain performance benchmarks. All shares of Series B Convertible Preferred Stock issuable to GRQ shall be pursuant to the 2014 Plan (as defined below) and shall be subject to shareholder approval of the 2014 Plan on or prior to September 16, 2015; the shareholders approved the 2014 Plan on July 31, 2015. The GRQ Consulting Agreement contains an acknowledgement that the conversion of the preferred stock into shares of the Company’s common stock is precluded by the equity blockers set forth in the certificate of designation and in Section 17 of the 2014 Plan to ensure compliance with NASDAQ Listing Rule 5635(d).

Common Stock

On June 24, 2013, the reverse stock split ratio of one (1) for thirteen (13) basis was approved by the Board of Directors. On July 18, 2013, the Company filed a certificate of amendment to its Amended and Restated Articles of Incorporation with the Secretary of State of the State of Nevada in order to effectuate a reverse stock split of the Company’s issued and outstanding Common Stock, par value $0.0001 per share on a one (1) for thirteen (13) basis. All share and per share values for all periods presented in the accompanying consolidated financial statements are retroactively restated for the effect of the reverse stock split.

On April 22, 2014, the Company issued 300,000 shares of restricted Common Stock to TT IP LLC pursuant to the acquisition of patents on November 13, 2013.

On June 2, 2014, the Company issued 48,078 shares of unrestricted Common Stock to an investor in the May 2013 PIPE, pursuant to the exercise of a warrant received in the May 2013 PIPE investment.

On June 30, 2014, the Company issued 200,000 shares of restricted Common Stock pursuant to the acquisition of Selene Communications Technologies, LLC (see Note 3). In connection with this transaction, the Company valued the shares at the fair market value on the date of grant at $4.90 per share or $980,000.

On July 18, 2014, the Company issues a total of 26,722 shares of Common Stock pursuant to the exercise of stock options held by a former member of the Company’s Board of Directors and the Company’s former Chief Financial Officer.

On September 16, 2014, the Company issued to two of its independent board members, in lieu of cash compensation, 6,178 shares of restricted Common Stock.  The shares shall vest quarterly over twelve (12) months commencing on the date of grant.

On September 30, 2014, the Company issued 50,000 shares of restricted Common Stock pursuant to the acquisition of the assets of Clouding IP, LLC (see Note 3). In connection with this transaction, the Company valued the shares at the quoted market price on the date of grant at $5.62 per share or $281,000.

For the three months ended September 30, 2014, certain holders of warrants exercised their warrants in a cashless, net exercise basis in exchange for 84,652 shares of the Company’s Common Stock.

On November 19, 2014, the Board of Directors of the Company declared a stock dividend (“Dividend”) pursuant to which holders of the Company’s Common Stock as of the close of business of the record date of December 15, 2014 shall receive one additional share of Common Stock at the close of business on December 22, 2014 for each share of Common Stock held by such holders.  Throughout this report, all share and per share values for all periods presented in the accompanying consolidated financial statements are retroactively restated for the effect of the stock dividend.

For the three months ended December 31, 2014, certain holders of warrants exercised their warrants in a cashless, net exercise basis in exchange for 29,230 shares of the Company’s Common Stock.

On January 29, 2015, the Company issued 134,409 shares of the Company’s Common Stock to DBD Credit Funding, LLC (“DBD”), an affiliate of Fortress Credit Corp. (“Fortress”), pursuant to the Fortress transaction as set forth in Note 6.

On March 13, 2015, the Company settled a dispute with a former consultant whereby the Company issued the consultant 60,000 shares of Common Stock for a full release of all claims.

For the three months ended March 31, 2015, certain holders of warrants exercised their warrants to purchase, in cash, 5,000 shares of the Company’s Common Stock.

For the three months ended June 30, 2015, certain holders of options exercised their options to purchase, on a net exercise basis, 33,968 (net) shares of the Company’s Common Stock.

In a series of transactions,if the Series B Convertible Preferred Stock associated with the GRQ Consulting Agreement wasand Series D Convertible Preferred Stock had been converted into shares of the Company’s Common Stock with 183,330 shares of Series B Convertible Preferred Stock converted into Common Stock prior to September 30, 2015.

On September 21, 2015, the Company issued 150,000 shares of the Company’s Common Stock to Alex Partners, LLC and Del Mar Consulting Group, Inc., pursuant to a services agreement entered into on September 21, 2015. In connection with this transaction, the Company valued the shares at the quoted market price on the date of grantsuch liquidation, dissolution or winding up of the Company, prior to any distributions to Junior Stock, which includes the Company’s Common Stock.

Voting Rights. Except as otherwise expressly required by law, each holder of Preferred Shares shall be entitled to vote on all matters submitted to shareholders of the Company and shall be entitled to the number of votes for each Preferred Share owned at $2.23 per sharethe record date for the determination of shareholders entitled to vote on such matter or, $334,500. The transaction did not involve any underwriters, underwriting discounts or commissions,if no such record date is established, at the date such vote is taken or any public offering. Thewritten consent of shareholders is solicited, equal to the number of shares of Common Stock such Preferred Shares are convertible into (voting as a class with Common Stock),

Conversion. Each share of Series D Convertible Preferred Stock may be converted at the holder’s option at any time after issuance into five shares of these securities was deemedCommon Stock, provided that the number of shares of Common Stock to be exempt from the registration requirementsissued pursuant to such conversion does not exceed, when aggregated with all other shares of Common Stock owned by such holder at such time, result in such holder beneficially owning (as determined in accordance with Section 13(d) of the Securities Exchange Act by virtue of Section 4(a)(2) thereof,1934, as a transaction by an issuer not involving a public offering.

On October 20, 2015,amended, and the remaining 16,666 sharesrules thereunder) in excess of Series B Convertible Preferred Stock associated with the GRQ Consulting Agreement was converted into 16,666 shares9.99% of all of the Company’s Common Stock.Stock outstanding at such time, unless otherwise waived in writing by the Company with ninety-one (61) days’ notice.

 

On November 4, 2015, the Company issued 300,000 shares of the Company’s Common Stock to Dominion Harbor Group LLC (“Dominion”), pursuant to a settlement agreement entered into with Dominion on October 30, 2015.  In connection with this transaction, the Company valued the shares at the quoted market price on the date of grant at $1.71 per share or $513,000. The transaction did not involve any underwriters, underwriting discounts or commissions, or any public offering. The issuance of these securities was deemed to be exempt from the registration requirements of the Securities Act by virtue of Section 4(a)(2) thereof, as a transaction by an issuer not involving a public offering.

On December 9, 2015, the Company entered into an agreement with Melechdavid, Inc. (“Melechdavid”), pursuant to which the Company agreed to issue 100,000 shares of the Company’s Common Stock. In connection with this transaction, the Company valued the shares at the quoted market price on the date of grant at $1.61 per share or $161,000. The transaction did not involve any underwriters, underwriting discounts or commissions, or any public offering. The issuance of these securities was deemed to be exempt from the registration requirements of the Securities Act by virtue of Section 4(a)(2) thereof, as a transaction by an issuer not involving a public offering.

 

On May 11, 2016, the Company entered into a consulting agreement with the Cooper Law Firm, LLC (“Cooper”), pursuant to which the Company agreed to issue 80,00020,000 shares of the Company’s Common Stock. In connection with this transaction, the Company valued the shares at the quoted market price on the date of grant at $1.70$6.80 per share or $136,000. The transaction did not involve any underwriters, underwriting discounts or commissions, or any public offering. The issuance of these securities was deemed to be exempt from the registration requirements of the Securities Act by virtue of Section 4(a)(2) thereof, as a transaction by an issuer not involving a public offering.

Common Stock Warrants

 

On MayDecember 9, 2016, the Company entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors for the sale of an aggregate of 870,500 shares of the Company’s common stock, at a purchase price of $6.00 per share, and warrants to purchase 435,249 shares of common stock for a purchase price of $0.01 per warrant, or $17,019.95 in total. None of the warrants were purchased prior to December 31, 2016, and all were subsequently purchased prior to the date of this report.

On February 1, 2014,2017, the Company issued warrants187,500 shares of common stock pursuant to an At-The-Market (“ATM”) securities offering with certain institutional investors at an average price of $6.96 per share, yielding gross proceeds of $1,301,923.

On April 12, 2017, pursuant to an amendment entered into on March 6, 2017 to the settlement agreement entered into on October 29, 2015 between the Company and Dominion Harbor, the Company issued 31,250 shares of common stock to Dominion Harbor. In connection with this transaction, the Company valued the shares at the quoted market price on the date of grant at $0.83 per share or $103,750.

On April 18, 2017, the Company entered into a securities purchase agreement (the “PIPE Warrants”“April Purchase Agreement”) with certain institutional investors for the sale of an aggregate of 950,000 shares of the Company’s common stock at a purchase price of $2.80per share and warrants to purchase 511,790570,000 shares of common stock at a purchase price of $3.32 per share.

20

On April 24, 2017, the Company issued one of its vendors 7,500 shares of Common Stock in exchange for cancellation of the vendor’s outstanding invoices. In connection with this transaction, the Company valued the shares at athe quoted market price on the date of $3.75grant at $3.32 per share or $24,897.

On August 9, 2017, the Company issued 250,000 shares of the Company’s Common Stock pursuant to the Private Placement describedconversion of 200,000 shares of Series D Convertible Preferred Stock.

On August 29, 2017, the Company issued 200,000 shares in detail below.total of the Company’s Common Stock to four different vendors in partial or total payment of outstanding invoices.

On September 5, 2017, the Company issued 62,500 shares of the Company’s Common Stock pursuant to the conversion of 50,000 shares of Series D Convertible Preferred Stock.

On September 6, 2017, the Company issued 534,710 shares of the Company’s Common Stock pursuant to the conversion of $427,768 in principal amount invested in the Convertible Note.

On September 13, 2017, the Company issued 315,925 shares of the Company’s Common Stock pursuant to the conversion of 252,750 shares of Series D Convertible Preferred Stock.

On September 29, 2017, the Company issued 598,500 shares of the Company’s Common Stock to holders of the warrants issued pursuant to the April Purchase Agreement following approval by the Company’s shareholders of the warrant exchange at a special meeting held on September 29, 2017.

Common Stock Warrants

Pursuant to the sales of securities underlying the Purchase Agreement entered into on December 9, 2016, the Company issued a warrant to the underwriter (“Underwriter’s Warrant”) to purchase 43,525 shares of Common Stock on December 9, 2016. The Underwriter’s Warrant has an exercise price of $6.92 per share. In addition, in a series of issuances in January 2017, the Company issued warrants to the investors (“Investor Warrants”) pursuant to the Purchase Agreement to purchase 435,249 shares of the Company’s Common Stock. The Investor Warrants have an exercise price of $6.80 per share. The warrants were issued in a series of transaction during January 2017 and were valued based on the Black-Scholes model, using the strike price of $6.80 per share, market prices ranging from $7.00 to $8.52 per share, an expected term of 3.25 years, volatility ranging from 38% to 39%, based on the average volatility of comparable companies over the comparable prior period, and a discount rate as published by the Federal Reserve ranging from 1.50% to 1.56%. The Company reviewed the issuance of the PIPEUnderwriter and Investor Warrants done in conjunction with the financing closed on May 1, 2014, and determined that pursuant to ASC 480 and ASC 815, the PIPEUnderwriter and Investor Warrants should be classified as a liability and marked to market every reporting period. Following acceptance by the SEC of the Company’s registration statement registering these warrants, the warrants were reclassified from a liability to equity.

On January 10, 2017, pursuant to the amendment to the Fortress debt, the Company issued a five-year warrant to DBD to purchase 46,875 shares of the Company’s Common Stock, exercisable at $6.80 per share, subject to adjustment. The warrant was valued based on the Black-Scholes model, using the strike and market prices of $6.80 and $7.60 per share, respectively, an expected term of 3.00 years, volatility of 39% based on the average volatility of comparable companies over the comparable prior period and a discount rate as published by the Federal Reserve of 1.52%. The Company reviewed the issuance of the Underwriter and Investor Warrants and determined that pursuant to ASC 480 and ASC 815, the Underwriter and Investor Warrants met the requirement to be classified as equity and were booked as Additional Paid-in Capital.  All PIPE Warrants have expired.

 

In conjunction withPursuant to the issuancesales of $5,550,000 in convertible debtsecurities underlying the April Purchase Agreement entered into on October 16, 2014,April 18, 2017, the Company issued two-year warrants (the “Debt Warrants”a warrant to the underwriter (“Underwriter’s Warrant”) to purchase 258,99814,250 shares of Common Stock. The Underwriter’s Warrant has an exercise price of $3.08 per share. In addition, also associated with the April Purchase Agreement, the Company issued warrants to the investors (“April Investor Warrants”) pursuant to the Purchase Agreement to purchase 570,000 shares of the Company’s Common Stock, par value $0.0001 per share pursuant to a securities purchase agreement.Stock. The DebtInvestor Warrants were valued at $164,020 and were recorded as a discount to the fair value of the convertible notes. The Debt Warrants are initially convertible into shares of the Company’s Common Stock athave an exercise price of $8.25$3.32 per share. The conversion and exercise prices are subject to adjustment in the event of certain events, including stock splits and dividends. The Company reviewed the instruments in the context of ASC 480 and determined that the convertible notes should be recorded as a liability and analyzed the conversion feature and bifurcation pursuant to ASC 815 and ASC 470, respectively, to determine that there was no beneficial conversion feature and that the conversion feature should not be bifurcated.  All DebtInvestor Warrants have expired or been exercised.

On January 29, 2015, the Company and certain of its subsidiaries entered into a series of Agreements including a Securities Purchase Agreement (“Fortress Securities Purchase Agreement”) with DBD, an affiliate of Fortress, under which the Company issued a five-year warrant (“Fortress Warrant”) to purchase 100,000 shares of the Company’s Common Stock exercisable at $7.44 per share, subject to adjustment.  The Company reviewed the instruments in the context of ASC 480 and determined that the convertible notes should be recorded as a liability, the warrants should be recorded as equity and analyzed the conversion feature and bifurcation pursuant to ASC 815 and ASC 470, respectively, to determine that the was no beneficial conversion feature and that the conversion feature should not be bifurcated.

During the year ended December 31, 2015, warrants to purchase 5,000 shares of Common Stock were exercised and no warrants to purchase shares of Common Stock were forfeited.

During the three and nine months ended September 30, 2015, the Company recorded stock based compensation expense of $0 and $3,465 in connection with the vested warrants associated with one warrant-based compensatory grant, compared to no compensation expenses for the three and nine months ended September 30, 2016 associated with this warrant. The warrant was valued at the time of grant on January 26, 2012, based on the Black-Scholes model, using the strike and market pricesprice of $3.25$3.08 per share, thean expected term of 102.5 years, volatility of 191%39%, based on the closing priceaverage volatility of comparable companies over the 50 trading sessions immediately preceding the grantcomparable prior period and a discount rate as published by the Federal Reserve of 1.96%1.60%. At December 31, 2015, thereThe Underwriter’s Warrant was valued based on the Black-Scholes model, using the strike price of $3.32 per share, an expected term of 3.25 years, volatility of 38%, based on the average volatility of comparable companies over the comparable prior period and a totaldiscount rate as published by the Federal Reserve of $01.72%. The Company reviewed the issuance of unrecognized compensation expense relatedthe Underwriter and Investor Warrants and determined that pursuant to future recognitionASC 480 and ASC 815, the Underwriter and Investor Warrants should be classified as equity.

21

Pursuant to the Unit Purchase Agreement entered into on August 14, 2017, the Company, in two closings, issued warrants to the investors (“Note Investor Warrants”) to purchase 6,875,000 shares of warrant-based compensation arrangements.the Company’s Common Stock. The Note Investor Warrants have an exercise price of $1.20 per share. The Note Investor Warrants from the first close were valued based on a Monte Carlo simulation model, using the strike price of $1.20 per share, remaining term of 5.50 years, volatility of 100%, based on the terms of the Unit Purchase Agreement which set the volatility at the greater 100% or the 100-day volatility immediately following certain events and a discount rate as published by the Federal Reserve of 1.76%. The Note Investor Warrants from the second close were valued based on a Monte Carlo simulation model, using the strike price of $1.20 per share, remaining term of 5.50 years, volatility of 100%, based on the methodology set forth above and a discount rate as published by the Federal Reserve of 1.98%. The Company reviewed the issuance of the Note Investor Warrants and determined that pursuant to ASC 480 and ASC 815, the Note Investor Warrants should be classified as a liability.

 

At September 30, 2017, the Company had warrants outstanding to purchase 7,487,894 shares of Common Stock with a weighted average remaining life of 5.35 years. A summary of the status of the Company’s outstanding stock warrants at September 30, 2016and changes during the period then ended is as follows:

 

 

Number of
Warrants

 

Weighted
Average Exercise
Price

 

Weighted
Average
Remaining Life

 Number of
Warrants
 Weighted
Average Exercise
Price
 

Weighted
Average
Remaining

Life

 

Balance at December 31, 2015

 

2,021,308

 

  $

4.27

 

0.87

Balance at December 31, 2016  116,520  $15.17   3.25 

Granted

 

-    

 

 

-    

 

-    

  7,941,374   1.70   5.01 

Cancelled

 

(1,464,636)

 

  $

3.42

 

-    

  -   -   - 

Forfeited

 

-    

 

 

-    

 

-    

  -   -   - 

Exercised

 

-    

 

  $

-    

 

-    

  570,000   3.32   - 

Balance at September 30, 2016

 

556,672

 

 

6.51

 

1.33

Balance at September 30, 2017 7,487,894  $1.86   5.35 

 

 

 

 

 

 

            

Warrants exercisable at September 30, 2016

 

556,672

 

 

 

 

Warrants exercisable at September 30, 2017  612,894         

Weighted average fair value of warrants granted during the period

 

 

 

  $

-    

 

 

     0.09     

 

At various times during the nine months ended September 30, 2016, warrants issued in conjunction with financings entered into by the Company in May 2013, August 2013 and May 2014 were cancelled as they passed their expiration dates unexercised.

Warrant Amendment Letter

On April 20, 2014, the Company sent a letter (the “Warrant Amendment Letter”) to all the holders of the warrants which were granted in connection with the sale of units pursuant to a securities purchase agreements which occurred between May 2013 and August 2013. The Warrant Amendment Letter offered to reduce the exercise price of the warrants from $6.50 per share to $5.75 per share, if the holders of the warrants accepted the Company’s offer to exercise the warrants in full for cash by April 22, 2014 (the “Expiration Date”).  The Company subsequently extended the Expiration Date to April 24, 2014. On April 24, 2014, one holder of warrants, who is an accredited investor, accepted the Company’s offer and thereby exercised his warrants, for gross proceeds to the Company of approximately $138,222. After analyzing the circumstances relative to the Warrant Amendment Letter – the extremely short period of time to exercise pursuant to the Amendment Letter, the relatively small change in the exercise price and the limited response to the Amendment Letter – the Company deemed that the change was not a significant modification of the terms of the warrant and did not assess a new fair value and consequently did not make an entry for any adjustment in the value.

 

On March 11, 2016, the Company entered into an agreement with the remaining investor in the Company’s convertible debt issued on October 9, 2014 to revise the strike price of their warrant, which could be exercised for the purchase of 23,3345,834 shares of Common Stock, in exchange for permanent waiver of certain consent rights held by the holder of the convertible debt. As a result of the amendment, the strike price was reduced from $4.125$16.50 to the lower of 1) $2.00$8.00 per share or 2) the same gross per share price as the Company sells shares of its Common Stock in any future public offering of the Company’s Common Stock.

 

Common Stock Options

On April 15, 2014, the Company issued a new board member a five-year option to purchase an aggregate of 20,000 shares of the Company’s Common Stock with an exercise price of $3.295 per share, subject to adjustment, which shall vest in twelve (12) monthly installments commencing on the date of grant. The option was valued based on the Black-Scholes model, using the strike and market prices of $3.295 per share, life of three years, volatility of 51% based on the closing price of the 50 trading sessions immediately preceding the grant and a discount rate as published by the Federal Reserve of 0.84%.

On May 14, 2014, the Company issued existing employees, ten-year options to purchase an aggregate of 80,000 shares of the Company’s Common Stock with an exercise price of $4.165 per share, subject to adjustment, which shall vest in three (3) annual installments, with 33% vesting on the first anniversary of the date of grant, 33% on the second anniversary of the date of grant and 34% on the third anniversary of the date of grant. The options were valued based on the Black-Scholes model, using the strike and market prices of $4.165 per share, life of 6.5 years, volatility of 63% based on the closing price of the 50 trading sessions immediately preceding the grant and a discount rate as published by the Federal Reserve of 1.97%.

On May 14, 2014, the Company issued to consultants, five-year options to purchase an aggregate of 160,000 shares of the Company’s Common Stock with an exercise price of $4.165 per share, subject to adjustment, which shall vest in three (3) annual installments, with 33% vesting on the first anniversary of the date of grant, 33% on the second anniversary of the date of grant and 34% on the third anniversary of the date of grant. The options were valued based on the Black-Scholes model, using the strike and market prices of $4.165 per share, life of 3.5 years, volatility of 50% based on the closing price of the 50 trading sessions immediately preceding the grant and a discount rate as published by the Federal Reserve of 1.00%.

On May 15, 2014, the Company entered into an executive employment agreement with Francis Knuettel II (“Knuettel Agreement”) pursuant to which Mr. Knuettel would serve as the Company’s Chief Financial Officer. As part of the consideration, the Company agreed to grant Mr. Knuettel a ten-year stock option to purchase an aggregate of 290,000 shares of Common Stock, with a strike price of $4.165 per share, vesting in thirty-six (36) equal installments on each monthly anniversary of the date of the Knuettel Agreement. The option was valued based on the Black-Scholes model, using the strike and market prices of $4.165 per share, life of 6.5 years, volatility of 63% based on the closing price of the 50 trading sessions immediately preceding the grant and a discount rate as published by the Federal Reserve of 1.97%.

On June 15, 2014, the Company issued to a consultant a five-year stock option to purchase an aggregate of 40,000 shares of the Company’s Common Stock with an exercise price of $5.05 per share, subject to adjustment, which shall vest in twenty-four (24) each monthly installments on each monthly anniversary date of the grant. The options were valued based on the Black-Scholes model, using the strike and market prices of $5.05 per share, life of 3.25 years, volatility of 50% based on the closing price of the 50 trading sessions immediately preceding the grant and a discount rate as published by the Federal Reserve of 1.05%.

On August 29, 2014, the Company entered into an executive employment agreement with Daniel Gelbtuch (“Gelbtuch Agreement”) pursuant to which Mr. Gelbtuch would serve as the Company’s Chief Marketing Officer. As part of the consideration, the Company agreed to grant Mr. Gelbtuch a ten-year stock option to purchase an aggregate of 290,000 shares of Common Stock, with a strike price of $5.62 per share, vesting in thirty-six (36) equal installments on each monthly anniversary of the date of the Gelbtuch Agreement. Mr. Gelbtuch’s employment with the Company was terminated as of January 20, 2015 and the vested shares at that time remained available for Mr. Gelbtuch to exercise until January 20, 2016.  The option was valued based on the Black-Scholes model, using the strike and market prices of $5.62 per share, life of 6.5 years, volatility of 62% based on the average volatility of comparable companies over the prior 10-year period and a discount rate as published by the Federal Reserve of 1.95%.

On September 16, 2014, the Company issued its independent board members five-year options to purchase an aggregate of 60,000 shares of the Company’s Common Stock with an exercise price of $7.445 per share, subject to adjustment, which shall vest monthly over twelve (12) months commencing on the date of grant. The options were valued based on the Black-Scholes model, using the strike and market prices of $7.445 per share, life of three years, volatility of 49% based on the average volatility of comparable companies over the prior 5-year period and a discount rate as published by the Federal Reserve of 1.04%.

On October 31, 2014, the Company entered into an executive employment agreement with Enrique Sanchez (“Sanchez Agreement”) pursuant to which Mr. Sanchez would serve as the Company’s Senior Vice President of Licensing. As part of the consideration, the Company agreed to grant Mr. Sanchez a ten-year stock option to purchase an aggregate of 160,000 shares of Common Stock, with a strike price of $6.40 per share, vesting in thirty-six (36) equal installments on each monthly anniversary of the date of the Sanchez Agreement. The options were valued based on the Black-Scholes model, using the strike and market prices of $6.40 per share, an expected term of 5.75 years, volatility of 53% based on the average volatility of comparable companies over the comparable prior period and a discount rate as published by the Federal Reserve of 1.78%.

On October 31, 2014, the Company entered into an executive employment agreement with Umesh Jani (“Jani Agreement”) pursuant to which Mr. Jani would serve as the Company’s Chief Technology Officer and SVP of Licensing. As part of the consideration, the Company agreed to grant Mr. Jani a ten-year stock option to purchase an aggregate of 100,000 shares of Common Stock, with a strike price of $6.40 per share, vesting in thirty-six (36) equal installments on each monthly anniversary of the date of the Jani Agreement. The options were valued based on the Black-Scholes model, using the strike and market prices of $6.40 per share, an expected term of 5.75 years, volatility of 53% based on the average volatility of comparable companies over the comparable prior period and a discount rate as published by the Federal Reserve of 1.78%.

On October 31, 2014, the Company issued existing employees, ten-year options to purchase an aggregate of 680,000 shares of the Company’s Common Stock with an exercise price of $6.40 per share, subject to adjustment, which shall vest in twenty-four (24) equal installments on each monthly anniversary. The options were valued based on the Black-Scholes model, using the strike and market prices of $6.40 per share, an expected term of 5.75 years, volatility of 53% based on the average volatility of comparable companies over the comparable prior period and a discount rate as published by the Federal Reserve of 1.78%.

On October 31, 2014, the Company issued to a consultant, a five-year option to purchase an aggregate of 30,000 shares of the Company’s Common Stock with an exercise price of $6.40 per share, subject to adjustment, which shall vest in twenty-four (24) equal installments on each monthly anniversary of the grant. The options were valued based on the Black-Scholes model, using the strike and market prices of $6.40 per share, an expected term of 3.25 years, volatility of 49% based on the average volatility of comparable companies over the comparable prior period and a discount rate as published by the Federal Reserve of 1.03%.

On February 5, 2015 the Company issued to a consultant, a five-year option to purchase an aggregate of 25,000 shares of the Company’s Common Stock with an exercise price of $6.80 per share, subject to adjustment, which shall vest in twenty-four (24) equal installments on each monthly anniversary of the grant. The options were valued based on the Black-Scholes model, using the strike and market prices of $6.80 per share, an expected term of 3.25 years, volatility of 47% based on the average volatility of comparable companies over the comparable prior period and a discount rate as published by the Federal Reserve of 0.92%.

On March 6, 2015 the Company issued a new board member a five-year option to purchase an aggregate of 20,000 shares of the Company’s Common Stock with an exercise price of $7.37 per share, subject to adjustment, which shall vest in twelve (12) equal installments on each monthly anniversary of the grant. The options were valued based on the Black-Scholes model, using the strike and market prices of $7.37 per share, an expected term of 3.00 years, volatility of 41% based on the average volatility of comparable companies over the comparable prior period and a discount rate as published by the Federal Reserve of 1.16%.

On March 18, 2015 the Company issued a new board member a five-year option to purchase an aggregate of 20,000 shares of the Company’s Common Stock with an exercise price of $6.61 per share, subject to adjustment, which shall vest in twelve (12) equal installments on each monthly anniversary of the grant. The options were valued based on the Black-Scholes model, using the strike and market prices of $6.61 per share, an expected term of 3.00 years, volatility of 41% based on the average volatility of comparable companies over the comparable prior period and a discount rate as published by the Federal Reserve of 0.92%.

On April 7, 2015 (the “Effective Date”), the Company entered into a consulting agreement (the “Consulting Agreement”) with Richard Chernicoff, a member of the Company’s Board of Directors, pursuant to which Mr. Chernicoff shall provide certain services to the Company, including serving as the interim General Counsel and interim General Manager of commercial product commercialization development. Pursuant to the terms of the Consulting Agreement, Mr. Chernicoff shall receive a monthly retainer of $27,000 and a ten-year stock option to purchase 280,000 shares of the Company’s Common Stock pursuant to the Company’s 2014 Plan. The stock options have an exercise price of $6.76 per share, the closing price of the Company’s common stock on the date immediately prior to the Board of Directors approval of such stock options and the options shall vest as follows: 25% of the option shall vest on the 12 month anniversary of the Effective Date and thereafter 2.083% on the 21st day of each succeeding calendar month for the following twelve months, provided Mr. Chernicoff continues to provide services (in addition to as a member of the Company’s Board of Directors) at the time of vesting. The option shall be subject in all respects to the terms of the 2014 Plan. Notwithstanding anything herein to the contrary, the remainder of the option shall be subject to the following as an additional condition of vesting: (A) options to purchase 70,000 shares of the Company’s Common Stock under the option shall not vest at all unless the price of the Company’s common stock while Mr. Chernicoff continues as an officer and/or director reaches $8.99 and (B) options to purchase 70,000 shares of the Company’s Common Stock under the option shall not vest at all unless the price of the Company’s common stock while Mr. Chernicoff continues as an officer and/or director reaches $10.14. For valuation purposes, the options were divided into two parts – the time-based vesting component and the performance-based vesting component. The time-based vesting component was valued based on the Black-Scholes model, using the strike and market prices of $6.76 per share, an expected term of 6.25 years, volatility of 53% based on the average volatility of comparable companies over the comparable prior period and a discount rate as published by the Federal Reserve of 1.53%. The performance-based vesting component was valued based on the Monte Carlo Simulation model, using the strike and market prices of $6.76 per share, an expected term of 10.0 years, volatility of 61% based on the average volatility of comparable companies over the comparable prior period and a discount rate as published by the Federal Reserve of 1.89%.  On May 15, 2016, the Company and Mr. Chernicoff entered into an amendment of his consulting agreement whereby the monthly retainer was eliminated and replaced with an hourly option for legal services and the portion of his option to purchase 140,000 shares of the Company’s common stock as set forth in clauses (A) and (B) above were terminated.

On September 16, 2015, the Company issued its independent board members ten-year options to purchase an aggregate of 80,000 shares of the Company’s Common Stock with an exercise price of $2.03 per share, subject to adjustment, which shall vest monthly over twelve (12) months commencing on the date of grant. The options were valued based on the Black-Scholes model, using the strike and market prices of $2.03 per share, an expected term of 5.5 years, volatility of 47% based on the average volatility of comparable companies over the comparable prior period and a discount rate as published by the Federal Reserve of 1.72%.

On October 14, 2015, the Company issued certain of its employees ten-year options to purchase an aggregate of 385,000 shares of the Company’s Common Stock with an exercise price of $1.86 per share, subject to adjustment, which shall vest monthly over twenty-four (24) months commencing on the date of grant. The options were valued based on the Black-Scholes model, using the strike and market prices of $1.86 per share, an expected term of 6.5 years, volatility of 49% based on the average volatility of comparable companies over the comparable prior period and a discount rate as published by the Federal Reserve of 1.57%.

On October 14, 2015, the Company issued certain of its consultants ten-year options to purchase an aggregate of 70,000 shares of the Company’s Common Stock with an exercise price of $1.86 per share, subject to adjustment, which shall vest monthly over twenty-four (24) months commencing on the date of grant. The options were valued based on the Black-Scholes model, using the strike and market prices of $1.86 per share, an expected term of 6.5 years, volatility of 49% based on the average volatility of comparable companies over the comparable prior period and a discount rate as published by the Federal Reserve of 1.57%.

 

On May 10, 2016, the Company entered into an executive employment agreement with Erich Spangenberg (“Spangenberg Agreement”) pursuant to which Mr. Spangenberg would serve as the Company’s Director of Acquisitions, Licensing and Strategy. As part of the consideration, the Company agreed to grant Mr. Spangenberg a ten-year stock option to purchase an aggregate of 500,000125,000 shares of Common Stock, with a strike price of $1.69$7.48 per share, vesting in twenty-four (24) equal installments on each monthly anniversary of the date of the Spangenberg Agreement. The options were valued based on the Black-Scholes model, using the strike and market prices of $1.69$7.48 per share, an expected term of 5.75 years, volatility of 47% based on the average volatility of comparable companies over the comparable prior period and a discount rate as published by the Federal Reserve of 1.32%.

22

On May 20, 2016, the Company entered into an employment agreement with Kathy Grubbs (“Grubbs Agreement”) pursuant to which Ms. Grubbs would serve as an analyst. As part of the consideration, the Company agreed to grant Ms. Grubbs a ten-year stock option to purchase an aggregate of 50,00012,500 shares of Common Stock, with a strike price of $2.25$9.00 per share, vesting in thirty-sixthirty-nine (36) equal installments on each monthly anniversary of the date of the Grubbs Agreement. The options were valued based on the Black-Scholes model, using the strike and market prices of $2.25$9.00 per share, an expected term of 6.50 years, volatility of 47% based on the average volatility of comparable companies over the comparable prior period and a discount rate as published by the Federal Reserve of 1.88%.

 

On July 1, 2016, in conjunction with an executive employment agreement with David Liu (“Liu Agreement”) pursuant to which Mr. Liu would serve as the Company’s CTO, entered into on June 29, 2016, the Company granted Mr. Liu a ten-year stock option to purchase an aggregate of 150,00037,500 shares of Common Stock, with a strike price of $2.79$11.16 per share, vesting in thirty-sixthirty-nine (36) equal installments on each monthly anniversary of the date of the Liu Agreement. The options were valued based on the Black-Scholes model, using the strike and market prices of $2.79$11.16 per share, an expected term of 6.50 years, volatility of 47% based on the average volatility of comparable companies over the comparable prior period and a discount rate as published by the Federal Reserve of 1.20%.

 

For the three and nine months ended September 30,On October 13, 2016, the Company recordedissued its independent board members ten-year options to purchase an aggregate of 20,000 shares of the Company’s Common Stock with an exercise price of $9.64 per share, subject to adjustment, which shall vest monthly over twelve (12) months commencing on the date of grant. The options were valued based on the Black-Scholes model, using the strike and market prices of $9.64 per share, an expected term of 5.5 years, volatility of 46% based on the average volatility of comparable companies over the comparable prior period and a discount rate as published by the Federal Reserve of 1.21%. As there were not sufficient shares in the Company’s equity incentive plans to accommodate these grants, Mr. Croxall forfeited a portion of one of his options to purchase 20,000 shares.

At September 30, 2017, there was a total of $7,072 of unrecognized compensation expenses related to non-rested option-based compensation expenses of $472,434 and $1,524,018, respectively. arrangements entered into during the year.A summary of the stock options as of September 30, 2016 is as follows:2017 and changes during the period are presented below:

 

 

Number of
Options

 

Weighted
Average Exercise
Price

 

Weighted
Average
Remaining Life

 Number of
Options
 Weighted
Average Exercise
Price
 

Weighted
Average
Remaining

Life

 

Balance at December 31, 2015

 

3,383,267

 

  $

4.25

 

7.11

Balance at December 31, 2016  879,034  $17.84   6.80 

Granted

 

700,000

 

  $

1.65

 

9.65

  -   -   - 

Cancelled

 

(291,772)

 

  $

5.69

 

-    

  48,542   -   - 

Forfeited

 

(126,181)

 

  $

5.18

 

-    

  217,298   16.71   - 

Exercised

 

-    

 

  $

-    

 

-    

  -   -   - 

Balance at September 30, 2016

 

3,665,314

 

  $

3.34

 

7.02

Balance at September 30, 2017 613,194  $17.04   3.06 

 

 

 

 

 

 

            

Options Exercisable at September 30, 2016

 

2,627,075

 

 

 

 

Options Exercisable at September 30, 2017  591,841  $13.83   2.91 

Options expected to vest

 

1,435,800

 

 

 

 

  21,354  $20.33   7.23 

Weighted average fair value of options granted during the period

 

 

 

  $

0.90

 

 

     $-     

 

Stock options outstanding at September 30, 2016 as disclosed in the above table have approximately $1,377,905 in intrinsic value at September 30, 2016.

 

Non-Controlling Interest

23

 

Non-controlling interest represents equity interests in consolidated subsidiaries that are not attributable, either directly or indirectly, to the Company’s ownership stake in 3D Nanocolor Corp. (“3D Nano”) or PG Tech, but rather, non-controlling interests includes the minority equity holders’ proportionate share of the equity of 3D Nano and PG Tech.

Ownership interests in subsidiaries held by parties other than the Company are presented as non-controlling interests within stockholders’ equity, separately from the equity held by the Company on the consolidated statements of stockholders’ equity. Revenues, expenses, net income and other comprehensive income are reported in the consolidated financial statements at the consolidated amounts, which includes amounts attributable to both the Company’s interest and the non-controlling interests in 3D Nano and PG Tech. Net income and other comprehensive income is then attributed to the Company’s interest and the non-controlling interests. Net income to non-controlling interests is deducted from net income in the consolidated statements of income to determine net income attributable to the Company’s common shareholders.

NOTE 6 – DEBT, COMMITMENTS AND CONTINGENCIES

 

Fortress TransactionDebt consists of the following:

  Maturity Interest  September 30,  December 31, 
  Date Rate  2017  2016 
            
Senior secured term notes 9-Jul-20  LIBOR + 9.75% $15,881,493  $15,620,759 
Less: debt discount        (1,686,090)  (1,425,167)
Total senior-term notes, net of discount       $14,195,403  $14,195,592 

  Maturity  Interest   September 30,   December 31, 
  Date  Rate   2017   2016 
               
Convertible Note 10-Oct-18  11% $0  $500,000 

  Maturity  Late   September 30,   December 31, 
  Date  Fee   2017   2016 
iRunway trade payable On Demand  1.5% per month  $0  $191,697 

  Maturity  Interest   September 30,   December 31, 
  Date  Rate   2017   2016 
Note payable 31-Jan-17  NA  $-  $103,000 

  Maturity  Interest   September 30,   December 31, 
  Date  Rate   2017   2016 
Siemens 30-Sep-17  NA  $-  $1,672,924 

  Maturity  Interest   September 30,   December 31, 
  Date  Rate   2017   2016 
Dominion Harbor 15-Oct-17  NA  $-  $125,000 

  Maturity  Interest   September 30,   December 31, 
  Date  Rate   2017   2016 
Oil & Gas On Demand  NA  $1,000,000  $944,296 

  Maturity  Interest   September 30,   December 31, 
  Date  Rate   2017   2016 
Convertible Note 10-May-18  0  $1,876,300  $- 
Less: debt discount        (1,851,171)  - 
Total Convertible notes, net of discount       $25,129  $- 

  Maturity  Interest   September 30,   December 31, 
  Date  Rate   2017   2016 
Convertible Note 31-May-18  5% $3,195,932  $- 
Less: debt discount        (2,834,308)  - 
Total Convertible notes, net of discount       $361,624  $- 

  Maturity  Interest   September 30,   December 31, 
  Date  Rate   2017   2016 
Medtech Note 1-May-18  NA  $-  $- 

  Maturity  Interest   September 30,   December 31, 
  Date  Rate   2017   2016 
3D Nano license Fee 31-Jan-17  NA  $-  $100,000 

  September 30, 2017  December 31, 2016 
Total $15,582,156  $17,832,509 
Less: current portion  (15,582,156)  (13,162,007)
Total, net of current portion $-  $4,670,502 

24
Table of Contents

 

Senior Secured Term Notes

On January 29, 2015, the Company and certain of its subsidiaries (each a “Subsidiary”) entered into a series of agreementsAgreements including a Fortress Securities Agreement and a SubscriptionPurchase Agreement with DBD Credit Funding LLC, (“DBD”) an affiliate of Fortress Credit Corp., under which the Company sold toterms of the purchasers: (i) $15,000,000 original principal amount of Senior Secured Notes (“Fortress Notes”), (ii) notes were:

(i)$15,000,000 original principal amount of Fortress Notes (the “Initial Note”);
(ii)a right to receive a portion of certain proceeds from monetization net revenues received by the Company (the “Revenue Stream”, after receipt by the Company of $15,000,000 of monetization net revenues and repayment of the Fortress Notes);
(iii) a five-year Fortress Warrant to purchase 25,000 shares of the Company’s Common Stock exercisable at $29.76 per share, subject to adjustment; and
(iv)33,603 shares of the Issuer’s Common Stock (the “Fortress Shares”).

On February 12, 2015, the Company (after receipt by the Company of $15,000,000 of monetization net revenues and repayment of the Fortress Notes), (the “Revenue Stream”), (iii) a five-year warrant (the “Fortress Warrant”) to purchase 100,000 shares of the Company’s Common Stock exercisable at $7.44 per share, subject to adjustment; and (iv) 134,409 shares of the Company’s Common Stock.  Under the Fortress Securties Purchase Agreement, the Company has the right to require the purchasers to purchaseissued an additional $5,000,000 of Fortress Notes (which will increase proportionately the Revenue Stream), subject to the achievement of certain milestones, and further contemplates that Fortress may, but is not obligated to, fund up to an additional $30,000,000, on equivalent economic terms.  The Company may use the proceeds to finance the monetization of its existing assets, provide further expansion capital for new acquisitions, to repay existing debt (including without limitation, the Company’s 11% convertible notes issued October 9, 2013 and for general working capital and corporate purposes..

 

Pursuant to the Fortress Securities Purchase Agreement entered into on January 29, 2015, the Company issued to Fortress a Note in the original principal amount of $15,000,000 (the “Initial Note”). The Initial Note matures on July 29, 2018. If any additional FortressAdditional Notes are issued pursuant to the Fortress Securities Purchase Agreement the maturity date of such additional Fortress Notes shall bemature 42 months after issuance. The unpaid principal amount of the Initial Note plus the additional $5,000,000 note (including any PIK Interest, as defined below) shall bear cash interest at a rate equal to LIBOR plus 9.75% per annum; provided that upon and during the continuance of an Event of Default (as defined in the Fortress Securities Purchase Agreement), the interest rate shall increase by an additional 2% per annum.  As of September 30, 2016, the twelve-month LIBOR USD rate was 1.55%. Interest on the Initial Note shall be paidannum payable on the last business day of each calendar month (the “Interest Payment Date”), commencing January 31, 2015.month. Interest shall beis paid in cash except that 2.75% per annum of the interest due on each Interest Payment Date shall be paid-in-kind, by increasing the principal amount of the Fortress Notes by the amount of such interest, effective asinterest. Monthly principal payments are due commencing one year after the anniversary dates of the applicable Interest Payment Date (“PIK Interest”).  PIK Interest shall be treated as added principal of the Initial Note for all purposes, including interest accrual and the calculation of any prepayment premium.

The Fortress Securities Purchase Agreement contains certain customary events of default, and also contains certain covenants including a requirement that the Company maintain minimum liquidity of $1,000,000 in unrestricted cash and cash equivalents and that the Company shall have Monetization Revenues (as defined in the Fortress Securities Purchase Agreement) for each of the four fiscal quarters commencing December 31, 2014 of at least $15,000,000.loans.

 

The terms of the Fortress Warrant provide that until January 29, 2020, the Fortress Warrant may be exercised for cash or on a cashless basis. Exercisability of the Fortress Warrant is limited if, upon exercise, the holder would beneficially own more than 4.99% of the Company’s Common Stock. The exercise price of the warrant is $29.76 and the warrant fair value was determined to be $318,679 utilizing the Black-Scholes model, with the fair value of the warrants recorded as additional paid-in capital and reducing the carrying value of the Notes. As of September 30, 2017 and December 31, 2016, the unamortized discount on the Notes was $1,686,090 and $1,425,167, respectively.

 

As partSenior Secured Term Note Amendment

On January 10, 2017 the Company and certain of the transaction, DBDits subsidiaries entered into a lock-up agreementthe Amended and Restated Revenue Sharing and Securities Purchase Agreement (“ARRSSPA”) with DBD Credit Funding LLC, under which the Company and DBD amended and restated the Revenue Sharing and Securities Purchase Agreement dated January 29, 2015 (the “Lock-Up“Original Agreement”) pursuant to which (i) Fortress purchased $20,000,000 in promissory notes, of which $15,881,493 is outstanding as of September 30, 2017, (ii) an interest in the partiesCompany’s revenues from certain activities and warrants to purchase 25,000 shares of the Company’s common stock. The ARRSSPA amends and restates the Original Agreement to provide for (i) the sale by the Company of a $4,500,000 promissory note (the “New Note”) and (ii) the insurance of additional warrants to purchase 46,875 shares of common stock (the “New Warrant”). Pursuant to the ARRSSPA, Fortress acquired an increased revenue stream right to certain related holders agreed untilrevenues generated by the earlierCompany through monetization of 12 monthsour patent portfolio (“Monetization Revenues”). The ARRSSPA increases the revenue stream basis to $1,225,000. The ARRSSPA provides for the potential issuance of up to $7,500,000 of additional notes (the “Additional Notes”), of which not more than $3,750,000 shall be made prior to June 30, 2017 and of which not more than $3,750,000 shall be made available during the period following June 30, 2017 and on or accelerationprior to December 31, 2017 and not more than two such issuances shall occur under the ARRSSPA.

The unpaid principal amount of the New Note (including any PIK Interest, as defined below) shall bear cash interest at a rate equal to LIBOR plus 9.75% per annum; provided that upon and during the continuance of an Event of Default (as defined in the Fortress Securities Purchase Agreement)Initial Note), the interest rate shall increase by an additional 2% per annum.

Interest on the Initial Note shall be paid on the last business day of each calendar month (the “Interest Payment Date”), commencing January 31, 2017. Interest shall be paid in cash except that they will not, directly or indirectly, (i) offer, sell, offer to sell, contract to sell, hedge, hypothecate, pledge, sell any option or contract to purchase any option or contract to sell, grant any option, right or warrant to purchase or sell (or announce any offer, sale, offer2.75% per annum of sale, contractthe interest due on each Interest Payment Date shall be paid-in-kind, by increasing the principal amount of sale, hedge, hypothecation, pledge, salethe Notes by the amount of such interest, effective as of the applicable Interest Payment Date (“PIK Interest”). PIK Interest shall be treated as added principal of the New Note for all purposes, including interest accrual and the calculation of any option or contract to purchase, purchaseprepayment premium. The Company paid a structuring fee of 2.0% of the New Note and would pay a 2.0% fee upon the issuance of any option or contract of sale, grant of any option, right or warrant to purchase or other sale or disposition), or otherwise transfer or dispose of (or enter into any transaction or device that is designed to, or could be expected to, result in the disposition by any person at any time in the future), the Lock-Up Shares (as defined in the Lock-Up Agreement), beneficially owned, within the meaning of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), by such Holder and his/her Related Group (as such terms are defined in the Lock-Up Agreement) on the dateAdditional Notes. The proceeds of the Lock-Up Agreement or thereafter acquired or (ii) enter intoNew Note and any swap orAdditional Notes may be used for working capital purposes, portfolio acquisitions, growth capital and other agreement or any transactiongeneral corporate purposes.

25
Table of Contents

The ARRSSPA contains certain customary events of default, and also contains certain covenants including a requirement that transfers,the Company maintain minimum liquidity of $1,250,000 in whole or in part, directly or indirectly, the economic consequence of ownershipunrestricted cash and cash equivalents.

The terms of the Lock-Up Shares, whetherNew Warrants provide that from July 10, 2017 until January 10, 2022, the Warrant may be exercised for cash or not any such swap or transaction described in clause (i) or (ii) above is to be settled by delivery of any Lock-Up Shares.  The Holders may purchase additional shareson a cashless basis. Exercisability of the Company’s Common Stock duringWarrant is limited if, upon exercise, the Lock-Up Period (as defined in the Lock-Up Agreement) to the extent that such purchase only increases the net holdingholder would beneficially own more than 4.99% of the Holders in the Company.Issuer’s Common Stock.

 

In connection with the transactions described above, TechDev, Audrey Spangenberg, Erich Spangenberg, and Granicus (the “Spangenberg Holders”) entered into a lock-up agreement (the “Spangenberg Lockup”) with respect to 1,626,924 shares of Common Stock, 48,078 shares of Common Stock underlying warrants, and 782,000 shares of Common Stock underlying preferred stock, pursuant to which the Spangenberg Holders agreed that until payment in full of the Note Obligations (as defined in the Fortress Notes), which shall include but not be limited to all principal and interest on outstanding Fortress Notes pursuant to the Fortress Securities Purchase Agreement, the Spangenberg Holders and certain related parties agreed that they will not, directly or indirectly, (i) offer, sell, offer to sell, contract to sell, hedge, hypothecate, pledge, sell any option or contract to purchase any option or contract to sell, grant any option, right or warrant to purchase or sell (or announce any offer, sale, offer of sale, contract of sale, hedge, hypothecation, pledge, sale of any option or contract to purchase, purchase of any option or contract of sale, grant of any option, right or warrant to purchase or other sale or disposition), or otherwise transfer or dispose of (or enter into any transaction or device that is designed to, or could be expected to, result in the disposition by any person at any time in the future), more than 5% of the Spangenberg Lockup shares (as defined in the Spangenberg Lock-Up Agreement), beneficially owned, within the meaning of Rule 13d-3 under the Exchange Act, by such Holder and his/her Related Group (as such terms are defined in the Spangenberg Lock-Up Agreement) on the date of the Spangenberg Lock-Up Agreement or thereafter acquired or (ii) enter into any swap or other agreement or any transaction that transfers, in whole or in part, directly or indirectly, the economic consequence of ownership of more than 5% of the Spangenberg Lock-Up Shares, whether or not any such swap or transaction described in clause (i) or (ii) above is to be settled by delivery of any Lock-Up Shares. The Spangenberg Holders may purchase additional shares of the Company’s Common Stock during the Lock-Up Period (as defined in the Spangenberg Lock-Up Agreement) to the extent that such purchase only increases the net holding of the Holders in the Company.

Pursuant to the Fortress Securities Purchase Agreement,ARSSPA, as security for the payment and performance in full of the Secured Obligations (as defined in the Fortress Securities Purchase Agreement)Security Agreement entered in favor of DBD,the Note purchasers (the “Security Agreement”) the Company and certain subsidiaries executed and delivered in favor of DBDthe purchasers a Security Agreement (“Security Agreement”) and a Patent Security Agreement, (“Patent Security Agreement”), including a pledge of the Company’s interests in certain of its subsidiaries. As further set forth in the Security Agreement, repayment of the Note Obligations (as defined in the Notes) is secured by a first priority lien and security interest in all of the assets of the Company, subject to certain permitted liens on permitted indebtedness that existed as of January 29, 2015. The security interest does not include a lien on the assets held by Orthophoenix, LLC.liens. Certain subsidiaries of the Company (excluding Orthophoenix) also executed guarantees in favor of the purchasers (each, a “Guaranty”), guaranteeing the Note Obligations.  As required by

Amendment to Senior Secured Term Note Amendment

On August 3, 2017, the termsCompany and certain of its operating subsidiaries entered into a First Amendment to Amended and Restated Revenue Sharing and Securities Purchase Agreement and Restructuring Agreement (the “First Amendment and Restructuring Agreement”) with DBD to cancel the indebtedness and other obligations of the Company under that certain notes issuedARRSSPA, dated January 10, 2017, which was originally entered into by the Company in October 2014 (“October Notes”), the October Note holders consented to the transactions described herein.

Within thirty days, the Company was required to open a cash collateral account into which all Company revenue shall be deposited and which shall be subject to a control agreement outlining the disbursement in accordance with the terms of the Fortress Securities Purchase Agreement of all proceeds.DBD on January 29, 2015.

 

Pursuant to the Fortress Securities PurchaseFirst Amendment and Restructuring Agreement, certain intellectual property owned by the Company (the “Designated IP”) is to be assigned to one or more newly created special purpose entities (the “SPE”) as elected by DBD, which to be formed SPE shall be under the management and control of an affiliate of DBD (the “IP Monetization Manager”). All intellectual property owned by the Company that will not be assigned to one or more newly created special purpose entities shall be referred to as “Non- Designated IP.” The patents that are part of the Designated IP are referred to as the “Designated Patents”. Until shareholder approval and the close of the First Amendment and Restructuring Agreement (the “Restructuring”), all Monetization Revenues arising from the Designated IP and Non-Designated IP shall be paid to an account that is under the sole and exclusive control of the Collateral Agent as the IP Monetization Manager. In addition, until the Restructuring, the Company shall be responsible for the expenses associated with the maintenance, prosecution and enforcement of all of the Company’s intellectual property including the Designated IP and the other IP owned by the Company which is not to be transferred to the SPE, and for any expenses associated with the pursuit of monetization activities relating to both the Designated IP and the Non-Designated IP. From and after the Restructuring, the SPE shall have sole responsibility for the expenses associated with the Designated IP and the Company shall have sole responsibility for the expenses associated with the Non-Designated IP.

On October 20, 2017, the Company and DBD satisfied all the closing conditions related to the First Amendment and Restructuring Agreement. With the close of the First Amendment and Restructuring Agreement, the Company exchanged the patent portfolios held by Dynamic Advances LLC, Magnus IP GmbH and Traverse Technologies Corp. (all wholly-owned subsidiaries of the Company) in exchange for the cancelation of all indebtedness and obligations to DBD.

As of September 30, 2017 and December 31, 2016, the outstanding balances were $15,881,493 and $15,620,759, respectively.

Convertible Note

In two transactions, on October 9, 2014 and October 16, 2014, the Company sold an aggregate $5,550,000 of principal amount of convertible notes (“Convertible Notes”) along with two-year warrants to purchase 32,375 shares of the Company’s Common Stock. The Convertible Notes are convertible into shares of the Company’s Common Stock at $30.00 per share and the Warrants have an exercise price of $33.00 per share. The Notes mature on October 10, 2018 and bear interest at the rate of 11% per annum, payable quarterly in cash on each of the three, nine, nine and twelve-month anniversaries of the issuance date and on each conversion date. The Notes may become secured by a security interest granted to the holder in certain future assets under certain circumstances. In the event the Company’s Common Stock trades at a price of at least $108.00 per share for four out of eight trading days, the Notes will be mandatorily converted into Common Stock of the Company at the then applicable conversion price per share. The Company repaid the Convertible Notes for all but one holder in early 2015, and exchanged the remaining balance for Series D Convertible Preferred Stock on August 7, 2017, with the Series D Convertible Preferred Stock converted in its entirety prior to September 30, 2017. The balance was $0 and $500,000 as of September 30, 2017 and December 31, 2016, respectively.

26
Table of Contents

iRunway

The Company converted a set of outstanding invoices related to work performed by one of the Company’s vendors to a short-term payable whereby the Company agreed to pay iRunway over time for the open invoices, subject to a payment schedule as defined. To the extent that the Company does not make payments according to that schedule, the remaining balance accrues interest at 1.5% per month. On August 20, 2017, the Company entered into the Fortress Patent License Agreementa release agreement with DBDiRunway pursuant to which the Company agreedmade an immediate cash payment to grant to the Licensee certain rights, including right to license certain patents and patent applications, which licensing rights to be available solely upon an accelerationiRunway in return for a release of the Note Obligations, as provided inremaining amount outstanding. As of September 30, 2017 and December 31, 2016, the Fortress Securities Purchase Agreement.principal balance was $0 and $191,697, respectively.

 

Note Payable

The Company entered into a short-term advance with an officer related to funds the Company was transferring from its European subsidiaries. The advance carried no interest and as of September 30, 2017 and December 31, 2016, the outstanding balance was $0 and $103,000, respectively.

Siemens Purchase Payment

The Company entered into a purchase agreement to acquire ownership of certain patents. As part of the purchase agreement, the Company agreed to certain future payments of cash consideration. The payment obligation bears no interest. On September 1, 2017, the Company entered into Share Purchase Agreement with GPat whereby the Company sold its 100% interest in Munitech, the wholly-owned subsidiary holding these patents, to GPat. As of September 30, 2017 and December 31, 2016, the outstanding balances were $0 and $1,672,924, respectively.

Dominion Harbor Settlement Note

The Company entered into a settlement agreement with Dominion Harbor, a former licensing agent for some of the Company’s subsidiaries, on October 29, 2015 whereby the Company agreed to issue 75,000 shares of the Company’s Common Stock to Dominion Harbor and make eight (8) payments of $25,000 each ending on October 15, 2017. The shares issued to Dominion Harbor were valued at the quoted market price on the date of the grant of $6.84 per share or $513,000. As of September 30, 2017 and December 31, 2016, $0 and $125,000, respectively, remained outstanding, following an agreement between the Company and Dominion wherein the Company paid $25,000 and issued 31,250 shares of Common Stock to Dominion in full resolution of the outstanding obligation.

Oil & Gas Purchase Payment

The Company entered into a purchase agreement to acquire monetization rights to certain patents. As part of the purchase agreement, the Company agreed to certain future payments of cash consideration. The payment obligation bears no interest and as of September 30, 2017 and December 31, 2016, the Company had an outstanding obligation for purchase of certain Siemens patents in the amount of $1,000,000 and $944,296, respectively, with such payments expected to be made by December 31, 2017.

Convertible Note

On August 14, 2017, the Company entered into a unit purchase agreement (the “Unit Purchase Agreement”) with certain accredited investors providing for the sale of up to $5,500,000 of 5% secured convertible promissory notes (the “Convertible Notes”), which are convertible into shares of the Corporation’s common stock, and the issuance of warrants to purchase 6,875,000 shares of the Company’s Common Stock (the “Warrants”). The Convertible Notes are convertible into shares of the Company’s Common Stock at the lesser of (i) $0.80 per share or (ii) the closing bid price of the Company’s common stock on the day prior to conversion of the Convertible Note; provided that such conversion price may not be less than $0.40 per share. The Warrants have an exercise price of $1.20 per share. The Convertible Notes mature on May 31, 2018 and bear interest at the rate of 5% per annum. In two closings of the Unit Purchase Agreement, the Company issued all $5,500,000 in Convertible Notes to the investors. As of September 30, 2017, the Company had an outstanding obligation pursuant to the Convertible Notes in the amount of $5,072,232.

27
Table of Contents

3D Nano Purchase Payment

3D Nano entered into a license and purchase agreement with HP Inc. (“HP”) to acquire the rights to use if 3D Nano chooses, the right to exercise an option to acquire, ownership of certain patents, trade secrets and other intellectual property (the “Technology”). As part of the purchase agreement, the Company agreed to license the Technology for two payments of $100,000 each, with the first payment made in April 2016 and the second payment due by January 31, 2017. Under the original agreement, the payment obligations bear no interest and as of September 30, 2017 and December 31, 2016, 3D Nano had an outstanding obligation in the amount of $0 and $100,000, respectively. On May 1, 2017, 3D Nano entered into an amendment with HP whereby the agreement was extended for two years. While 3D Nano does not have the obligation under the amendment to make additional payments, should 3D Nano desire to do so, payments in the amount of $100,000 in each of 2018 and 2019 would be due to HP for the agreement to remain in effect.

Medtech Note

On May 31, 2017, the Company entered into a note payable with Medtronic, Inc. (“Medtronic”), the original owner of the patents in the Company’s Medtech portfolio, whereby the Company agreed to pay Medtronic a total of $750,000 in ten equal monthly installments for patent enforcement related expenses incurred by Medtronic. Following two payments of $75,000 each in May and June 2017, the Company entered into an agreement on August 29, 2017 to pay a discounted amount in return for a full release from the remaining obligations. The note payable carries no interest and since the note payable arose after December 31, 2016 and was repaid in full prior to September 30, 2016, as of September 30, 2017 and December 31, 2016, the outstanding balance, was $0 and $0, respectively.

Total Future Minimum Principal Payments

Future minimum principal payments for all items set forth above are as follows:

2017 $16,881,493 
2018  5,072,232 
Total $21,953,725 

Office Lease

 

In October 2013, the Company entered into a net-lease for its current office space in Los Angeles, California. The lease commencedwill commence on May 1, 2014 and runs for seven years through April 30, 2021, with monthly lease payment escalating each year of the lease. In addition, to paying a deposit of $7,564 and the monthly base lease cost, the Company is required to pay a pro rata share of operating expenses and real estate taxes. Under the terms of the lease, the Company will not be required to pay rent for the first five months but must remain in compliance with the terms of the lease to continue to maintain that benefit. In addition, the Company has a one-time option to terminate the lease in the 42th month of the lease. Minimum future lease payments under this lease at September 30, 2016,2017, for the next five years and thereafter are as follows:

 

2016

 

$

17,304

 

2017

 

 

71,288

 

2017 (Three Months) $18,081 

2018

 

 

74,540

 

  74,540 

2019

 

 

77,872

 

  77,872 

2020

 

 

81,336

 

  81,336 

Thereafter

 

 

27,504

 

2021  27,504 

Total

 

$

349,844

 

 $297,333 

28
Table of Contents

 

NOTE 7 – SUBSEQUENT EVENTS

 

NoneOn October 20, 2017, the Company and DBD satisfied all the closing conditions related to the First Amendment and Restructuring Agreement. With the close of the First Amendment and Restructuring Agreement, the Company exchanged the patent portfolios held by Dynamic Advances LLC, Magnus IP GmbH and Traverse Technologies Corp. (all wholly-owned subsidiaries of the Company) in exchange for the cancelation of all indebtedness and obligations to DBD.

On October 27, 2017, the Company entered into the Assignment with Luxone whereby the Company assigned all of its ownership interest in PG Tech to Luxone. Pursuant to the Assignment, Luxone assumed the Company’s ownership interest in PG Tech and the Company removed from its balance sheet all the liabilities and debt associated with PG Tech and received in return a revenue share associated with future earnings from the PG Tech portfolio. Luxone is owner or controlled by a former affiliate of the Company.

On November 1, 2017, the Company entered into an agreement to acquire, through its wholly-owned subsidiary, Global Bit Ventures Acquisition Corp., a Nevada corporation (“GBVAC”), 100% of the Capital Stock of Global Bit Ventures, Inc., a Nevada corporation (“GBV”), which currently secures and powers digital asset blockchains by running specialized servers. Under the terms of the Agreement and Plan of Merger (the “Merger Agreement”), the Company will issue 126,674,557 shares of the Company’s Common Stock in exchange for one-hundred (100%) percent of the shares of GBV’s capital stock. At the closing of the merger, GBVAC shall be merged with and into GBV pursuant to the Merger Agreement and the separate existence of GBVAC shall cease and GBV shall be the surviving company. The closing of the acquisition is subject to certain closing conditions including approval of the Merger Agreement by the Company’s Shareholders.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

This report on Form 10-Q (“Report”) and other written and oral statements made from time to time by us may contain so-called “forward-looking statements,” all of which are subject to risks and uncertainties. Forward-looking statements can be identified by the use of words such as “expects,” “plans,” “will,” “forecasts,” “projects,” “intends,” “estimates,” and other words of similar meaning. One can identify them by the fact that they do not relate strictly to historical or current facts. These statements are likely to address our growth strategy, financial results and product and development programs. One must carefully consider any such statement and should understand that many factors could cause actual results to differ from our forward lookingforward-looking statements. These factors may include inaccurate assumptions and a broad variety of other risks and uncertainties, including some that are known and some that are not. No forward-looking statement can be guaranteed and actual future results may vary materially.

 

Information regarding market and industry statistics contained in this Report is included based on information available to us that we believe is accurate. It is generally based on industry and other publications that are not produced for purposes of securities offerings or economic analysis. We have not reviewed or included data from all sources, and cannot assure investors of the accuracy or completeness of the data included in this Report. Forecasts and other forward-looking information obtained from these sources are subject to the same qualifications and the additional uncertainties accompanying any estimates of future market size, revenue and market acceptance of products and services. We do not assume any obligation to update any forward-looking statement. As a result, investors should not place undue reliance on these forward-looking statements.

 

Overview

 

We acquire

The Company has acquired patents and patent rights from owners or other ventures and seekseeks to monetize the value of the patents through litigation and licensing strategies, alone or with others.  Part of our acquisition strategy is to acquire or invest in patents and patent rights that cover a wide-range of subject matter which allows us to seek the benefits of a diversified portfolio of assets in differing industries and countries.  Generally, the patents and patent rights that we seek to acquire have large identifiable targets who are or have been using technology that we believe infringes our patents and patent rights. We generally monetize our portfolio of patents and patent rights by entering into license discussions, and if that is unsuccessful, initiating enforcement activities against any infringing parties with the objective of entering into comprehensive settlement and license agreements that may include the granting of non-exclusive retroactive and future rights to use the patented technology, a covenant not to sue, a release of the party from certain claims, the dismissal of any pending litigation and other terms. Our strategy has been developed with the expectation that it will result in a long-term, diversified revenue stream for the Company. As of September 30, 2016,2017, we owned 519170 patents and had economic rights to over 10,000 additional patents, both of which include U.S. patents and certain foreign patents.counterparts, covering technologies used in a wide variety of industries. The greater than 10,000 patents to which the Company has economic rights were assigned to Luxone in an agreement entered into in October 2017; the Company retained an earn-out associated with future income from this portfolio, but no longer manages or is responsible for costs associated with licensing the portfolio.

 

The Company previously announced that it intended to review alternative business directions with the goal of enhancing shareholder value, and on November 1, 2017, the Company announced that it will be entering into the cryptocurrency mining market pursuant to the agreement to acquire 100% ownership of GBV, a digital asset technology company that mines cryptocurrencies. GBV is a technology company that powers and secures Blockchains by operating custom hardware and software, which verify Blockchain transactions. Blockchains are decentralized digital ledgers that record and enable secure peer-to-peer transactions without third party intermediaries. With the acquisition of GBV, the Company will be supplementing its existing business with this new business opportunity. GBV currently owns 250GH/s of GPU mining servers and plans to add 14PH/s of ASIC hashing servers, with significant capability for expansion.

29
Table of Contents

Our principal office is located at 11100 Santa Monica Blvd., Suite 380, Los Angeles, CA 90225.90025. Our telephone number is (703) 232-1701.

 

We were incorporated in the State of Nevada on February 23, 2010 under the name “Verve Ventures, Inc.” On December 7, 2011, we changed our name to “American Strategic Minerals Corporation” and were engaged in exploration and potential development of uranium and vanadium minerals business. During June 2012, we discontinued our minerals business and began to invest in real estate properties in Southern California. In November 2012, we discontinued our real estate business.

 

On July 18, 2013, we2017, shareholders of record holding a majority of the outstanding voting capital of the Company approved a reverse stock split of the Company’s issued and outstanding common stock by a ratio of not less than one-for-four and not more than one-for-twenty-five, with such ratio to be determined by the Board of Directors, in its sole discretion. On October 25, 2017, the reverse stock split ratio of one (1) for four (4) basis was approved by the Board of Directors. On October 30, 2017, the Company filed a certificate of amendment to ourits Amended and Restated Articles of Incorporation with the Secretary of State of the State of Nevada in order to effectuate a reverse stock split of ourthe Company’s issued and outstanding common stock, par value $0.0001 per share on a one (1) for thirteen (13) basis (the “Reverse Split”). The Reverse Split became effective with FINRA at the open of business on July 22, 2013. As a result of the Reverse Stock Split, every thirteen shares of our pre-reverse split common stock was combined and reclassified into one share of our common stock. No fractional shares of common stock were issued as a result of the Reverse Split. Stockholders who otherwise would be entitled to a fractional share received the next highest number of whole shares.four (4) basis.

 

On November 19, 2014, the Board of Directors of the Company declared a stock dividend (“Dividend”) pursuant to which holders of the Company’s Common Stock as of the close of business of the record date of December 15, 2014 received one additional share of Common Stock at the close of business on December 22, 2014 for each share of Common Stock held by such holders. Throughout this Report, allAll share and per share values for all periods presented in the accompanying condensed consolidated financial statements are retroactively restated foradjusted as of September 30, 2017 to reflect the effect of the stock dividend.Reverse Split.

 

Throughout this Report, each instance in which we refer to a number of shares of our Common Stock, the number refers to the number of shares of Common Stock after giving effect to the Reverse Split and the Dividend, unless otherwise indicated.

Critical Accounting Policies and Estimates

 

The discussion and analysis of our financial condition and results of operations are based upon our financial statements, which have been prepared in accordance with US GAAP. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, we evaluate our estimates based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

 

Management believes the following critical accounting policies affect the significant judgments and estimates used in the preparation of the financial statements.

 

Basis of Presentation and Principles of Consolidation

 

The accompanying consolidated condensed financial statements arehave been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). Certain information and disclosures normally included in financial statements prepared in accordance with US GAAPaccounting principles generally accepted in the United States of America (U.S. GAAP) have been condensed or omitted pursuant to such rules and regulations. These consolidated condensed financial statements reflect all adjustments (consisting only of normal recurring adjustments) which, in the opinion of management, are necessary to present fairly the financial statementsposition, the results of operations and cash flows of the Company and our wholly-owned and majority owned subsidiaries.  Infor the preparation of ourperiods presented. It is suggested that these consolidated condensed financial statements intercompany transactionsbe read in conjunction with the consolidated condensed financial statements and balancesthe notes thereto included in the Company’s most recent Annual Report on Form 10-K. The results of operations for the interim periods are eliminated.not necessarily indicative of the results to be expected for the full year.

 

Variable Interest Entities

Financial Accounting Standards Board, or FASB, accounting guidance concerning variable interest entities, or VIE, addresses the consolidation of a business enterprise to which the usual condition of consolidation (ownership of a majority voting interest) does not apply. This guidance focuses on controlling financial interests that may be achieved through arrangements that do not involve voting interests. The guidance requires an assessment of who the primary beneficiary is and whether the primary beneficiary should consolidate the VIE. The primary beneficiary is identified as the variable interest holder that has both the power to direct the activities of the variable interest entity that most significantly impacts the entity’s economic performance and the obligation to absorb losses or the right to receive benefits from the entity that could potentially be significant to the variable interest entity. Application of the VIE consolidation requirements may require the exercise of significant judgment by management.

On August 11, 2016, PG Technologies S.a.r.l. (“PG Tech”), a Luxembourg limited liability company jointly owned with a large litgation financing fund, entered into a Patent Funding and Exclusive License Agreement (the “ELA”) to manage the monetization of greater than 10,000 patents in a single industry vertical with a Fortune 50 company. The patents cover all the major global economies including China, France, Germany, the United Kingdom and the United States. The Company determined that the the Company’s ownership interest constitutes a VIE and that the Company is the primary beneficiary because the Company satisfies both the power and benefits criterion pursuant to ASC 810. As a result, the Company will consolidate the VIE within its financial statements.

Use of Estimates and Assumptions

 

The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates made by management include, but are not limited to, estimating the useful lives of patent assets, the assumptions used to calculate fair value of warrants and options granted, goodwill impairment, realization of long-lived assets, deferred income taxes, unrealized tax positions and business combination accounting.

 

30
Table of Contents

Revenue Recognition

 

The Company recognizes revenue in accordance with ASCAccounting Standards Codification (“ASC”) Topic 605, “Revenue Recognition.”Recognition”. Revenue is recognized when (i) persuasive evidence of an arrangement exists, (ii) all obligations have been substantially performed, (iii) amounts are fixed or determinable and (iv) collectability of amounts is reasonably assured. In general, revenue arrangements provide for the payment of contractually determined fees in consideration for the grant of certain intellectual property rights for patented technologies owned or controlled by the Company.

These rights typically include some combination of the following: (i) the grant of a non-exclusive, perpetual license to use patented technologies owned or controlled by the Company, (ii) a covenant-not-to-sue, (iii) the dismissal of any pending litigation.

The intellectual property rights granted typically are perpetual in nature. Pursuant to the terms of these agreements, the Company has no further obligation with respect to the grant of the non-exclusive licenses, covenants-not-to-sue, releases, and other deliverables, including no express or implied obligation on the Company’s part to maintain or upgrade the technology, or provide future support or services. Generally, the agreements provide for the grant of the licenses, covenants-not-to-sue, releases, and other significant deliverables upon execution of the agreement. As such, the earnings process is complete and revenue is recognized upon the execution of the agreement, when collectability is reasonably assured, and when all other revenue recognition criteria have been met.

 

The Company also considers the revenue generated from aits settlement and licensing agreementagreements as one unit of accounting under ASC 605-25, “Multiple-Element Arrangements” as the delivered items do not have value to customers on a standalone basis, there are no undelivered elements and there is no general right of return relative to the license. Under ASC 605-25, the appropriate recognition of revenue is determined for the combined deliverables as a single unit of accounting and revenue is recognized upon delivery of the final elements, including the license for past and future use and the release.

 

Also, due to the fact that the settlement element and license element for past and future use are the Company’s major central business, the Company presents these two elements as one revenue category in its statement of operations. The Company does not expect to provide licenses that do not provide some form of settlement or release.

 

Accounting for Acquisitions

 

In the normal course of its business, the Company makes acquisitions of patent assets and may also make acquisitions of businesses. With respect to each such transaction, the Company evaluates facts of the transaction and follows the guidelines prescribed in accordance with ASC 805 Business Combinations to determine the proper accounting treatment for each such transaction and then records the transaction in accordance with the conclusions reached in such analysis. The Company performs such analysis with respect to each material acquisition within the consolidated group of entities.

Intangible AssetsAsset - Patents

 

Intangible assets include patents purchased and patents acquired in lieu of cash in licensing transactions. The patents purchased are recorded based on the cost to acquire them and patents acquired in lieu of cash are recorded at their fair market value. The costs of these assets are amortized over their remaining useful lives. Useful lives of intangible assets are periodically evaluated for reasonableness and the assets are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may no longer be recoverable. The Company recorded an impairment chargescharge to its intangible assets during the three and nine months ended September 30, 2017 in the amount of $723,218 and $723,218, respectively, compared to an impairment charge associated with the end of life of a number of the Company’s portfolios during the three and nine months ended September 30, 2016 in the amounts of $5,531,383 and 6,525,273, respectively, associated with the end of life of a number of the Company’s portfolios, compared to an impairment charge in the amount of $0 and $766,498, respectively, during the three and nine months ended September 30, 2015 associated with the reduction in the carrying value of one the Company’s portfolios.$6,525,273, respectively.

31
Table of Contents

Goodwill

 

Goodwill

Goodwill is tested for impairment at the reporting unit level at least annually in accordance with ASC 350, and between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying value. In accordance with ASC 350-30-65, “Intangibles - Goodwill and Others”, the Company assesses the impairment of identifiable intangibles whenever events or changes in circumstances indicate that the carrying value may not be recoverable. Factors the Company considers to be important which could trigger an impairment review include the following:

1.                                      Significant underperformance relative to expected historical or projected future operating results;

2.                                      Significant changes in the manner of use of the acquired assets or the strategy for the overall business;

3.                                      Significant negative industry or economic trends; and

4.                                      Significant reduction or exhaustion of the potential licenses of the patents which gave rise to the goodwill.

When the Company determines that the carrying value of intangibles may not be recoverable based upon the existence of one or more of the above indicators of impairment and the carrying value of the asset cannot be recovered from projected undiscounted cash flows, the Company records an impairment charge. The Company measures any impairment based on a projected discounted cash flow method using a discount rate determined by management to be commensurate with the risk inherent in the current business model. When conducting its annual goodwill impairment assessment, the Company initially performs a qualitative evaluation of whether it is more likely than not that goodwill is impaired. If it is determined by a qualitative evaluation that it is more likely than not that goodwill is impaired, the Company then applies a two-step impairment test. The two-step impairment test first compares the fair value of the Company’s reporting unit to its carrying or book value. If the fair value of the reporting unit exceeds its carrying value, goodwill is not impaired and the Company is not required to perform further testing.impaired. If the carrying value of the reporting unit exceeds its fair value, the Company determines the implied fair value of the reporting unit’s goodwill and if the carrying value of the reporting unit’s goodwill exceeds its implied fair value, then an impairment loss equal to the difference is recorded in the consolidated condensed statement of operations. The Company performs the annual testing for impairment of goodwill at the reporting unit level during the quarter ended September 30.

 

For the three and nine months ended September 30, 20162017, the Company recorded anno impairment charge to its goodwill in the amount of $0 and $83,000, respectively.  For the three and nine months ended September 30, 2015 the Company recorded an impairment charge to its goodwill in the amount of $0 and $0, respectively.  The impairment charge to goodwill for the three and nine months ended September 30, 2016, resulted from the determinationCompany recorded an impairment to its Goodwill in the amount of $0 and $83,000, respectively.

Other Intangible Assets

In accordance with ASC 350-30-65, “Intangibles - Goodwill and Others”, the Company assesses the impairment of identifiable intangibles whenever events or changes in circumstances indicate that onethe carrying value may not be recoverable. Factors the Company considers to be important which could trigger an impairment review include the following: (1) significant underperformance relative to expected historical or projected future operating results; (2) significant changes in the manner of use of the Company’s portfolios had reachedacquired assets or the end of its useful life.strategy for the overall business; and (3) significant negative industry or economic trends.

 

When the Company determines that the carrying value of intangibles may not be recoverable based upon the existence of one or more of the above indicators of impairment and the carrying value of the asset cannot be recovered from projected undiscounted cash flows, the Company records an impairment charge. The Company measures any impairment based on a projected discounted cash flow method using a discount rate determined by management to be commensurate with the risk inherent in the current business model.

For the three and nine months ended September 30, 2017 and September 30, 2016, the Company recorded no impairment charge to its other intangible assets.

Impairment of Long-lived Assets

The Company accounts for the impairment or disposal of long-lived assets according to the ASC 360 “Property, Plant and Equipment”. The Company continually monitors events and changes in circumstances that could indicate that the carrying amounts of long-lived assets may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated future net undiscounted cash flows expected to be generated by the asset. When necessary, impaired assets are written down to estimated fair value based on the best information available. Estimated fair value is generally based on either appraised value or measured by discounting estimated future cash flows. Considerable management judgment is necessary to estimate discounted future cash flows. Accordingly, actual results could vary significantly from such estimates. The Company recognizes an impairment loss when the sum of expected undiscounted future cash flows is less than the carrying amount of the asset.

The Company did not record any impairment charges on its long-lived assets during the three and nine months ended September 30, 2017 and September 30, 2016.

Stock-based Compensation

 

Stock-based compensation is accounted for based on the requirements of the Share-Based Payment Topic of ASC 718 which requires recognition in the consolidated financial statements of the cost of employee and director services received in exchange for an award of equity instruments over the period the employee or director is required to perform the services in exchange for the award (presumptively, the vesting period). The ASC also requires measurement of the cost of employee and director services received in exchange for an award based on the grant-date fair value of the award. As stock-based compensation expense is recognized based on awards expected to vest, forfeitures are also estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.

32
Table of Contents

For the three and nine months ended September 30, 2017, the expected forfeiture rate was 12.75%, which resulted in an expense of $60,115 and $108,748, for the three and nine months ended September 30, 2017, respectively, recognized in the Company’s compensation expenses. For the three and nine months ended September 30, 2016, the expected forfeiture rate was 11.03%, which resulted in an expense of $9,570 and $36,832 for the three and nine months ended September 30, 2016, respectively, recognized in the Company’s compensation expenses. The Company will continue to re-assess the impact of forfeitures if actual forfeitures increase in future quarters.

 

Pursuant to ASC Topic 505-50, for share-based payments to consultants and other third parties, compensation expense is determined at the “measurement date.” The expense is recognized over the vesting period of the award. Until the measurement date is reached, the total amount of compensation expense remains uncertain. The Company initially records compensation expense based on the fair value of the award at the reporting date. As stock-based compensation expense is recognized based on awards expected to vest, forfeitures are also estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. For both the three and nine months ended September 30, 2016, the expected forfeiture rate was 11.03%, which resulted in an expense of $9,570 and $36,832 for the three and nine months ended September 30, 2016, respectively, recognized in the Company’s compensation expenses. For both the three and nine months ended September 30, 2015, the expected forfeiture rate was 11.66%, which resulted in an expense of $8,423 and $16,004 for the three and nine months ended September 30, 2015, respectively, recognized in the Company’s compensation expenses.

The Company will continue to re-assess the impact of forfeitures if actual forfeitures increase in future quarters.

 

Liquidity and Capital Resources

 

At September 30, 2016,2017, we had approximately $1.3$.1 million in unrestricted cash and acash equivalents, $3.9 million in restricted cash and an unrestricted working capital deficit of approximately $14.8 million, compared to approximately $2.6 million in cash and a working capital deficit of approximately $12.2 million as of December 31, 2015.$20.3 million.

 

Based on the Company’s current revenue and profit projections, management is uncertain that the Company’s existing cash and accounts receivables will be sufficient to fund its operations through at least the next twelve months.months, raising substantial doubt regarding the Company’s ability to continue operating as a going concern. If we do not meet our revenue and profit projections or the business climate turns negative, then we will need to:

 

·                                          raise additional funds to support the Company’s operations. There is no assurance that the Company will be able to raise such additional funds on acceptable terms, if at all. If the Company raises additional funds by issuing securities, existing stockholders may be diluted; and

·                                          review strategic alternatives.

raise additional funds to support the Company’s operations; however, there is no assurance that the Company will be able to raise such additional funds on acceptable terms, if at all. If the Company raises additional funds by issuing securities, existing stockholders may be diluted; and
review strategic alternatives.

 

If adequate funds are not available, we may be required to curtail our operations or other business activities or obtain funds through arrangements with strategic partners or others that may require us to relinquish rights to certain technologies or potential markets.

 

Recent Accounting Pronouncements

In August 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-15 StatementResults of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments (“ASU 2016-15”). The standard is intended to eliminate diversity in practice in how certain cash receipts and cash payments are presented and classified in the statement of cash flows. ASU 2016-15 will be effective for fiscal years beginning after December 15, 2017. Early adoption is permitted for all entities. The Company is currently evaluating the impact of this guidance on its consolidated financial statements.Operations

 

In March 2016, the FASB issued ASU No. 2016-09, “Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting” (“ASU 2016-09”). The standard is intended to simplify several areas of accounting for share-based compensation arrangements, including the income tax impact, classification on the statement of cash flows and forfeitures. ASU 2016-09 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2016, and early adoption is permitted. Accordingly, the standard is effective for us on September 1, 2017 and we are currently evaluating the impact that the standard will have on our consolidated financial statements.

In March 2016, the FASB issued ASU 2016-07, “Simplifying the Transition to the Equity Method of Accounting.” The amendments in the ASU eliminate the requirement that when an investment qualifies for use of the equity method as a result of an increase in the level of ownership interest or degree of influence, an investor must adjust the investment, results of operations, and retained earnings retroactively on a step-by-step basis as if the equity method had been in effect during all previous periods that the investment had been held. The amendments require that the equity method investor add the cost of acquiring the additional interest in the investee to the current basis of the investor’s previously held interest and adopt the equity method of accounting as of the date the investment becomes qualified for equity method accounting. Therefore, upon qualifying for the equity method of accounting, no retroactive adjustment of the investment is required. This ASU is effective for annual reporting periods beginning after December 15, 2016, and interim periods within those years and should be applied prospectively upon the effective date. Early adoption is permitted. The Company is currently evaluating the provisions of this guidance.

In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842)” (“ASU 2016-02”). The standard requires a lessee to recognize assets and liabilities on the balance sheet for leases with lease terms greater than 12 months. ASU 2016-02 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018, and early adoption is permitted. Accordingly, the standard is effective for us on September 1, 2019 using a modified retrospective approach. We are currently evaluating the impact that the standard will have on our consolidated financial statements.

In November 2015, the FASB issued ASU 2015-17, Balance Sheet Classification of Deferred Taxes.  This update requires an entity to classify deferred tax liabilities and assets as noncurrent within a classified statement of financial position.  ASU 2015-17 is effective for annual and interim reporting periods beginning after December 15, 2016.  This update may be applied either prospectively to all deferredtax liabilities and assets or retrospectively to all periods presented.  Early application is permitted as of the beginning of the interim or annual reporting period.  The Company adopted this standard for the annual period ending December 31, 2015.  The effect of adopting the new guidance on the balance sheet was not significant.

In September 2015, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update No. 2015-16, Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments, or ASU 2015-16. This amendment requires the acquirer in a business combination to recognize in the reporting period in which adjustment amounts are determined, any adjustments to provisional amounts that are identified during the measurement period, calculated as if the accounting had been completed at the acquisition date. Prior to the issuance of ASU 2015-16, an acquirer was required to restate prior period financial statements as of the acquisition date for adjustments to provisional amounts.  The new standard for an annual reporting period beginning after December 15, 2017 with an earlier effective application is permitted only as of annual reporting periods beginning after December 15, 2016.  The new guidance is not expected to have significant impact on the Company’s consolidated financial statements.

In April 2015, the FASB issued ASU 2015-05, Intangibles-Goodwill and Other — Internal-Use Software; Customer’s Accounting for Fees Paid in a Cloud Computing Arrangement. Prior to this ASU, U.S. GAAP did not include explicit guidance about a customer’s accounting for fees paid in a cloud computing arrangement. Examples of cloud computing arrangements include software as a service, platform as a service, infrastructure as a service, and other similar hosting arrangements. This ASU provides guidance to customers about whether a cloud computing arrangement includes a software license, in which case the customer should account for such license consistent with the acquisitions of other software licenses. If the cloud computing arrangement does not include a software license, the customer should account for the arrangement as a service contract. The ASU does not change the accounting for service contracts. The new standard is effective for us on January 1, 2016 with early adoption permitted. We do not expect the adoption of ASU 2015-05 to have a significant impact on our consolidated financial statements.

In April 2015, the FASB issued new guidance on the presentation of debt issuance costs (ASU 2015-03, Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs), effective for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years and should be applied retrospectively to all periods presented. Early adoption of the new guidance is permitted for financial statements that have not been previously issued. The new guidance will require that debt issuance costs be presented in the balance sheet as a direct deduction from the related debt liability rather than as an asset, consistent with debt discounts.  The Company adopted ASU 2015-03 and as such, the debt issuance costs for Fortress note was presented in the balance sheet as direct deduction from the related debt liability.

In August 2014, the FASB issued Accounting Standards Update No. 2014-15, Disclosure of Uncertainties About an Entity’s Ability to Continue as a Going Concern. This standard update provides guidance around management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote disclosures. The new guidance is effective for all annual and interim periods ending after December 15, 2016. The new guidance is not expected to have a significant impact on the Company’s consolidated financial statements.

In May 2014, the Financial Accountings Standards Board (“FASB”) issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers, or ASU 2014-09, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The standard will replace most existing revenue recognition guidance in US GAAP when it becomes effective and shall take effective on January 1, 2017. The standard permits the use of either the retrospective or cumulative effect transition method and the early application of the standard is not permitted. The Company is presently evaluating the effect that ASU 2014-09 will have on its consolidated financial statements and related disclosures and has not yet selected a transition method.

There were other updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to have a material impact on the Company’s financial position, results of operations or cash flows.

Results of Operations

For the Three and Nine Months Ended September 30, 20162017 and 20152016

 

We generated revenues of $162,713 and $609,650 during the three and nine months ended September 30, 2017 as compared to $43,113 and $36,452,551 during the three and nine months ended September 30, 2016, respectively, as compared to $6,407,997 and $11,870,851 during2016. For the three and nine months ended September 30, 2015, respectively.  For the three months ended September 30, 2016, this represented a decrease of $6,364,884 or 99% and for the nine months ended September 30, 2016,2017, this represented an increase of $24,581,700$119,600 or 207%.277% and a decrease of $35,842,901 or 98%, respectively. On an absolute basis, revenue for the three and nine months ended September 30, 2017 was derived from the issuance of a one-time technology license outside of litigation and recurring royalties from the Company’s Medtech portfolio and for the three and nine months ended September 30, 2016 revenue was primarily derived from the issuance of one-time patent licenses with a small amountthe remainder of the revenue derived from recurring royaltiesroyalties.

The Company had no revenues from the issuance of one-time patent licenses to certain of the Company’s patent portfolios for the three months and nine ended September 30, 2017 and 0% and 99% for the three and nine months ended September 30, 2015 revenue was derived from both the issuance of one-time patent licenses and recurring royalties.  The increase in revenue from 2015 to 2016, resulted from a number of larger one-time license agreements entered into by the Company’s Dynamic Advances and Medtech subsidiaries.

Revenues from the issuance of one-time licenses to certain of the Company’s patent portfolios accounted for approximately 0% and 99% of our revenues for the three months and nine ended September 30, 2016 and 97% and 94% for the three and nine months ended September 30, 2015, respectively. For the three months ended September 30, 2016, the Company had2017, there were no revenue from the issuance of one-time licenses,patent settlement and license agreements, whereas revenues from the five largest settlement and license agreements accounted for 87%99% of the Company’s revenue for the comparable period ending September 30, 2015.

While the Company added a number of patent portfolios during the periods ending June 30, 2016 and September 30, 2016, and the Company intends to move towards a recurring revenue model associated with the new, larger portfolios, the Company expects that until such transition is fully enacted that a significant portion of its revenues in the upcoming periods will be based on one-time grants of similar non-recurring, non-exclusive, non-assignable licenses to a relatively small number of entities and their affiliates. Further, with the expected small number of firms with which the Company enters into license agreements, and the amount and timing of such license agreements, the Company also expects that its revenues may be highly variable from one period to the next.2016.

 

Direct cost of revenues during the three and nine months ended September 30, 20162017 amounted to $1,094,378$64,836 and $19,202,118,$1,544,322, respectively and for the three and nine months ended September 30, 2015,2016, the direct cost of revenues amounted to $4,002,040$1,094,378 and $12,190,415,$19,202,118, respectively. For the three and nine months ended September 30, 2016,2017, this represented a decrease of $2,907,661$1,479,486 or 73%94% and for the nine months ended September 30, 2016, this represented an increase of $7,011,703$18,107,740 or 58%.92%, respectively. Direct costs of revenue include contingent payments to patent enforcement legal costs, patent enforcement advisors and inventors as well as various non-contingent costs associated with enforcing the Company’s patent rights and otherwise in developing and entering into settlement and licensing agreements that generate the Company’s revenue. For the three and nine months ended September 30, 2016,2017, the Company had nolower contingent fee costs associated with contingent payments as there were no new licenses during this period.  For the three months ended September 30, 2015, the Company had higher direct costlower levels of revenus associated with contingent payments relative to new licenses issued as well as trial fees associated with the IP Liquidity portfolio.revenue and fewer number of active infringement cases. Direct cost of revenues were 2538%40% and 53%253%, respectively, for the three and nine months ended September 30, 20162017 and direct costs of revenues were 62%2,538% and 103%53%, respectively, for the comparable periods in 2015.2016.

 

33
Table of Contents

We incurred other operating expenses of $4,014,856 and $8,720,754 for the three and nine months September 30, 2017, respectively and $9,688,527 and $18,884,827 for the three and nine months September 30, 2016, respectively and $5,491,363 and $17,632,070 for the three and nine months ended September 30, 2015,2016, respectively. For the three and nine months ended September 30, 2016,2017, this represented an increasea decrease in other operating expenses of $4,197,164$5,669,671 or 76%59% and $1,321,407$10,164,073 or 7%54%, respectively. These expenses primarily consisted of amortization of patents, general expenses, compensation to our officers, directors and employees, professional and consulting fees incurred in connection with the day-to-day operation of our business and patent and goodwill impairment charges. The year over year increasedecline in other operating expenses for the three and nine months ended September 30, 20162017 resulted primarily from declines in patent amortization and impairment costs and consulting fees, offset by increases in compensation, professional fees and other general and administrative costs, compared to 2016. The increase in compensation expenses in 2016; everyis related to costs associated with the cancellation of existing employment agreements between the Company and the Company’s CEO, CFO and COO, as well as other category of expense declined during the nine months ended September 30, 2016 versus the comparable period of 2015.termination provisions for non-executive employees.

 

TheOther operating expenses consisted of the following:

 

 

 

Total Other Operating Expenses

 

 

 

For the Three
Months Ended
September 30, 2016

 

For the Three
Months Ended
September 30, 2015

 

For the Nine Months
Ended September 30,
2016

 

For the Nine Months Ended September 30,
2015

 

 

 

 

 

 

 

 

 

 

 

Amortization of intangible assets (1)

 

2,030,886

 

2,884,269

 

6,018,196

 

8,511,730

 

Compensation and related taxes (2)

 

1,252,571

 

903,685

 

3,406,841

 

3,571,817

 

Consulting fees (3)

 

257,420

 

643,702

 

903,032

 

1,869,326

 

Professional fees (4)

 

432,496

 

882,213

 

1,336,201

 

2,230,748

 

Other general and administrative (5)

 

183,771

 

177,494

 

612,284

 

681,951

 

Goowill Impairment (6)

 

-

 

-

 

83,000

 

766,498

 

Patent Impairment (7)

 

5,531,383

 

-

 

6,525,273

 

-

 

Total

 

9,688,527

 

5,491,363

 

18,884,827

 

17,632,070

 

  Total Other Operating Expenses  Total Other Operating Expenses 
  For the Three Months Ended
September 30, 2017
  For the Three Months Ended
September 30, 2016
  For the Nine Months Ended
September 30, 2017
  For the Nine Months Ended
September 30, 2016
 
                 
Amortization of patents(1) $457,419  $2,030,886  $1,803,264  $6,018,196 
Compensation and related taxes (2)  1,871,946   1,252,571   3,718,034   3,406,841 
Consulting fees (3)  133,018   257,420   189,819   903,032 
Professional fees (4)  616,125   432,496   1,686,955   1,336,201 
Other general and administrative (5)  213,130   183,771   599,464   612,284 
Goodwill impairment (6)  -   -   -   83,000 
Patent Impairment (7)  723,218   5,531,383   723,218   6,525,273 
Total $4,014,856  $9,688,527  $8,720,754  $18,884,827 

Operating expenses for the three and nine months ended September 30, 20162017 include non-cash operating expenses totaling $8,053,556$2,541,798 and $14,332,533,$4,069,413, respectively, and for the three and nine month ended September 30, 2015,2016, the Company incurred non-cash operating expenses of $3,787,346$8,053,556 and $12,404,184,$14,332,533, respectively. Non-cash operating expenses consisted of the following:

 

 

Non-Cash Operating Expenses

 

 Non-Cash Operating Expenses Non-Cash Operating Expenses 

 

For the Three
Months Ended
September 30, 2016

 

For the Three
Months Ended
September 30, 2015

 

For the Nine Months
Ended September 30,
2016

 

For the Nine Months
Ended September 30,
2015

 

 For the Three Months Ended
September 30, 2017
 For the Three Months Ended
September 30, 2016
 For the Nine Months Ended
September 30, 2017
 For the Nine Months Ended
September 30, 2016
 

 

 

 

 

 

 

 

 

 

         

Amortization of intangible assets (1)

 

2,030,886

 

2,884,269

 

6,018,196

 

8,511,730

 

Amortization of patents (1) $457,419  $2,030,886  $1,803,264  $6,018,196 

Compensation and related taxes (2)

 

440,161

 

444,558

 

1,306,399

 

1,682,361

 

  1,319,629   440,161   1,636,906   1,306,399 

Consulting fees (3)

 

30,038

 

448,361

 

345,510

 

1,403,555

 

  42,910   30,038   (91,228)  345,510 

Professional fees (4)

 

8,620

 

8,527

 

25,707

 

25,582

 

  108   8,620   325   25,707 

Other general and administrative (5)

 

12,468

 

1,631

 

28,448

 

14,458

 

  (1,486)  12,468   (3,072)  28,448 

Goodwill impairment (6)

 

-

 

-

 

83,000

 

766,498

 

  -   -   -   83,000 

Patent Impairment (7)

 

5,531,383

 

-

 

6,525,273

 

-

 

  723,218   5,531,383   723,218   6,525,273 

Total

 

8,053,556

 

3,787,346

 

14,332,533

 

12,404,184

 

 $2,541,798  $8,053,556  $4,069,413  $14,332,533 

 

34
Table of Contents

(1)

Amortization of intangibles and depreciation: Amortization expenses associated with patents and the Company’s website were $2,030,886$457,419 and $6,018,196$1,803,264 during the three and nine months ended September 30, 2016,2017, respectively, a decrease of $853,383$1,573,467 or 30%77% and $2,493,534$4,214,932 or 29%70% relative to the three and nine months ended September 30, 2015.2016. The decrease results from the partial or full impairment in fourof numerous of the Company’s portfolios reducing the carrying fair value and the partial impairment of another of the Company’s portfolios during the intervening period of time.related amortization expenses. When the Company acquires patents and patent rights, the Company capitalizes the cost of those assets and amortizes those costs over the remaining useful lives of the assets. All patent amortization expenses are non-cash expenses.

(2)

Compensation expense and related taxes: Compensation expense includes cash compensation and related payroll taxes and benefits, and non-cash equity compensation expenses. For the three and nine months ended September 30, 2016,2017, respectively, compensation expense and related payroll taxes were $1,252,571,$1,871,946 and $3,718,034, an increase of $348,886$619,375 or 39%49% and for311,193 or 9% relative to the three and nine months ended September 30, 2016, compensation expense and related payroll taxes were 3,406,841, a decrease of 164,976 or 5% relative to the nine months ended September 30, 2015.2016. The increase in compensation for the three months ended September 30, 2016 primarily reflects salariesexpenses is related to costs associated with new employeesthe cancellation of existing employment agreements between the Company and the decrease in compensation expenseCompany’s CEO, CFO and COO, as well as other termination provisions for the nine months ended September 30, 2016 primarily reflects bonuses incurred and paid during the nine months ended September 30, 2015.non-executive employees. We recognized non-cash employee and board equity based compensation of $1,319,629 and $1,636,906, respectively, for the three and nine months ended September 30, 2017 and $440,161 and $1,306,399, respectively, for the three and nine months ended September 30, 2016 and $444,558 and $1,682,361, respectively, for the three and nine months ended September 30, 2015.

2016.

(3)

Consulting fees: For the three and nine months ended September 30, 2016,2017, respectively, we incurred consulting fees of $257,420$133,018 and $903,032.$189,819. This represented a decreasedecreases in the amount of $386,283$124,402 or 60%48% and a decrease of $966,294$713,213 or 52%79% compared to the three and nine months ended September 30, 2015.2016. Consulting fees include both cash and non-cash related consulting fees primarily for investor relations, public relations and general consulting services. The decrease duringin consulting fees for the three and nine months ended September 30, 2017 compared to the nine months ended September 30, 2016 primarily reflectreflects a declinereduction in non-cash equity compensation expensesactivity related to the acquisition of new portfolios as well as a credit recognized during the three months ended March 31, 2017 associated with the engagementmark to market of numerous consultants inan option grant issued to a consultant who no longer derives a majority of his compensation from the investor relationsCompany. As a result, the Company must mark to market his option grant on a quarterly basis. The credit for the three months ended March 31, 2017 was partially offset by a mark to market expense of the same option during the three months ended September 30, 2017. During the three ended September 30, 2017, we recognized non-cash equity based consulting expenses of $42,910 and for generalduring the nine months ended September 30, 2017, we recognized a non-cash equity based consulting areas incurred in 2015 that expired during 2015 and 2016.credit of $91,228. During the three and nine months ended September 30, 2016, we recognized non-cash equity basedequity-based consulting expenses of $30,038 and $345,510, respectively compared to non-cash equity-based consulting expenses of $448,361 and $1,403,555 for the three and nine months ended September 30, 2015.

respectively.

(4)

Professional fees: For the three and nine months ended September 30, 2016,2017, we incurred professional fees of $432,496$616,125 and $1,336,201,$1,686,955, respectively, a decreasean increase of $449,717$183,629 or 51%42% and $894,547$350,754 or 40%26% over the comparable periods in 2015.2016. Professional fees primarily reflect the costs of professional outside accounting fees, legal fees and audit fees. The decreaseincrease in professional fees for the three and nine months ended September 30, 20162017 over the three and nine months ended September 30, 20152016 relate to lowerhigher professional outside legal, accounting and audit fees resulting from the absence of significant costs associated with closing the Fortress transactionrestructuring in January 2017, the equity issuance in April 2017, the Convertible Note issuance in August, the restructuring of other indebtedness and preparing for the subsequently terminated Uniloc transaction.entrance into the merger agreement with GBV. During the three and nine months ended September 30, 2016,2017, we recognized non-cash equity basedequity-based professional expenses of $108 and $325, respectively, compared to non-cash equity-based professional expenses of $8,620 and $25,707, respectively, compared to non-cash professional expenses of $8,527 and $25,582, respectively, during the same periods in 2015.

2016.

(5)

Other general and administrative expenses: For the three and nine months ended September 30, 2016,2017, we incurred other general and administrative expenses of $183,773$213,130 and $612,284,$599,464, respectively, an increase of $6,277$29,359 or 4%16% for the three months ended September 30, 2016 compared to the comparable period in 2015, but2017 and a decrease of $69,667$12,820 or 10% for the nine months ended September 30, 2016 compared to2% over the comparable periodperiods in 2015.2016. General and administrative expenses reflect the other non-categorized operating costs of the Company and include expenses related to being a public company, rent, insurance, technology and other expenses incurred to support the operations of the Company. During the three and nine months ended September 30, 2016,2017, we recognized non-cash equity based other generalG&A credits of $1,486 and administrative$3,072, respectively, compared to non-cash equity-based other G&A expenses of $12,468 and $28,448, respectively, compared to non-cash professional expenses of $1,631 and $14,458, respectively, during the same periods in 2015.

2016.

35
Table of Contents

 

(6)

(6)

Goodwill impairment: For the three and nine months ended September 30, 2017, there was no impairment of goodwill. Based on the Company’s determination thatdecision to end of life one of its portfolios, had reached the end of its useful life, the Company took an impairment charge during the three and nine months ended September 30, 2016 in the carrying value of the related goodwill in the amount of $0 and $83,000 compared to a goodwill impairment charge in the amount of $0 and $766,498, respectively, during$83,000.

(7)Patent impairment: For the three and nine months ended September 30, 2015.

(7)

Patent impairment:2017, the Company took an impairment charge of the carrying value of the Company’s Clouding portfolio patents in the amount of $723,218 and $723,218, respectively. Based on changes in the expected timing of proceeds from the Clouding portfolio, as well as the determination that a numberimpairment of one portfolio during the Company’sthree months ended September 30, 2016 and two portfolios had reachedduring the end of their useful lives,three months ended March 31, 2016, the Company took impairment charges for three and nine months September 30, 2016 in the carrying value of the Company’s patents assets in the amount of $5,531,383 and 6,525,273, respectively, compared to no impairment charges for three and nine months September 30, 2015 in the carrying value of the Company’s patents assets.

$6,525,273, respectively.

Operating Income (Loss)

 

We reported operating income (loss) of $(3,916,979) and $(9,655,378) for the three and nine months ended September 30, 2017 and operating income (loss) of $(10,739,792) and $(1,634,394) for the three and nine months ended September 30, 20162016. For the three and nine months ended September 30, 2017, this represented an increase in operating income (loss) of $(3,085,406)$6,822,813 for the three months ended September 30, 2017 and $(17,951,634),a decrease in operating income of $8,020,984 for the three months ended September 30, 2017. The increase in operating income for the three months ended September 30, 2017 results from markedly lower expenses and the decreased income from operations in 2017 relative to 2016 was primarily attributable to lower revenue and higher direct cost of revenues as a percentage of revenue, only partially offset by lower cash and non-cash operating expenses.

Other Income (Expenses)

Total other income (expenses) was $(2,468,316) and $(2,675,400) for the three and nine months ended September 30, 2015.  For the three months ended September 30, 2016, this represented a decrease in operating income of $7,654,386, but for the nine months ended September 30, 2016, this represented an increased operating income of $16,317,240. For the nine months ended September 30, 2016, the increased income from operations was primarily attributable to higher revenue, lower direct cost of revenues2017, respectively, and lower patent amortization costs.

Other Income (Expenses)

Total other income (expenses) was $1,093,278 and $(682,040) for the three and nine months ended September 30, 2016, respectively, and $(1,148,877) and $(1,383,261) for the three and nine months ended September 30, 2015, respectively. For the three and nine months ended September 30, 2016, this represented an increase in other incomeexpense of $2,242,155$3,561,594 and $701,221,$1,993,360, respectively.  The principal component of the increase in other income for

Income Tax Benefit (Expense)

For the three months ended September 30, 2016 compared to the comparable period in 2015 was a decline in interest expenses, an increase in the gain associated with the change in the fair value of the Clouding IP earn out and a loss on debt extinguishment in 2015, offset by an increase in foreign exchange loss in 2016.  The principal component of the increase in other income for the nine months ended September 30, 2016, compared to the comparable period in 2015 include the items set forth aboveCompany recognized no income tax benefit as well, with the exceptiona result of the gain associated withCompany’s profit. We recognized an income tax expense for the change in the fair value of the Clouding IP earn out, which was greater for thethree and nine months ended September 30, 2015 as compared to2017 in the nine months ended September 30, 2016.

Income Tax Benefit (Expense)

We recognizedamounts of $(12,191) and $(29,433), respectively and an income tax benefit (expense) in the amount of $3,347,909 and $26,974 for the three and nine months ended September 30, 2016, respectively, attributable to the Company’s operatingrespectively.

Net Income (Loss)

We reported net income in 2016, compared to the recognition(loss) of income tax benefits in the amounts of $483,815$(6,677,486) and $6,300,159, respectively,$(12,484,925) for the three and nine months ended September 30, 2015.

Net Income (Loss)

We reported2017, respectively, and net income (loss) of $(6,298,605)$(6,274,410) and $(2,289,460)$(2,261,542) for the three and nine months ended September 30, 2016, respectively,respectively. For the three and nine months ended September 30, 2017, this represented a decrease in the net income of $98,881 and $10,070,751, respectively.

Non-GAAP Reconciliation

Non-GAAP earnings as presented in this Annual Report is a supplemental measure of our performance that is neither required by, nor presented in accordance with, U.S. generally accepted accounting principles (“US GAAP”). Non-GAAP earnings is not a measurement of our financial performance under US GAAP and should not be considered as alternative to net income, operating income, or any other performance measures derived in accordance with US GAAP, or as alternative to cash flow from operating activities as a measure of our liquidity. In addition, in evaluating Non-GAAP earnings, you should be aware that in the future we will incur expenses or charges such as those added back to calculate Non-GAAP earnings. Our presentation of Non-GAAP earnings should not be construed as an inference that our future results will be unaffected by unusual or nonrecurring items.

Non-GAAP earnings has limitations as an analytical tool, and you should not consider it in isolation, or as substitutes for analysis of our results as reported under US GAAP. Some of these limitations are (i) it does not reflect our cash expenditures, or future requirements for capital expenditures or contractual commitments, (ii) they do not reflect changes in, or cash requirements for, our working capital needs, (iii) it does not reflect interest expense, or the cash requirements necessary to service interest or principal payments, on our debt, (iv) although depreciation and amortization are non-cash charges, the assets being depreciated and amortized will often have to be replaced in the future, and Non-GAAP earnings does not reflect any cash requirements for such replacements, (v) it does not adjust for all non-cash income or expense items that are reflected in our statements of cash flows, and (vi) other companies in our industry may calculate this measure differently than we do, limiting its usefulness as comparative measures.

36
Table of Contents

We compensate for these limitations by providing specific information regarding the US GAAP amounts excluded from such non-GAAP financial measures. We further compensate for the limitations in our use of Non-GAAP financial measures by presenting comparable US GAAP measures more prominently.

We believe that Non-GAAP earnings facilitates operating performance comparisons from period to period by isolating the effects of some items that vary from period to period without any correlation to core operating performance or that vary widely among similar companies. These potential differences may be caused by variations in capital structures (affecting interest expense), tax positions (such as the impact on periods or companies of changes in effective tax rates or net operating losses) and the age and book depreciation of facilities and equipment (affecting relative depreciation expense). We also present Non-GAAP earnings because (i) we believe that this measure is frequently used by securities analysts, investors and other interested parties to evaluate companies in our industry, (ii) we believe that investors will find these measures useful in assessing our ability to service or incur indebtedness, and (iii) we use Non-GAAP earnings internally as benchmark to compare our performance to that of our competitors.

The Company uses a Non-GAAP reconciliation of net income (loss) and earnings (EPS reconciliation loss) per share in the presentation of $(3,750,468)financial results here. Management believes that this presentation may be more meaningful in analyzing our income generation.

On a Non-GAAP basis, the Company’s recorded a Non-GAAP loss of $(1,448,278) and $(13,034,736)$(6,187,993) for the three and nine months ended September 30, 2015, respectively.

2017, respectively, compared to Non-GAAP Reconciliation

The Company recorded non-GAAP reconciliation itemsloss in the amount of $3,039,318$(3,235,092) and $13,135,582non-GAAP income of $10,874,080 for the three and nine months ended September 30, 2016, respectively, compared to non-GAAP reconciliation items in the amount of $3,662,028 and $6,533,543 for the three and nine months ended September 30, 2015.respectively. The details of thesethose expenses and non-GAAP reconciliation of these non-cash items are set forth below:

 

 

Non-GAAP Reconciliation

 

 

 

For the Three
Months Ended
September 30, 2016

 

For the Three
Months Ended
September 30, 2015

 

For the Nine Months
Ended September 30,
2016

 

For the Nine Months
Ended September 30,
2015

 

Net income (loss) attributable to Marathon Patent Group, Inc. common shareholders

 

(6,274,410)

 

(3,750,468)

 

(2,261,542)

 

(13,034,736)

 

Non-GAAP

 

 

 

 

 

 

 

 

 

Amortization of intangible assets

 

2,030,886

 

2,884,269

 

6,018,196

 

8,511,730

 

Equity-based compensation

 

478,819

 

901,446

 

1,677,616

 

3,111,498

 

Impairment of Intellectual Property

 

5,531,383

 

-

 

6,608,273

 

766,498

 

Change in Earn Out Liability

 

(1,954,378)

 

(597,047)

 

(2,122,208)

 

(2,901,348)

 

Non-cash interest expense

 

288,049

 

301,544

 

952,231

 

1,926,866

 

Deferred tax (benefit) / Tax expense

 

(3,347,909)

 

(483,815)

 

(26,974)

 

(6,300,159)

 

Loss on note payable

 

-

 

654,000

 

-

 

654,000

 

Clawback on Medtronic debt

 

-

 

-

 

-

 

750,000

 

Other

 

12,468

 

1,631

 

28,448

 

14,458

 

Non-GAAP net income (loss)

 

(3,235,092)

 

(88,440)

 

10,870,040

 

(6,501,193)

 

 

 

 

 

 

 

 

 

 

 

Weighted average common shares outstanding:

 

 

 

 

 

 

 

 

 

Basic

 

15,047,141

 

14,376,118

 

14,944,852

 

14,094,891

 

Fully diluted

 

15,047,141

 

14,376,118

 

15,984,269

 

14,094,891

 

 

 

 

 

 

 

 

 

 

 

Non-GAAP net income (loss) per common share - basic and diluted

 

 

 

 

 

 

 

 

 

Basic

 

$

(0.21)

 

$

(0.01)

 

$

0.73

 

$

(0.46)

 

Fully diluted

 

$

(0.21)

 

$

(0.01)

 

$

0.68

 

$

(0.46)

 

  Non-GAAP Reconciliation  Non-GAAP Reconciliation 
  For the Quarter Ended
September 30, 2017
  For the Quarter Ended
September 30, 2016
  For the Nine Months Ended
September 30, 2017
  For the Nine Months Ended
September 30, 2016
 
Net income (loss) attributable to Common Shareholders $(6,677,486) $(6,274,410) $(12,484,925) $(2,261,542)
Non-GAAP                
Amortization of intangible assets & depreciation  457,719   2,030,886   1,804,512   6,018,196 
Equity-based compensation  1,371,480   478,819   1,554,835   1,677,616 
Impairment of intangible assets  723,218   5,531,383   723,218   6,608,273 
Change in the fair value of the clouding IP liability  (754,320)  (1,954,378)  (768,199)  (2,122,208)
Loss on debt extinguishment  283,237   -   283,237   - 
Loss on sale of companies  1,519,875   -   1,519,875   - 
Warrant (Income) Expense, net  1,909,879   -   1,914,786   - 
Non-cash Other (Income) expense, net  (1,323,407)  -   (2,221,939)  - 
Non-cash interest expense  1,043,012   288,049   1,489,678   952,231 
Deferred tax benefit  -   (3,347,909)  -   (26,974)
Other  (1,486)  12,468   (3,072)  28,488 
Non-GAAP earnings (loss) $(1,448,278) $(3,235,092) $(6,187,993) $10,874,080 

37

The following table sets forth the computation of basic and diluted loss per share on a Non-GAAP basis:

  Non-GAAP Reconciliation  Non-GAAP Reconciliation 
  For the Quarter Ended
September 30, 2017
  For the Quarter Ended
September 30, 2016
  For the Nine Months Ended
September 30, 2017
  For the Nine Months Ended
September 30, 2016
 
Non-GAAP net income (loss) $(1,448,278) $(3,235,092) $(6,187,993) $10,874,080 
                 
Denominator                
Weighted average common shares - Basic  6,270,299   3,761,785   5,564,465   3,736,213 
Weighted average common shares - Diluted  6,270,299   3,761,785   5,564,465   3,996,067 
                 
Non-GAAP earnings (loss) per common share:                
Non-GAAP earnings (loss) - Basic $(0.23) $(0.86) $(1.11) $2.91 
Non-GAAP earnings (loss) - Diluted  NA    NA    NA    2.72 

Liquidity and Capital Resources

 

Liquidity is the ability of a company to generate funds to support its current and future operations, satisfy its obligations, and otherwise operate on an ongoing basis. At September 30, 2016,2017, the Company’s unrestricted cash balances totaled $1,294,950$122,172 compared to $2,555,151$4,998,314 at December 31, 2015.2016 and the Company’s restricted cash balances totaled $3,919,718 at September 30, 2017 and $0 at December 31, 2016. The decrease in the cash balances of $1,260,201$4,876,142 resulted primarily from net cash used in operations, acquisition of new patent portfolios andoffset by cash amortizationreceived upon the issuance of the Fortress debt.Convertible Note and equity.

 

NetThe unrestricted net working capital deficit declined by $2,619,870$5,323,251 to $14,792,616$(20,262,835) at September 30, 20162017 from $(12,172,746)$(14,939,583) at December 31, 2015.2016. The decrease in net working capital resulted primarily from a decrease in current assets related to cash from operations and an increase in current liabilities associated with an increasereduction in the current portionCompany’s cash as well as the reclassification of all Fortress indebtedness into short-term liabilities in anticipation of the Fortress debt.Restructuring.

 

Cash provided (used) in operating activities was $(14,805,103) during the nine months ended September 30, 2017 and cash provided in operating activities of was $11,214,122 during the nine months ended September 30, 2016. The difference between the nine months ended September 30, 2016, during which the Company generated cash from operating activities, and the nine months ended September 30, 2017, during which the Company used cash provided (used) in operating activities, was $(2,921,505)is largely tied to the much lower level of revenues during the nine months ended September 30, 2015.2017 as compared to the comparable period in 2016.

 

Cash provided (used) in investing activities was $(3,561,043)$2,765,466 for the nine months ended September 30, 20162017 compared to $(22,520)$(3,561,043) cash used in investing activities for the nine months ended September 30, 2015.2016. The additional usegeneration of cash in investing activities during the nine months ended September 30, 2017 was primarily related to the disposition of certain patent portfolios, offset slights by the purchases of property, equipment and other non-patent intangible assets and cash used during the nine months ended September 30, 2016 was almost exclusively related toprimarily the acquisition of new patent portfolios.

 

Cash (used)provided in financing activities was $(8,981,688)$11,066,704 during the nine months ended September 30, 20162017 compared to cash provided byin financing activities in the amount of $1,266,251$(8,911,688) during the nine months ended September 30, 2015.2016. Cash generated by financing activities for the nine months ended September 30, 2017 resulted from the issuance of equity, issuance of Convertible Notes, offset by the repayment of some outstanding debt. Cash used in financing activities for the nine months ended September 30, 2016 resulted from the repayment of allnotes payable related to the acquisition of the Medtech portfolio acquisition debt as well as a portionportfolios, the repayment of principal on the outstanding Fortress debt and cash provided by financing activities for the nine months ended September 30, 2015 resulted from the transaction entered into with Fortress on January 29, 2015, less repayment of general and patent portfolio acquisitionother minor debt of equal or shorter terms, incurred during 2014.obligations.

 

Management is uncertain that the balance of cash and cash equivalents of $1,294,950$122,172 in unrestricted cash at September 30, 20162017 is sufficient to continue to fund the Company’s operations through at least the next twelve months.months and there is no certainty that the Company will achieve the milestones to have the restricted cash released from escrow. The Company’s operations are subject to various risks and there is no assurance that changes in the operations of the Company will not require the Company to raise additional cash sooner than planned in order to continue uninterrupted operations. In that event, the Company would seek to raise additional capital from the sale of the Company’s securities, from borrowing or from other sources. Should the Company seek to raise capital from the issuances of its securities, such transactions would be subject to the risks of the market for the Company’s securities at the time.

 

38
Table of Contents

Based on the Company’s current revenue and profit projections, management is uncertain that the Company’s existing cash and accounts receivables will be sufficient to fund its operations through at least the next twelve months, raising substantial doubt regarding the Company’s ability to continue operating as a going concern. If we do not meet our revenue and profit projections or the business climate turns negative, then we will need to:

raise additional funds to support the Company’s operations; provided, however, there is no assurance that the Company will be able to raise such additional funds on acceptable terms, if at all. If the Company raises additional funds by issuing securities, existing stockholders may be diluted; and
review strategic alternatives.

If adequate funds are not available, we may be required to curtail our operations or other business activities or obtain funds through arrangements with strategic partners or others that may require us to relinquish rights to certain technologies or potential markets.

Off-balance Sheet Arrangements

 

We have not entered into any other financial guarantees or other commitments to guarantee the payment obligations of any third parties. We have not entered into any derivative contracts that are indexed to our shares and classified as stockholder’s equity or that are not reflected in our consolidated condensed financial statements. Furthermore, we do not have any retained or contingent interest in assets transferred to an unconsolidated entity that serves as credit, liquidity or market risk support to such entity.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

 

Not required for smaller reporting companies.

 

Item 4. Controls and Procedures.

 

Disclosure Controls and Procedures.

 

We maintain “disclosure controlsOur management is responsible for establishing and procedures,”maintaining adequate internal control over financial reporting as such term is defined in Rules 13a-15(e)13a-15(f) and 15d-15(e)15d-15(f) under the Exchange Act, that are designed to ensure that informationAct. Our management is also required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized,assess and reported within the time periods specified in Securities and Exchange Commission rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and our Chief Financial Officer, to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, management recognized that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Additionally, in designing disclosure controls and procedures, our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures. The design of any disclosure controls and procedures also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

We conducted an evaluation ofreport on the effectiveness of our “disclosure controls and procedures” (“Disclosure Controls”), as defined by Rules 13a-15(e) and 15d-15(e)internal control over financial reporting in accordance with Section 404 of the ExchangeSarbanes-Oxley Act as of September 30, 2016,2002 (“Section 404”). Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the endreliability of financial reporting and the period covered by this Quarterly Report on Form 10-Q. The Disclosure Controls evaluation was done underpreparation of financial statements for external purposes of accounting principles generally accepted in the supervision and with the participation of management, including our Chief Executive Officer and Chief Financial Officer. There are inherent limitations toUnited States. Management assessed the effectiveness of any systemour internal control over financial reporting as of disclosure controls and procedures. Accordingly, even effective disclosure controls and procedures can only provide reasonable assuranceDecember 31, 2016. In making this assessment, we used the criteria set forth by the Committee of achieving their control objectives. Based upon this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, dueSponsoring Organizations of the Treadway Commission (COSO) in Internal Control - Integrated Framework in the 2013 COSO framework.

Due to our limited internal audit function, our Disclosure Controls weresize and nature, segregation of all conflicting duties may not effective as of September 30, 2016, such that the information required toalways be disclosed by us in reports filed under the Exchange Act is (i) recorded, processed, summarizedpossible and reported within the time periods specified in the SEC’s rules and forms and (ii) accumulated and communicated to our management, including our Chief Executive Officer and out Chief Financial Officer, as appropriate to allow timely decisions regarding disclosure.

Management is in the process of determining how best to change our current system and implement a more effective system to insure that information required tomay not be disclosed in this Quarterly Report on Form 10-Q has been recorded, processed, summarized and reported accurately. Our management acknowledges the existence of this problem, and intends to develop procedures to address themeconomically feasible. However, to the extent possible, given limitationswe will implement procedures to assure that the initiation of transactions, the custody of assets and the recording of transactions will be performed by separate individuals.

We believe that the foregoing steps if implemented, will help remediate the material weakness identified above, and we will continue to monitor the effectiveness of these steps and make any changes that our management deems appropriate. Due to the nature of this material weakness in our internal control over financial and manpower resources. While managementreporting, there is workingmore than a remote likelihood that misstatements which could be material to our annual or interim financial statements could occur that would not be prevented or detected.

39
Table of Contents

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a plan, no assurance can be made at this pointtimely basis. A significant deficiency is a deficiency, or a combination of deficiencies, in internal control over financial reporting that is less severe than a material weakness, yet important enough to merit attention by those responsible for oversight of the company’s financial reporting.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the implementationdegree of such controlscompliance with the policies and procedures will be completed in a timely manner or that they will be adequate once implemented.may deteriorate.

 

Changes in Internal Controls.

 

There have been no changes in our internal control over financial reporting during the quarter ended September 30, 20162017 that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.

PART II - OTHER INFORMATION

 

Item 1. Legal Proceedings.

In the ordinary course of business, we actively pursue legal remedies to enforce our intellectual property rights and to stop unauthorized use of our technology. There are no proceedings in which any of our directors, officers or affiliates, or any registered beneficial shareholder, are adverse to the Company or has a material interest adverse to us.

 

In the normal course of our business of patent monetization, it is generally necessary for us to initiate litigation in order to commence the process of protecting our patent rights. Such litigation is expected to lead to a monetization event. Accordingly, we are, and in the future, expect to become, a party to ongoing patent enforcement related litigation alleging infringement by various third parties of certain patented technologies owned and/or controlled by us. Litigation is commenced by and managed through the subsidiary that owns the related portfolio of patents or patent rights. In connection with our enforcement activities, we are currently involved in multiple patent infringement cases. As of September 30, 2017, the Company is involved into a total of 5 lawsuits against defendants in the following jurisdictions:

United States
District of Delaware5

Marathon Patent Group, Inc. and Clouding Corp. are currently defendants in a lawsuit captioned as Symantec Corporation v. IP Navigation Group, LLC; Clouding IP, LLC, et al., Los Angeles County Superior Court, Case No.: BC640931. Symantec alleges the following causes of action against Marathon and Clouding in the First Amended Complaint: fraudulent misrepresentation; interference with contractual relations; violation of Business and Professions Code section 17200, et seq.; and accounting. A Post Mediation Status Conference is scheduled for January 24, 2018 (although the parties have not discussed mediation or any other form of alternative dispute resolution). A Final Status Conference is scheduled for March 16, 2018. Trial of the matter is scheduled to commence on March 26, 2018.

Marathon Patent Group, Inc., Doug Croxall and Francis Knuettel II are currently defendants in a lawsuit captioned as Jeffrey Feinberg v. Marathon Patent Group, Inc., Doug Croxall, Francis Knuettel II and Does 1-10, inclusive, Los Angeles County Superior Court, Case No.: BC673128. Mr. Feinberg alleges the following causes of action against Marathon, Doug Croxall and Francis Knuettel II: violation of Section 11 of the Securities Act; violation of Section 12(a)(2) of the Securities Act; violation of Section 15 of the Securities Act; fraud and fraudulent concealment; constructive fraud; and negligent misrepresentation. On November 9, 2017, Mr. Feinberg filed a request for dismissal.

Other than as disclosed herein, we know of no other material, active or pending legal proceedings against us, nor are we involved as a plaintiff in any material proceedings or pending litigation other than in the normal course of business.

 

Item 1A. Risk Factors.

 

Not required for smaller reporting companies.

40
Table of Contents

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

 

None.On August 9, 2017, the Company issued 250,000 shares of the Company’s Common Stock pursuant to the conversion of 200,000 shares of Series D Convertible Preferred Stock.

On August 29, 2017, the Company issued 200,000 shares in total of the Company’s Common Stock to four different vendors in partial or total payment of outstanding invoices.

On September 5, 2017, the Company issued 62,500 shares of the Company’s Common Stock pursuant to the conversion of 50,000 shares of Series D Convertible Preferred Stock.

On September 6, 2017, the Company issued 534,710 shares of the Company’s Common Stock pursuant to the conversion of $427,768 in principal amount invested in the Convertible Note.

On September 13, 2017, the Company issued 315,925 shares of the Company’s Common Stock pursuant to the conversion of 252,750 shares of Series D Convertible Preferred Stock.

On September 29, 2017, the Company issued 598,500 shares of the Company’s Common Stock to holders of the warrants issued pursuant to the April Purchase Agreement following approval by the Company’s shareholders of the warrant exchange at a special meeting held on September 29, 2017.

 

Item 3. Defaults Upon Senior Securities.

 

None.

 

Item 4. Mine Safety Disclosures.

 

Not applicable.

 

Item 5. Other Information.

 

Certain officers of the Company have received stock grants and / or options in 3D Nanocolor Corp. (“3D Nano”), a wholly-owned subsidiary of the Company, pursuant to 3D Nano’s 2016 Equity Incentive Plan.

 

Item 6. Exhibits.

 

31.1

Certification of the Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*

31.2

Certification of the Principal Financial and Accounting Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*

32.1

Certification of the Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*

32.2

Certification of the Principal Financial and Accounting Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*

101.ins

XBRL Instance Document**

101.sch

XBRL Taxonomy Extension Schema **

Document**

101.cal

XBRL Taxonomy Extension Calculation Document**

101.defXBRL Taxonomy Linkbase Document**

101.def

101.lab

XBRL Taxonomy Extension Definition Linkbase Document**

101.lab

XBRL Taxonomy Extension Label Linkbase Document**

101.pre

XBRL Taxonomy Extension Presentation Linkbase Document**

 

* Furnished herewith

** Filed herein

41
Table of Contents

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

Date: November 14, 201620, 2017

 

MARATHON PATENT GROUP, INC.

By:

By:

/s/ Doug Croxall

Name: Doug Croxall

Title: Chief Executive Officer and Chairman

(Principal Executive Officer)

By:

By:

/s/ Francis Knuettel II

Name: Francis Knuettel II

Title: Chief Financial Officer

(Principal Financial and Accounting Officer)

45